Validating ECOFF Values and Intrinsic Resistance Breakpoints: A Comprehensive Guide for Antimicrobial Research and Drug Development

Abstract

This article provides a comprehensive framework for researchers, scientists, and drug development professionals on the validation of Epidemiological Cut-off (ECOFF) values and intrinsic resistance breakpoints. It covers foundational principles distinguishing ECOFFs from clinical breakpoints, methodological approaches for determination using standardized tools like ECOFFinder, troubleshooting for challenging distributions, and validation through case studies and comparative analysis. Aligned with EUCAST and CLSI standards, the content addresses critical needs in antimicrobial resistance surveillance, supporting accurate susceptibility testing and informed breakpoint setting in both human and veterinary medicine.

Understanding ECOFFs and Intrinsic Resistance: Defining the Wild-Type Baseline

The Epidemiological Cut-Off Value (ECOFF) represents a fundamental microbiological concept distinguishing wild-type microorganisms from those with acquired resistance mechanisms. Unlike clinical breakpoints that predict treatment outcomes, ECOFFs provide a pure phenotypic measure of resistance development by defining the upper end of the minimum inhibitory concentration (MIC) distribution for organisms lacking detectable resistance mechanisms. This comprehensive analysis examines ECOFF methodology, determination protocols, and research applications within antimicrobial resistance surveillance. We detail the standardized experimental frameworks required for ECOFF determination, present comparative data analysis techniques, and explore how ECOFFs serve as essential tools for resistance mechanism identification and method calibration. The precise definition and application of ECOFFs enable researchers to track resistance trends across temporal, geographic, and host boundaries, providing critical reference points for antimicrobial susceptibility testing standardization and resistance surveillance in public health.

The Epidemiological Cut-Off Value (ECOFF) is formally defined as "the highest MIC for organisms devoid of phenotypically detectable, acquired resistance mechanisms" [1]. This value delineates the upper boundary of the wild-type (WT) MIC distribution, providing a standardized reference for identifying organisms without detectable resistance mechanisms. ECOFFs are species-specific and remain consistent irrespective of isolate source, geographic origin, or collection period [1]. This stability makes them invaluable for global antimicrobial resistance (AMR) surveillance and technical standardization of antimicrobial susceptibility testing (AST).

ECOFFs fundamentally differ from clinical breakpoints, which categorize microorganisms as Susceptible (S), Susceptible with Increased Exposure (I), or Resistant (R) based on the likelihood of treatment success [2] [3]. While clinical breakpoints incorporate pharmacological and host factors, ECOFFs provide a purely phenotypic measure of resistance development based on in vitro behavior [4]. This distinction is critical—an organism may be wild-type (below ECOFF) yet clinically resistant due to intrinsic resistance, where the wild-type MIC exceeds clinically achievable concentrations [2].

The European Committee on Antimicrobial Susceptibility Testing (EUCAST) systematically collects international MIC distributions to establish ECOFFs, requiring at least five independent contributions from different sources before defining an ECOFF [5] [1]. This extensive aggregation encompasses variation between investigators, laboratories, geographic locations, and time periods, ensuring robust and representative reference values [5].

ECOFF Determination: Methodological Framework

Experimental Protocols and Data Requirements

The determination of ECOFFs follows rigorous standardized protocols to ensure consistency and reliability across studies:

• Reference Methodologies: MIC values must be determined using reference broth microdilution methods performed by or calibrated to ISO standard 20776-1 [5] [6]. For antifungal agents, established reference methods such as those from EUCAST or CLSI are employed [1]. Disk diffusion data are accepted only when generated using quality-controlled EUCAST methodology [5].

• Twofold Dilution Series: Testing must utilize traditional twofold dilution series (e.g., 0.125, 0.25, 0.5, 1, 2, 4, 8 mg/L) to facilitate analysis. Values between standard concentrations are rounded up to the next twofold value [1].

• Species-Level Identification: Isolates must be identified to the species level, or to species complex when members cannot be distinguished by standard methods like MALDI-TOF [1].

• Comprehensive Concentration Range: The dilution series must adequately cover the putative wild-type distribution. Studies with distributions truncated within the wild-type range are excluded from ECOFF determination [5] [1].

Table 1: Essential Methodological Requirements for ECOFF Determination

Requirement Category	Specification	Purpose
Reference Method	Broth microdilution (ISO 20776-1) or calibrated equivalent	Standardization across laboratories
Dilution Scheme	Twofold dilution series (0.5, 1, 2, 4 mg/L, etc.)	Facilitates comparative analysis
Organism Identification	Species level (or species complex if indistinguishable)	Ensures species-specific distributions
Data Source Requirements	Minimum 5 independent distributions from different sources	Ensves representative population sampling
Quality Control	Inclusion of appropriate control strains (ATCC)	Verifies methodological accuracy

Data Aggregation and ECOFF Setting Process

EUCAST follows a systematic approach for data curation and ECOFF determination, codified in Standard Operating Procedure 10.2 [7]:

• Data Collection: The EUCAST database aggregates MIC distributions from worldwide sources, including surveillance programs, published literature, pharmaceutical industry studies, veterinary programs, and individual laboratories [5]. The database currently contains over 30,000 MIC distributions curated by designated experts [5].

• Distribution Analysis: Putative wild-type distributions are identified as monomodal, log-normal distributions representing isolates without phenotypically detectable resistance mechanisms [1]. In distributions containing both wild-type and non-wild-type populations, the wild-type component remains identifiable using statistical methods [1].

• ECOFF Estimation: The upper end of the wild-type distribution is determined using statistical methods, though no international standard method exists for this process [1]. Both EUCAST and CLSI have developed similar but non-identical approaches, with EUCAST employing a more prescriptive analytical framework [1].

• Tentative vs. Confirmed ECOFFs: Tentative ECOFFs (TECOFFs) are based on 3-4 distributions and are displayed in parentheses, while confirmed ECOFFs require at least 5 distributions and may be based on up to 100 or more distributions [5].

Diagram 1: ECOFF Determination Workflow - This diagram illustrates the systematic process for establishing ECOFF values, from initial data collection through final validation.

Comparative Analysis: ECOFF vs. Clinical Breakpoints

Conceptual and Practical Distinctions

ECOFFs and clinical breakpoints serve fundamentally different purposes in antimicrobial susceptibility testing, though they are often misinterpreted or used interchangeably by those unfamiliar with their distinct applications:

• Purpose and Application: ECOFFs detect the presence of resistance mechanisms phenotypically and are primarily used for resistance surveillance and technical standardization [2] [4]. Clinical breakpoints predict the likelihood of treatment success and guide therapeutic decision-making [2] [3].

• Basis for Determination: ECOFFs are derived solely from microbiological data—the wild-type MIC distributions of specific microorganism-antimicrobial combinations [1] [4]. Clinical breakpoints incorporate additional pharmacological parameters, including pharmacokinetic/pharmacodynamic (PK/PD) properties, dosing regimens, and site of infection considerations [3].

• Interpretive Categories: ECOFFs categorize isolates as wild-type (WT) or non-wild-type (NWT) based solely on the presence of detectable resistance mechanisms [1]. Clinical breakpoints use Susceptible (S), Susceptible with Increased Exposure (I), and Resistant (R) categories that correlate with probable treatment outcomes [3].

Table 2: Comparative Analysis: ECOFF vs. Clinical Breakpoints

Parameter	ECOFF	Clinical Breakpoints
Primary Function	Detect resistance mechanisms	Predict treatment outcome
Basis	Wild-type MIC distributions	MIC distributions + PK/PD + clinical data
Categorization	Wild-type vs. Non-wild-type	Susceptible (S), Increased Exposure (I), Resistant (R)
Clinical Utility	Surveillance & technical standardization	Therapeutic decision guidance
Dose Consideration	Not considered	Integral to categorization
Influence of Infection Site	None	Significant for breakpoint setting

Complementary Roles in Antimicrobial Resistance Management

Despite their differences, ECOFFs and clinical breakpoints play complementary roles in comprehensive antimicrobial resistance management:

• Breakpoint Development: ECOFFs provide the essential foundation for establishing clinical breakpoints. As stated by EUCAST, "it would be difficult to define the abnormal (resistance by breakpoints) without first having agreed on the normal" [1]. Clinical breakpoints are deliberately positioned to avoid splitting wild-type distributions, ensuring better reproducibility of susceptibility categorization [1].

• Resistance Surveillance: ECOFFs offer the most sensitive measure for detecting resistance development in a bacterial population [1]. They enable consistent resistance monitoring across different breakpoint systems, temporal changes in breakpoints, and variations between human and veterinary breakpoints [1].

• Technical Validation: ECOFFs serve as international references for calibrating antimicrobial susceptibility testing methods. Laboratories can compare their wild-type distributions with EUCAST reference distributions, with modal values expected to align within one twofold dilution [5].

Diagram 2: Relationship Between MIC Distributions, ECOFF, and Clinical Breakpoints - This diagram illustrates how MIC distributions form the foundation for both ECOFFs and clinical breakpoints, which then serve distinct but complementary applications in microbiology and clinical practice.

Research Applications and Experimental Data

Resistance Mechanism Identification

ECOFF-based analysis has demonstrated superior performance in identifying specific resistance mechanisms compared to clinical breakpoint-based interpretation:

• Aminoglycoside Resistance in E. coli: A 2019 study developed the Aminoglycoside Resistance Mechanism Inference Algorithm (ARMIA) based on ECOFFs rather than clinical breakpoints. The ECOFF-based approach showed 96.3% congruence with whole genome sequencing data for identifying resistance mechanisms, compared to 85.6% with EUCAST clinical breakpoints [8]. ARMIA reduced very major errors from 12.9% to 0.4%, demonstrating ECOFFs' enhanced accuracy in detecting resistance mechanisms that may affect therapeutic efficacy despite minimal MIC elevation [8].

• Detecting Emerging Resistance: ECOFFs provide the earliest possible indication of resistance development in bacterial populations, often identifying resistance mechanisms before they reach clinical significance [1]. This early detection capability is invaluable for antimicrobial stewardship programs and public health surveillance.

Technical Standardization and Quality Control

ECOFFs serve as essential references for methodological standardization across laboratory networks:

• Method Calibration: Laboratories can validate their AST methods by comparing their wild-type MIC distributions with EUCAST reference distributions. Significant deviations (modal values differing by ≥2 twofold dilutions) indicate methodological issues, inadequate materials, or non-standardized methods [5].

• Data Quality Assessment: The EUCAST curation process excludes approximately 10-20% of submitted distributions, most commonly due to "lower end truncation" where the dilution series fails to adequately capture the complete wild-type distribution [5]. This rigorous quality control ensures the reliability of reference ECOFFs.

Table 3: Experimental Data Supporting ECOFF Applications in Resistance Mechanism Identification

Study Focus	Methodology	Key Findings	Implications
Aminoglycoside Resistance in E. coli [8]	Comparison of ECOFF-based (ARMIA) vs. clinical breakpoint-based interpretation against WGS	ECOFF-based: 96.3% congruence with WGSBreakpoint-based: 85.6% congruence with WGS	ECOFFs more accurately identify biochemical resistance mechanisms
Error Rate Analysis [8]	Very major error (vME) calculation comparing methods	ECOFF-based: 0.4% vMEBreakpoint-based: 12.9% vME	ECOFFs minimize false susceptibility categorization
Multicenter Method Validation [5]	Comparison of wild-type distributions across laboratories	>80% of laboratories within one twofold dilution of reference mode	ECOFFs enable effective interlaboratory standardization

Essential Research Toolkit for ECOFF Studies

Standardized Reagents and Methodologies

Researchers conducting ECOFF-related investigations require specific materials and methodologies to ensure data compatibility with international reference systems:

• Reference Strains: Appropriate ATCC control strains must be included for quality assurance, such as E. coli ATCC 25922, S. aureus ATCC 29213, P. aeruginosa ATCC 27853, and S. pneumoniae ATCC 49619, selected based on the bacterial group and antimicrobial agent tested [6].

• Culture Media: Mueller-Hinton medium forms the foundation for both broth and agar dilution methods, with specific supplements for fastidious organisms—MH-F broth with defibrinated horse blood and β-NAD for streptococci, and lysed horse blood with hemin and Vitamin K for anaerobes [6].

• Antibiotic Preparation: Standardized solvent and diluent systems are required for antibiotic stock solutions. While most β-lactams use water, specific antibiotics require specialized solvents—macrolides and chloramphenicol need alcohol, while rifampicin requires dimethyl sulfoxide [6].

• Reference Methodologies: Broth microdilution following ISO standard 20776-1 represents the reference method, with agar dilution specified for certain antibiotics like fosfomycin and mecillinam [6].

Researchers can actively contribute to the expanding ECOFF knowledge base through these mechanisms:

• Data Submission: EUCAST provides Excel template files for standardized MIC and zone diameter distribution submissions, which are curated by designated experts before inclusion in the aggregated database [5].

• Statistical Tools: While EUCAST does not specify particular statistical software, the ECOFF determination process follows standardized procedures outlined in EUCAST SOP 10.2, which details the analytical approach for wild-type distribution characterization [1] [7].

• Database Access: The EUCAST MIC and zone diameter distribution database (http://mic.eucast.org) serves as the primary resource for reference distributions and established ECOFF values, regularly updated with new data [5] [1].

ECOFFs provide an essential foundation for antimicrobial resistance surveillance and methodological standardization in microbiology. By defining the highest MIC value for organisms without detectable resistance mechanisms, ECOFFs establish a phenotypic baseline that distinguishes wild-type from non-wild-type populations independent of clinical considerations. The rigorous methodological requirements for ECOFF determination—including standardized reference methods, appropriate dilution schemes, and multi-source data aggregation—ensure robust, reproducible values that transcend geographical and temporal boundaries.

While ECOFFs and clinical breakpoints serve distinct purposes, their complementary relationship strengthens the overall framework of antimicrobial susceptibility testing. ECOFFs enable sensitive detection of resistance emergence and provide critical reference points for technical standardization, while clinical breakpoints translate these findings into therapeutic guidance. For researchers and drug development professionals, understanding ECOFF principles and applications is crucial for advancing antimicrobial resistance research, developing accurate diagnostic tools, and informing stewardship strategies in an era of escalating antimicrobial resistance challenges.

In the critical field of antimicrobial susceptibility testing (AST), two distinct types of interpretive criteria are essential for different purposes: Epidemiological Cut-Off Values (ECOFFs) and Clinical Breakpoints. While both utilize minimum inhibitory concentration (MIC) or zone diameter measurements, their underlying philosophies and applications diverge significantly. ECOFFs are microbiological tools designed to detect any phenotypically reduced susceptibility in a bacterial population, serving surveillance and research needs. In contrast, clinical breakpoints are patient-care tools that integrate pharmacological and clinical data to predict treatment success, guiding therapeutic decisions [9] [4] [1].

Understanding this distinction is fundamental to appropriate data interpretation, particularly in research contexts focused on validating intrinsic resistance or detecting emerging resistance mechanisms. Misapplication of these standards can lead to profoundly different conclusions about resistance prevalence and clinical relevance, as evidenced by studies showing significantly higher resistance estimates when using ECOFFs compared to clinical breakpoints for certain drug-bug combinations [9].

Conceptual Comparison: Core Definitions and Applications

Table 1: Fundamental Characteristics of ECOFFs and Clinical Breakpoints

Feature	Epidemiological Cut-Off Values (ECOFFs)	Clinical Breakpoints
Primary Purpose	Detect non-wild type populations with acquired resistance mechanisms [1]	Predict likelihood of clinical treatment success [10]
Basis for Setting	Microbiological data (MIC distributions of wild-type isolates) [5] [1]	Integration of MIC data, PK/PD parameters, and clinical outcomes [11]
Interpretive Categories	Wild-type (WT) vs. Non-wild-type (NWT) [1]	Susceptible (S), Intermediate (I), Resistant (R) [10]
Dependence on Dosing	No (insensitive to pharmacokinetics) [4]	Yes (highly dependent on dosing regimen) [11]
Regulatory Bodies	EUCAST, CLSI [1]	FDA, CLSI, EUCAST [11]
Key Application	Antimicrobial resistance surveillance & research [5]	Guiding individual patient therapy [10]

The Role of ECOFFs in Research and Surveillance

ECOFFs serve as a microbiological benchmark to distinguish bacteria without phenotypically detectable acquired resistance mechanisms (wild-type) from those that have developed such mechanisms (non-wild-type) [1]. The EUCAST definition states: "For a given microbial species and antimicrobial agent, the epidemiological cut-off value (ECOFF) is the highest MIC for organisms devoid of phenotypically detectable, acquired resistance mechanisms" [1]. This makes ECOFFs exceptionally sensitive for detecting minor changes in susceptibility within bacterial populations, which is invaluable for:

• Antimicrobial Resistance (AMR) Surveillance: Tracking the emergence and spread of resistant clones independently of clinical dosing considerations [5].
• Research Studies: Particularly those in animal health, environmental microbiology, and low-income settings where clinical breakpoints may be less applicable [9].
• Method Calibration: Serving as an international reference for calibrating antimicrobial susceptibility testing methods [5].

The Role of Clinical Breakpoints in Therapeutic Decision-Making

Clinical breakpoints translate laboratory measurements into predictive categories for therapeutic outcomes. They answer the fundamental clinical question: "Is this antibiotic likely to work for this patient's infection?" [10] Establishing clinical breakpoints requires integrating three key data types:

• Microbiological Data: MIC distributions of target pathogens [11].
• Pharmacokinetic/Pharmacodynamic (PK/PD) Data: How the drug behaves in the human body (absorption, distribution, metabolism, excretion) and its relationship to antimicrobial effect [11].
• Clinical Outcome Data: Correlation between MIC values and patient treatment success or failure [11].

This integration explains why clinical breakpoints may change over time with new dosing information, emerging resistance patterns, or additional clinical evidence [10] [11].

Methodological Approaches and Experimental Protocols

Determining ECOFFs: Statistical Analysis of Wild-Type Distributions

The establishment of ECOFFs relies on analyzing wild-type MIC distributions collected from multiple international sources. The process involves:

• Data Collection: Aggregating MIC distributions from thousands of isolates worldwide, using reference methods or methods calibrated to them [5] [1].
• Distribution Analysis: Wild-type MICs for a single species/agent combination follow a log-normal distribution due to technical assay variation and biological variation [1].
• ECOFF Setting: The ECOFF is positioned at the upper end of the wild-type distribution, typically set to encompass 99% of the wild-type population [1]. EUCAST requires at least five independent distributions from different sources before setting an ECOFF to ensure representativeness [1].

Figure 1: ECOFF Determination Workflow. The process emphasizes microbiological data aggregation and statistical analysis to define the wild-type population boundary.

Establishing Clinical Breakpoints: Integrating Multidisciplinary Evidence

Setting clinical breakpoints involves a more complex, multidisciplinary approach that synthesizes diverse data sources:

• PK/PD Modeling: Using Monte Carlo simulations to predict the likelihood of achieving target drug exposures at different MIC values across a patient population [11].
• Clinical Correlation: Analyzing outcomes from registrational clinical trials and post-marketing surveillance, though these data are often limited for resistant isolates [11].
• Breakpoint Avoidance: EUCAST explicitly avoids setting clinical breakpoints that split the wild-type distribution to ensure better reproducibility and because no differences in clinical outcomes have been demonstrated for isolates with different MICs within the wild-type distribution [1].

Figure 2: Clinical Breakpoint Setting Process. This integrative approach combines microbiological, pharmacological, and clinical evidence to define therapeutic categories.

Comparative Analysis: Experimental Evidence and Data Interpretation

Quantitative Comparisons in Research Settings

A 2023 study provides compelling experimental evidence of how breakpoint selection dramatically influences resistance interpretation. The research compared AMR prevalence in Escherichia coli poultry isolates using CLSI breakpoints, EUCAST ECOFFs, and Normalized Resistance Interpretation (NRI) breakpoints [9].

Table 2: Comparative AMR Prevalence (%) in E. coli Using Different Breakpoints [9]

Antimicrobial Agent	CLSI Breakpoints	EUCAST ECOFFs	NRI Breakpoints
Ceftazidime (CEF)	1.7%	45.8%	1.7%
Imipenem (IMI)	3.4%	35.6%	4.0%
Ciprofloxacin (CIPRO)	32.2%	64.4%	18.6%
Tetracycline (TET)	67.8%	67.8%	69.5%

The data reveals striking disparities, particularly for ceftazidime and imipenem, where ECOFFs detected resistance rates 27-fold and 10-fold higher than CLSI breakpoints, respectively. These differences stem from ECOFFs' sensitivity to minor decreases in susceptibility that may not yet translate to clinical resistance but signal emerging resistance mechanisms [9]. For tetracycline, where resistance is widespread and well-established, all methods showed general agreement.

The Evolving Concept of "Expected Resistant Phenotypes"

EUCAST has recently abandoned the term "intrinsic resistance" in favor of "expected resistant phenotype" to describe species-drug combinations where ≥90% of isolates are resistant, and "expected susceptible phenotype" where wild-type isolates are susceptible and ≥99% lack acquired resistance [12]. This conceptual shift acknowledges that susceptibility is exposure-dependent and may change with new dosing strategies, while providing clear guidance that susceptibility testing is unnecessary for these predictable phenotypes [12].

Table 3: Essential Research Materials for Breakpoint Studies

Resource	Function & Application	Source
EUCAST MIC Database	Reference wild-type distributions & ECOFFs for method calibration [5]	https://www.eucast.org/micandzonedistributionsand_ecoffs
Breakpoint Implementation Toolkit (BIT)	Templates & protocols for verification/validation studies [13]	CLSI/APHL/ASM/CAP/CDC Collaboration
CDC/FDA AR Bank Isolates	Quality-controlled strains for breakpoint validation studies [13]	CDC & FDA Antibiotic Resistance Isolate Bank
Reference Broth Microdilution	Gold standard method for MIC determination according to ISO 20776-1 [1]	Commercial manufacturers
EUCAST Disk Diffusion	Standardized method for zone diameter determinations [5]	Commercial manufacturers

Implementation Frameworks for Clinical Laboratories

For researchers transitioning discoveries to clinical applications, understanding implementation pathways is crucial. Regulatory requirements now mandate that clinical laboratories update AST breakpoints within three years of publication by standards organizations [10]. The Breakpoint Implementation Toolkit provides a structured framework for:

• Verification: Demonstrating that performance matches manufacturer claims for FDA-cleared breakpoints [10].
• Validation: More extensive evaluation required for off-label use of breakpoints not cleared for specific devices [10].
• Documentation: Maintaining comprehensive records of breakpoints in use and update studies for accreditation purposes [13].

The distinction between ECOFFs and clinical breakpoints is not merely semantic but fundamental to their appropriate application in research and clinical practice. ECOFFs provide the sensitive detection capability needed for surveillance and early warning of emerging resistance, acting as a microbiological radar system. Clinical breakpoints synthesize complex pharmacological and clinical evidence to guide therapeutic decisions at the patient bedside.

For researchers validating intrinsic resistance patterns or monitoring resistance evolution, ECOFFs offer the precision necessary to detect subtle population shifts. However, translating these findings to clinical relevance requires understanding how they correlate with pharmacological parameters and treatment outcomes. As antimicrobial resistance continues to evolve, the strategic application of both interpretive frameworks will be essential for preserving the efficacy of existing agents and guiding the development of new therapeutic approaches.

The Critical Role of Wild-Type MIC Distributions in Antimicrobial Surveillance

In the critical field of antimicrobial surveillance, the wild-type Minimum Inhibitory Concentration (MIC) distribution serves as the fundamental reference point for distinguishing normal microbial susceptibility from acquired resistance. Conceptually, the wild-type distribution represents the range of MIC values for microorganisms of a particular species that lack phenotypically detectable, acquired resistance mechanisms to a specific antimicrobial agent [1]. These distributions are not single values but rather follow a log-normal pattern, forming a unimodal curve that captures both biological variation and technical assay variability [1].

The Epidemiological Cut-off Value (ECOFF) defines the upper boundary of this wild-type population—the highest MIC value at which organisms without phenotypically detectable resistance mechanisms are still found [1] [5]. Unlike clinical breakpoints, which incorporate pharmacological and clinical outcome data to categorize isolates as susceptible, intermediate, or resistant, ECOFFs are determined purely based on microbiological data [4]. This makes them invaluable tools for surveillance and resistance detection, providing the most sensitive measure for identifying emerging resistance in bacterial and fungal populations [1].

Table 1: Key Definitions in Wild-Type MIC Analysis

Term	Definition	Primary Application
Wild-Type MIC Distribution	The log-normal distribution of MIC values for a microorganism species devoid of phenotypically detectable acquired resistance mechanisms [1]	Reference for normal susceptibility patterns; foundation for ECOFF setting
ECOFF (Epidemiological Cut-off Value)	The highest MIC for organisms devoid of phenotypically detectable acquired resistance mechanisms; defines upper end of wild-type distribution [1]	Distinguishing wild-type from non-wild-type populations; resistance surveillance
Non-Wild-Type	Microorganisms with MIC values above the ECOFF, indicating presence of acquired resistance mechanisms [1]	Identification of resistant isolates
Clinical Breakpoint	Pre-determined MIC or zone diameter values categorizing isolates as Susceptible, Intermediate, or Resistant based on clinical outcome data [10]	Guiding clinical treatment decisions
TECOFF (Tentative ECOFF)	Preliminary ECOFF based on 3-4 distributions, requiring further validation [5]	Early-stage analysis when limited data available

Methodological Framework: ECOFF Determination and Analysis

Standardized Protocols for MIC Distribution Collection

The determination of reliable wild-type MIC distributions requires strict methodological standardization. According to EUCAST protocols, MIC values must be determined using methods calibrated to the reference broth microdilution method (ISO 20776-1) [1] [5]. The testing involves traditional twofold dilution series (e.g., 0.125, 0.25, 0.5, 1, 2, 4, 8 mg/L), with any values between these standard concentrations rounded up to the next dilution [1]. A critical requirement is that the dilution series must encompass the entire putative wild-type range without truncation at either end, as truncated distributions distort analysis and are excluded from ECOFF determination [1] [5].

The EUCAST database, which contains over 40,000 MIC distributions from worldwide sources, requires contributions from at least five different independent sources to establish a definitive ECOFF [1] [5] [14]. This multi-source approach ensures that the aggregated distributions encompass the natural variation between investigators, laboratories, geographic locations, and time periods, enhancing the representativeness and utility of the resulting ECOFF [5]. The data curation process typically excludes 10-20% of submitted distributions, most commonly due to lower-end truncation within the wild-type range [5].

Statistical Analysis and ECOFF Setting

The process of defining ECOFFs involves identifying the point at which the wild-type distribution ends and non-wild-type populations begin. Both EUCAST and CLSI have established methodologies for this analysis, with similarities but important distinctions [1]. The EUCAST approach, codified in Standard Operating Procedure 10.2, is more prescriptive in its analytical methods compared to the CLSI standards outlined in documents M23 and M57 [1].

The fundamental principle is that the wild-type distribution appears as a monomodal, log-normal curve, while the presence of resistance mechanisms creates additional modes (non-wild-type populations) [1]. Despite this complexity, statistical methods can typically identify the wild-type component, allowing for establishment of the ECOFF at the upper end of this distribution [1]. This process requires precise identification of isolates to the species level and careful curation of data to ensure only quality-controlled results inform the final cut-off values [1].

Comparative Analysis: EUCAST vs. CLSI Approaches

Organizational Methodologies for ECOFF Development

While both major standards organizations recognize the importance of wild-type distributions and epidemiological cut-offs, their approaches exhibit notable differences. EUCAST and CLSI definitions, while similar, are not identical, reflecting variations in philosophical approach and methodological rigor [1]. The EUCAST methodology places greater emphasis on data aggregation from multiple sources and strict calibration to reference methods [1] [14].

Table 2: Comparison of EUCAST and CLSI ECOFF Determination Methods

Feature	EUCAST Approach	CLSI Approach	Implications
Isolate Identification	To species level (or species complex if indistinguishable by MALDI-TOF) [1]	To species level only [1]	EUCAST allows for more practical grouping of closely related species
Testing Methods	ISO 20776-1 and methods calibrated to it (including CLSI M7) [1]	CLSI-specific standards (M7, M11, M27, etc.) [1]	EUCAST incorporates broader methodological standardization
Dilution Series	Strict twofold dilution series based on 0.5, 1, 2, 4, etc. [1]	Not strictly specified but generally defaults to standard twofold series [1]	EUCAST provides more explicit guidance on dilution preparation
Mycobacterium tuberculosis	Includes reference method for MIC distributions [1]	No reference method for generating MIC distributions [1]	EUCAST offers more comprehensive pathogen coverage
Data Aggregation	Requires minimum 5 independent distributions for definitive ECOFF [1] [5]	Not explicitly specified in available documentation	EUCAST emphasizes multi-source validation

Applications in Antimicrobial Resistance Surveillance

Wild-type MIC distributions and ECOFFs serve critical functions in antimicrobial resistance monitoring that extend beyond clinical breakpoint applications. They provide the most sensitive indicator of emerging resistance in microbial populations, often detecting resistance development before clinical breakpoints are exceeded [1]. This early warning function makes ECOFFs invaluable for public health surveillance and antimicrobial stewardship programs.

A key application lies in enabling cross-system comparisons of resistance data between systems employing different clinical breakpoints, breakpoints that evolve over time, and divergent breakpoints between human and veterinary medicine [1]. This comparability is particularly valuable for global surveillance programs like the Study for Monitoring Antimicrobial Resistance Trends (SMART), which has collected nearly 500,000 isolates from over 60 countries during its 20-year history [15]. Furthermore, ECOFFs provide reference ranges for quality control and method calibration, allowing laboratories to verify that their susceptibility testing methods produce wild-type distributions consistent with international standards [5].

Experimental Data and Research Applications

Research Reagent Solutions for MIC Determination

The experimental determination of wild-type MIC distributions requires specific reagents and methodological controls to ensure reproducible, reliable results. The following table details essential materials and their functions in susceptibility testing protocols.

Table 3: Essential Research Reagents for MIC Distribution Studies

Reagent/Material	Specification	Function/Application	Quality Control
Broth Microdilution Panels	ISO 20776-1 compliant [1]	Standardized MIC determination in twofold dilution series	Verify cation content and pH meet specifications
Culture Media	Mueller-Hinton broth with standardized cation concentrations [1]	Supports reproducible bacterial growth for MIC testing	Check performance with quality control strains
Antimicrobial Agents	Reference powder with known potency [1]	Preparation of accurate antimicrobial dilutions	Verify potency and purity through validation testing
Quality Control Strains	EUCAST/CLSI recommended reference strains [16]	Monitoring assay performance and reproducibility	Regular testing to ensure within expected MIC ranges
Inoculum Preparation	0.5 McFarland standard [1]	Standardized bacterial density for consistent results	Verify density using spectrophotometry
Disk Diffusion Materials	EUCAST-approved disks if using disk diffusion [5]	Zone diameter measurements for alternative method	Regular calibration against reference method

Case Study: Establishing ECOFFs for Veterinary Pathogens

Recent research demonstrates the practical application of wild-type distribution analysis in addressing significant gaps in veterinary antimicrobial susceptibility testing. A 2025 study focused on establishing ECOFFs for sulfonamides and trimethoprim in veterinary pathogens highlighted both the process and challenges of this work [16]. The researchers performed broth microdilution according to EUCAST recommendations, testing pathogens including Escherichia coli, Staphylococcus pseudintermedius, and Streptococcus suis against trimethoprim-sulfamethoxazole combination and individual agents [16].

The study successfully generated MIC distributions that met EUCAST criteria for trimethoprim-sulfamethoxazole, sulfamethoxazole, and trimethoprim alone, enabling the proposal of presumptive ECOFFs for these agent-pathogen combinations [16]. However, for sulfadiazine and sulfadimethoxine, the tested concentration ranges (>256 mg/L) proved insufficient for ECOFF estimation, demonstrating the importance of appropriate concentration range selection in experimental design [16]. This research will form the foundation for an inter-laboratory study to generate aggregated MIC data for submission to EUCAST, ultimately supporting the appropriate use of these first-line veterinary antibiotics [16].

Critical Considerations and Future Directions

Common Misconceptions and Limitations

Several important misconceptions surround wild-type MIC distributions and ECOFFs that researchers must recognize. A fundamental misunderstanding is the perception of MIC values as absolute biological constants rather than relative measurements significantly influenced by methodological variations [1]. In reality, MIC values demonstrate considerable technical variation, with even optimally standardized conditions producing results that typically vary by one twofold dilution step in either direction [1].

Another significant limitation concerns the appropriate use of EUCAST distribution data. The database explicitly states that these distributions cannot be used to compare resistance rates among agents, over time, or across geographic locations because different studies intentionally include varying proportions of resistant organisms [5]. Additionally, while ECOFFs excel at distinguishing wild-type from non-wild-type populations, they provide no direct information on clinical outcomes, as they deliberately exclude pharmacological and clinical data that inform clinical breakpoints [1] [4].

The Impact of Breakpoint Revisions on Resistance Surveillance

A emerging challenge in antimicrobial resistance monitoring is "breakpoint drift"—the phenomenon whereby revisions to clinical breakpoints independently affect reported resistance rates without any biological change in microbial populations [17]. Research has demonstrated that applying updated CLSI and EUCAST breakpoints to historical isolate collections can substantially increase reported resistance rates solely due to changes in interpretive criteria [17]. This creates significant challenges for longitudinal surveillance, as apparent increases in AMR may reflect evolving diagnostic conventions rather than genuine microbial evolution [17].

This phenomenon underscores the value of ECOFFs as stable reference points for resistance surveillance. While clinical breakpoints understandably evolve with new pharmacological and clinical evidence, ECOFFs remain fixed to the wild-type distribution, providing consistent benchmarks for detecting resistance emergence [1] [17]. The establishment of breakpoint epochs with standardized nomenclature (e.g., "S[CLSI2012]" or "R[EUCAST2021]") has been proposed to facilitate accurate longitudinal analysis of resistance trends [17].

Wild-type MIC distributions and their corresponding ECOFFs provide the essential foundation for reliable antimicrobial susceptibility testing and resistance surveillance. By establishing the phenotypic characteristics of microorganisms without acquired resistance mechanisms, they create the reference point against which abnormal resistance can be identified. Their purely microbiological basis makes them uniquely valuable for detecting emerging resistance, calibrating methodology across laboratories and systems, and providing stable benchmarks amid evolving clinical breakpoints.

As antimicrobial resistance continues to pose significant global health challenges, the systematic development and application of ECOFFs remains critical for accurate surveillance, antimicrobial stewardship, and public health response. The ongoing curation of the EUCAST database, which now exceeds 40,000 distributions, and continued research to establish ECOFFs for underrepresented pathogen-drug combinations, will enhance our ability to monitor and respond to the evolving threat of antimicrobial resistance across human and veterinary medicine.

Intrinsic resistance presents a fundamental challenge in antimicrobial therapy, occurring when an organism's inherent wild-type minimum inhibitory concentration (MIC) exceeds clinically achievable antibiotic levels. This review explores the critical role of epidemiological cut-off values (ECOFFs) in delineating wild-type susceptibility distributions from non-wild-type populations with acquired resistance mechanisms. We examine experimental approaches for characterizing intrinsic resistance pathways, comparative resistance profiles across environments, and methodological frameworks for ECOFF determination. By integrating data from clinical surveillance, environmental monitoring, and genetic screening studies, this analysis provides researchers with standardized protocols and conceptual models for validating intrinsic resistance breakpoints and advancing ECOFF research.

The conceptual foundation of intrinsic resistance rests upon understanding wild-type minimum inhibitory concentration (MIC) distributions and their relationship to clinically achievable drug levels. The wild-type MIC distribution encompasses strains of a microorganism devoid of phenotypically detectable, acquired resistance mechanisms to a specific antimicrobial agent [1]. These distributions characteristically follow a log-normal pattern that is remarkably consistent across geographical origins, time periods, and isolation sources for a given species-agent combination [1]. The epidemiological cut-off value (ECOFF) defines the upper limit of this wild-type population, representing the highest MIC for organisms without acquired resistance mechanisms [1].

When the ECOFF—the upper boundary of the wild-type population—exceeds concentrations safely achievable in human tissues during therapy, the organism is considered intrinsically resistant to that antimicrobial agent [18]. This phenomenon distinguishes intrinsic resistance from acquired resistance, as it represents a universal characteristic of a bacterial species rather than a trait emerging in specific isolates through mutation or horizontal gene transfer. The clinical breakpoints used to define susceptibility categories (S/I/R) are conceptually distinct from ECOFFs, though ideally placed to avoid splitting wild-type distributions to ensure reproducible categorization and because different clinical outcomes have not been demonstrated for isolates with varying MICs within the wild-type range [1].

Table 1: Key Definitions in Wild-Type MIC and ECOFF Characterization

Term	Definition	Primary Application
Wild-type MIC	MIC values for organisms lacking phenotypically detectable acquired resistance mechanisms	Reference for species-specific natural susceptibility
ECOFF/ECV	The highest MIC of the wild-type distribution; separates wild-type from non-wild-type	Ecological resistance detection; sensitive measure of resistance development
Clinical Breakpoint	MIC threshold determining likelihood of treatment success (S/I/R)	Clinical decision making for antibiotic therapy
Intrinsic Resistance	Innate, chromosomally-encoded resistance independent of horizontal gene transfer	Understanding species-specific antibiotic spectra
Intrinsic Resistome	All chromosomal elements contributing to intrinsic resistance, including efflux pumps, permeability barriers, and metabolic functions	Identification of novel targets for antibiotic adjuvants

Experimental Approaches to Characterizing Intrinsic Resistance Mechanisms

Genome-Wide Screening for Intrinsic Resistance Determinants

Advanced genetic screening techniques have enabled systematic identification of genes comprising the "intrinsic resistome"—chromosomal elements that contribute to antibiotic resistance independent of horizontal gene transfer [18]. Genome-wide screens using the Keio collection of E. coli knockouts (approximately 3,800 single-gene deletions) have identified numerous hypersensitive mutants that illuminate pathways governing intrinsic resistance [19] [20]. These screens typically involve growing knockout libraries in media supplemented with antibiotics at IC50 values or without antibiotics (control), with optical density measurements used to identify hypersensitive strains showing significantly impaired growth specifically in antibiotic-containing media [19].

Key findings from these systematic approaches reveal that intrinsic resistance is an emergent property conferred by diverse cellular systems beyond classical resistance elements. Functional categorization of hypersensitivity hits shows enrichment in several core cellular processes [19]:

• Cell envelope biogenesis (rfaG, lpxM affecting LPS biosynthesis)
• Membrane transport (acrB encoding efflux pump components)
• Information transfer pathways
• Metabolic functions (nudB in folate metabolism)

Notably, while some hypersensitive mutants are antibiotic-specific, others confer hypersensitivity to multiple chemically distinct antibiotics, indicating their role as general intrinsic resistance determinants [19].

Experimental Validation of Resistance Determinants

Hypersensitivity candidates identified through primary screening require rigorous validation through targeted genetic and phenotypic analyses. Confirmation experiments typically include [19]:

• Growth assays on solid media supplemented with graded antibiotic concentrations (MIC, MIC/3, MIC/9)
• Construction of clean deletions in defined genetic backgrounds (e.g., E. coli K-12 MG1655)
• Susceptibility profiling across multiple antibiotic classes
• Experimental evolution under antibiotic pressure to assess resistance development

Studies validating acrB (efflux pump), rfaG (LPS biosynthesis), and lpxM (lipid A modification) knockouts demonstrate these intrinsic resistance determinants can sensitize otherwise resistant E. coli strains to antibiotics, with ΔacrB showing particular promise for "resistance proofing" due to severely compromised evolution of resistance [19].

Comparative Resistance Profiling Across Environments and Ecosystems

Surveillance studies examining Escherichia coli resistance patterns across diverse environments provide critical insights into the distribution and stability of intrinsic and acquired resistance traits. Comparative analyses reveal striking consistencies in wild-type distributions regardless of isolate origin, supporting the concept that intrinsic resistance mechanisms are conserved within species [1].

Table 2: Comparative Antimicrobial Resistance Patterns in E. coli Across Niches

Source Environment	Key Resistance Findings	Notable Resistance Determinants	Study References
Clinical Isolates (Gaza, Palestine)	Highest resistance to ampicillin (90.3%), co-amoxiclav (78.7%); lowest to colistin (6.3%), meropenem (9.9%)	ESBL phenotypes prevalent; resistance varies by specimen type (sputum > urine)	[21]
Austrian Rivers (Mur/Drava)	25.85% (Mur) and 23.66% (Drava) resistance to ≥1 antibiotic; highest to ampicillin, amoxicillin-clavulanic acid, tetracycline	ESBL genes identified; KPC-2 carbapenemase in one isolate	[22]
Pristine vs Human-Impacted Rivers (Japan)	18% (upstream) vs 20% (downstream) resistance to ≥1 drug; seasonal variation (higher in summer)	Resistance profiles changed between upstream/downstream sites, suggesting gene transfer/loss	[23]
Patient vs Environmental Isolates (Austria)	Patient isolates significantly higher resistance than environmental; biofilms showed higher resistance than open water	ESBL-producers in biofilms but not open water; last-line antibiotic resistances rare in both	[24]

Environmental comparative studies yield several fundamental observations regarding intrinsic resistance patterns. First, wild-type distributions remain consistent regardless of isolation source, supporting their use as species-specific references [1]. Second, biofilm communities may serve as reservoirs for resistant strains, with sediment isolates sometimes showing different resistance profiles than open water isolates from the same river [22] [24]. Third, seasonal variations in resistance rates observed in pristine environments suggest complex ecological dynamics beyond direct anthropogenic pressure [23].

Methodological Framework for ECOFF Determination

Standardized Protocols for MIC Distribution Analysis

Robust ECOFF determination requires strict methodological standardization and appropriate statistical analysis of MIC distributions. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) have established standardized approaches with key common requirements [1]:

• Species-level identification of isolates
• Twofold dilution series (0.125, 0.25, 0.5, 1, 2, 4, 8 mg/L, etc.)
• Reference methodology following ISO 20776-1 or calibrated equivalents
• Comprehensive dilution series encompassing entire putative wild-type range
• Multiple independent data sources (minimum five for EUCAST)

MIC values obtained between standard twofold dilutions should be rounded up to the next dilution to maintain consistency across datasets [1]. This standardization is critical given the inherent variability of MIC measurements, which typically show ±1 twofold dilution variation even under optimal conditions due to technical and biological variation [1].

Statistical Characterization of Wild-Type Distributions

Statistical analysis of wild-type MIC distributions presents unique challenges due to the categorical nature of twofold dilution data. The log-normal distribution provides the best fit for wild-type MIC distributions when properly modeled [25]. Advanced statistical approaches include:

• Non-linear least squares regression fitting cumulative counts to cumulative log-normal distributions
• Parameter estimation for subset size, mean (log2), and standard deviation (log2)
• Wild-type range determination using MICs corresponding to lower and upper 0.1% of distribution
• Rounding to nearest twofold dilution and calculating probabilities of values beyond these limits

This approach successfully captures ≥98.5% of wild-type MIC values within the calculated range when applied to antibiotic-bacterium datasets [25]. The EUCAST method is particularly prescriptive in analysis parameters, while CLSI provides more general guidance [1].

Visualization of Key Concepts and Workflows

ECOFF and Intrinsic Resistance Determination - This diagram illustrates the workflow for determining intrinsic resistance by comparing ECOFF values with clinically achievable drug concentrations.

The Researcher's Toolkit: Essential Reagents and Methodologies

Table 3: Essential Research Tools for Intrinsic Resistance and ECOFF Studies

Tool/Reagent	Specifications	Research Application	Example Use
Keio E. coli Knockout Collection	~3,800 single-gene deletion mutants	Genome-wide intrinsic resistome screening	Identification of hypersensitive mutants [19]
Reference Broth Microdilution	ISO 20776-1 standard	MIC determination for ECOFF setting	Generation of comparable MIC distributions [1]
Chromogenic Media	CHROMagar ECC, MacConkey agar	Selective isolation and presumptive identification	E. coli isolation from complex samples [23]
Twofold Antibiotic Dilution Series	0.125, 0.25, 0.5, 1, 2, 4, 8 mg/L	Standardized MIC testing	ECOFF distribution generation [1]
Efflux Pump Inhibitors	Chlorpromazine, piperine, verapamil	Validation of efflux-mediated resistance	Adjuvant studies with antibiotics [19] [18]
Statistical Analysis Software	R, SPSS with custom scripts	ECOFF calculation and distribution modeling	Log-normal distribution fitting [25]

The determination of intrinsic resistance through ECOFF analysis represents a fundamental methodology in antimicrobial resistance research, providing a standardized approach for defining wild-type susceptibility boundaries. The integration of genetic screening, comparative resistance profiling, and statistical modeling of MIC distributions enables robust characterization of intrinsic resistance mechanisms that transcend geographic and temporal boundaries. Future research directions should focus on expanding ECOFF datasets for underrepresented species-antibiotic combinations, developing high-throughput methods for intrinsic resistome screening, and exploring the potential of intrinsic resistance pathways as targets for antibiotic adjuvants. As the antimicrobial resistance crisis intensifies, precise understanding of intrinsic resistance mechanisms will play an increasingly critical role in antibiotic discovery, stewardship, and clinical practice.

Epidemiological Cut-Off Values (ECOFFs or ECVs) represent a fundamental concept in antimicrobial susceptibility testing (AST), providing a critical threshold that separates microbial populations into those with and without acquired resistance mechanisms based on their phenotypes. The wild-type (WT) distribution comprises organisms devoid of phenotypically detectable, acquired resistance mechanisms, while the non-wild-type (NWT) population includes isolates with reduced susceptibility due to resistance mechanisms. Both the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) have developed standardized approaches to define these values, though their methodologies and applications exhibit important distinctions. ECOFFs provide the most sensitive measure of resistance development in a species against an agent and serve as an essential first step in establishing clinical breakpoints [1] [7].

The core definition shared by both organizations identifies the ECOFF as the highest minimum inhibitory concentration (MIC) for organisms lacking phenotypically detectable resistance mechanisms. EUCAST specifically defines it as "the highest MIC for organisms devoid of phenotypically detectable, acquired resistance mechanisms," which defines the upper end of the wild-type MIC distribution [1]. CLSI offers a similar but distinct definition: "the minimal inhibitory concentration (MIC) or zone diameter value that separates microbial populations into those with and without acquired and/or mutational resistance based on their phenotypes" [1]. These nuanced definitional differences reflect variations in conceptual approach and application that will be explored throughout this comparison.

Core Conceptual Differences Between EUCAST and CLSI

Philosophical Approaches and Underlying Principles

EUCAST and CLSI share the common goal of standardizing antimicrobial susceptibility testing, but their philosophical approaches to ECOFF determination reflect different priorities and historical developments. EUCAST systematically characterizes species-specific MIC distributions of isolates lacking phenotypically detectable resistance mechanisms as a reference for discussing and setting clinical breakpoints [1]. This approach is founded on the principle that "it would be difficult to define the abnormal (resistance by breakpoints) without first having agreed on the normal" [1]. The committee actively encourages the scientific community to question MIC distributions and contribute data, fostering a collaborative development process [1].

CLSI incorporates similar microbiological data but places additional emphasis on the practical implementation of standards across diverse laboratory settings. Both organizations recognize that wild-type MIC distributions for a single species with a single antimicrobial agent form a log-normal distribution rather than a single value, resulting from a combination of technical assay variation and biological variation [1]. This shared understanding of the fundamental nature of MIC distributions provides common ground between the two systems despite their methodological differences.

Key Methodological Differences

The methodological distinctions between EUCAST and CLSI approaches to ECOFF determination can be categorized across several key parameters, as summarized in Table 1.

Table 1: Comparison of EUCAST and CLSI ECOFF Methodologies

Feature	EUCAST Approach	CLSI Approach	Significance of Difference
Isolate Identification	To species level (or species complex if indistinguishable by MALDI-TOF) [1]	To species level only [1]	EUCAST offers more flexibility for closely related species
Reference Methods	ISO 20776-1 and calibrated methods; specific antifungal and antimycobacterial reference methods [1]	CLSI M7, M11, M27, M38, M44, M45, M51, and VET05 series [1]	Different reference standards may affect cross-organization comparability
Dilution Series	Strict twofold series (0.5, 1, 2, 4, etc.); intermediate values rounded up [1]	Not strictly specified but generally defaults to standard twofold dilution series [1]	EUCAST provides more specific guidance on series preparation
Data Aggregation	Requires at least five contributions from different sources [1]	Minimum laboratory requirements specified in M23 and M57 [1]	Both emphasize multi-laboratory data for robust ECOFFs
ECOFF Determination	Prescriptive statistical analysis per SOP 10.2 [1]	General principles described in M23 and M57 [1]	EUCAST offers more standardized statistical approach

The differences in methodology reflect each organization's operational philosophy. EUCAST employs a more prescriptive approach codified in Standard Operating Procedure SOP 10.2, while CLSI provides general principles in its M23 and M57 standards [1]. This distinction affects the reproducibility and harmonization of ECOFFs across different laboratories and geographic regions.

Experimental Protocols and Data Analysis Methods

ECOFF Determination Workflows

The process of determining ECOFFs follows a systematic workflow in both EUCAST and CLSI systems, though with distinct procedural requirements. The following diagram illustrates the core ECOFF determination process:

The experimental protocols begin with proper species identification, followed by MIC determination using approved reference methods. EUCAST requires strict twofold dilution series based on 0.5, 1, 2, 4, etc., with concentrations between traditional twofold values rounded up to the next twofold value [1]. Both organizations emphasize the importance of dilution series that ideally include all concentrations in the putative wild type, as series truncated within either end of the putative wild type will distort the analysis and must be excluded [1].

Data Aggregation and Quality Requirements

A critical component of ECOFF determination is the aggregation of data from multiple sources to ensure representativeness. EUCAST specifically requires at least five contributions from different sources before defining a wild-type distribution and ECOFF, favoring participation from many investigators and materials to increase general representativeness [1]. This multi-laboratory approach ensures that the resulting ECOFFs incorporate both intra- and inter-laboratory variation, increasing their utility across different settings [1].

Data quality assessment involves careful review of individual distributions against established criteria. Distributions must be assessed for modal characteristics, with wild-type distributions typically appearing monomodal in the absence of resistance mechanisms [1]. In the presence of phenotypically detectable resistance, the distribution will have at least one more mode (non-wild-type), but despite this, the wild-type distribution is most often identifiable using the same methods [1]. This ability to identify wild-type populations even in mixed distributions is essential for surveillance of emerging resistance.

Comparative Performance Data

Agreement Studies Between EUCAST and CLSI

Several studies have directly compared the performance and categorical agreement between EUCAST and CLSI breakpoints and ECOFFs. A 2016 study comparing antibiotic susceptibility for 5,165 Escherichia coli, 1,103 Staphylococcus aureus, and 532 Pseudomonas aeruginosa isolates found varying levels of agreement depending on the organism-antibiotic combination [26].

Table 2: Agreement Between EUCAST and CLSI Interpretations for E. coli [26]

Antibiotic	Concordance Rate (%)	Kappa Statistic (κ)	Agreement Level
Ampicillin	99.5	0.985 (0.979, 0.991)	Perfect
Ciprofloxacin	98.4	0.969 (0.963, 0.975)	Almost perfect
Cefuroxime	96.5	0.924 (0.914, 0.934)	Almost perfect
Meropenem	99.8	0.797 (0.771, 0.823)	Substantial
Amoxicillin-Clavulanate	78.2	0.581 (0.567, 0.595)	Moderate
Nitrofurantoin	87.6	0.351 (0.314, 0.388)	Fair
Amikacin	99.6	0.079 (0.053, 0.105)	Poor

For S. aureus, most antibiotics showed perfect to almost perfect agreement, with kappa statistics of 1.0 for penicillin, trimethoprim-sulfamethoxazole, levofloxacin, oxacillin, linezolid, and vancomycin [26]. The high agreement rates for many drug-bug combinations suggest general harmonization between the two systems, while the moderate to poor agreement for others highlights the impact of methodological differences.

Resistance Classification Comparisons

A 2023 study comparing AMR interpretation in E. coli isolates using ECOFFs, CLSI, and Normalized Resistance Interpretation (NRI) breakpoints demonstrated how the choice of breakpoint significantly influences resistance prevalence estimates [9]. As shown in Table 3, ECOFFs typically produced higher resistance estimates compared to CLSI breakpoints, particularly for certain antibiotic classes.

Table 3: Comparison of Resistance Prevalence Using Different Breakpoints in E. coli [9]

Antibiotic	CLSI Breakpoint (% Resistance)	EUCAST ECOFF (% Resistance)	NRI Breakpoint (% Resistance)
Tetracycline	67.8	67.8	69.5
Ciprofloxacin	32.2	64.4	18.6
Imipenem	3.4	35.6	4.0
Ceftazidime	1.7	45.8	1.7

The dramatic differences observed for ciprofloxacin, imipenem, and ceftazidime highlight how methodological approaches to ECOFF determination can significantly impact resistance classification and surveillance data [9]. These differences have important implications for antimicrobial resistance monitoring and reporting across different systems and regions.

Applications in Clinical and Research Settings

Clinical Applications and Breakpoint Setting

ECOFFs play a fundamental role in clinical breakpoint development. When EUCAST determines clinical breakpoints, the committee avoids setting breakpoints that split wild-type distributions of target species [1]. This practice serves two important purposes: it avoids the poorer reproducibility of susceptibility categorization when breakpoints split major populations, and it reflects the finding that different clinical outcomes have not been identified for isolates with different MIC values inside the wild-type distribution [1].

EUCAST has introduced the concept of "breakpoints in brackets" to warn against the use of specific agents without additional therapeutic measures [27]. These breakpoints are essentially ECOFFs that distinguish between isolates with and without acquired resistance, and because they sometimes serve more than a single species, they may represent a "best fit" ECOFF [27]. When uncertainty exists about the validity of a bracketed breakpoint, clinicians and microbiologists are directed to the EUCAST website to find the precise ECOFF for a specific species [27].

Surveillance and Resistance Detection

ECOFFs provide valuable tools for antimicrobial resistance surveillance and the early detection of emerging resistance. In laboratory practice, the ECOFF is used to screen for and exclude resistance, enabling comparisons of resistance between systems with different breakpoints from different organizations, breakpoints evolving over time, and different breakpoints between human and animal medicine [1]. This application is particularly valuable for tracking resistance patterns across geographic regions and temporal trends.

The ability of ECOFFs to detect non-wild-type populations has proven valuable in antifungal susceptibility testing. Studies have demonstrated that Etest fluconazole ECVs can effectively detect Candida non-wild-type isolates, with one study correctly identifying 59 of 61 non-wild-type isolates across 4 of 6 species [28]. This capability for early detection of isolates with reduced susceptibility is crucial for guiding therapy and containing the spread of resistant pathogens.

Laboratory Implementation Toolkit

Implementing proper ECOFF determination requires specific laboratory tools and resources. Both EUCAST and CLSI provide essential platforms for data analysis and interpretation, though their accessibility models differ significantly.

Table 4: Essential Research Tools for ECOFF Determination and Analysis

Tool/Resource	Source	Function	Accessibility
EUCAST MIC Distribution Website	EUCAST [1]	Collection and presentation of MIC distributions as histograms with ECOFFs	Freely available
ECOFF Finder	CLSI [29]	Estimates epidemiological cutoff values for wild-type bacterial or fungal populations	Subscription-based
RangeFinder MIC & Disk	CLSI [29]	Excel spreadsheet calculators for estimating quality control ranges	Subscription-based
EUCAST SOP 10.2	EUCAST [1]	Standardized procedure for ECOFF determination	Freely available
CLSI M23 & M57 Standards	CLSI [1]	Principles and procedures for developing epidemiological cutoff values	Subscription-based

The difference in accessibility between EUCAST (freely available) and CLSI (subscription-based) resources has significant implications for global implementation, particularly in resource-limited settings [26]. This accessibility difference may influence which system is adopted in various regions and laboratories.

Quality Assurance and Validation

Both organizations provide extensive resources for quality assurance and method validation. EUCAST offers calibration and validation graphs related to breakpoint tables, which are regularly updated to include new agents and species [30]. These tools are essential for laboratories to verify their implementation of reference methods and ensure consistent results.

CLSI provides supplementary resources including the QMSGAP Gap Analysis Tool, Method Navigator, and implementation kits designed to support laboratories through verification or validation studies to update breakpoints [29]. These resources help standardize implementation across different laboratory environments and ensure the reliability of susceptibility testing results.

EUCAST and CLSI have developed sophisticated, systematic approaches to ECOFF determination that share common foundations but differ in methodological details, statistical approaches, and implementation requirements. Both systems recognize the wild-type MIC distribution as the fundamental reference point for defining resistance, acknowledging that these distributions are log-normal and remarkably consistent across geographic regions and time periods when appropriate reference methodologies are employed [1].

The comparison reveals that EUCAST's strength lies in its standardized, prescriptive methodology and freely accessible resources, while CLSI offers comprehensive implementation tools within a subscription framework. The choice between systems often depends on regional preferences, resource availability, and specific application requirements. For global antimicrobial resistance surveillance and research, understanding both systems and their harmonization efforts is essential for accurate data interpretation and comparison across different laboratory systems and geographic regions.

Future harmonization efforts should focus on reducing significant discrepancies in resistance classification for specific drug-bug combinations while maintaining each system's strengths. The continued development of freely accessible tools and educational resources will be crucial for supporting global antimicrobial resistance surveillance efforts, particularly in resource-limited settings where the burden of antimicrobial resistance is often highest.

Determining ECOFF Values: Standardized Methods and Practical Applications

Table of Contents

• Introduction
• Species Identification in Antimicrobial Resistance Research
• Two-Fold Dilution Series: The Backbone of MIC Determination
• Comparative Analysis: Methodologies for ECOFF Development
• Essential Research Reagent Solutions
• Conclusion

In the global fight against antimicrobial resistance (AMR), the validation of intrinsic resistance breakpoints and Epidemiological Cut-Off (ECOFF) values represents a critical frontier in public health microbiology. This research relies fundamentally on two cornerstone methodologies: accurate species identification of microbial isolates and precise antimicrobial susceptibility testing (AST), for which the two-fold serial dilution is the internationally recognized standard. ECOFFs differentiate wild-type microbial populations from those with acquired resistance traits by defining the upper limit of the minimum inhibitory concentration (MIC) distribution for a wild-type population [31]. Establishing these values is a prerequisite for defining clinical breakpoints that guide therapeutic decisions [32]. This guide provides a comparative analysis of the essential protocols and emerging alternatives for species identification and dilution-based AST, framing them within the experimental workflow of validating ECOFF values for emerging and challenging pathogens.

Species Identification in Antimicrobial Resistance Research

Accurate species identification is the first critical step in AMR surveillance and ECOFF development. It ensures that MIC data is aggregated and analyzed for a genetically coherent population, which is essential for defining a meaningful wild-type distribution.

Molecular Methods for Species Identification

While phenotypic methods are used, molecular techniques offer superior accuracy, especially for closely related species or poorly preserved samples.

• DNA Barcoding: This method uses a short, standardized genetic marker from a conserved region to identify species. For animals and bacteria, the cytochrome c oxidase subunit I (COI) gene is a common target, whereas for plants, a combination of markers may be necessary due to closer evolutionary relationships [33] [34]. The process involves DNA extraction, PCR amplification of the barcode region, followed by Sanger sequencing and comparison to a reference database [34].
• Non-Human Forensic Genetics (NHFG) Workflow: This broader framework encompasses the collection, analysis, and interpretation of non-human biological evidence. The molecular analysis phase for species identification typically involves DNA extraction, PCR amplification, and sequencing of variable genomic regions, followed by bioinformatic alignment and comparison with reference databases [33].

The workflow for molecular species identification, from sample collection to data interpretation, can be visualized as follows:

Figure 1: A generalized workflow for molecular species identification, highlighting the three major working areas: pre-analytics, analytics, and post-analytics [33].

Two-Fold Dilution Series: The Backbone of MIC Determination

The two-fold serial dilution is the definitive method for determining the Minimum Inhibitory Concentration (MIC), the quantitative value used to establish ECOFFs and clinical breakpoints.

Protocol for Two-Fold Serial Dilution in Broth Microdilution

The following step-by-step protocol is adapted from standardized methods used in AST [35] [36].

• Diluent Preparation: Select an appropriate diluent, typically Cation-Adjusted Mueller Hinton Broth (CAMHB) for most aerobic bacteria [37]. Dispense a precise volume (e.g., 50 µL) into all wells of a microtiter plate except the first.
• First Dilution: Add an equal volume (e.g., 50 µL) of the antimicrobial stock solution at its starting concentration to the first well containing diluent. Mix thoroughly by aspirating and expelling the solution several times with a pipette. This creates the first two-fold dilution (a 1:2 reduction in concentration) [35].
• Serial Dilution Transfer: Using a fresh pipette tip, transfer the same volume (e.g., 50 µL) from the first well to the second well. Mix thoroughly. This step is repeated, serially transferring and mixing from one well to the next, until the penultimate well. The last well, which contains only diluent, serves as a negative growth control [35] [36].
• Inoculation: Inoculate each well with a standardized bacterial suspension (e.g., 5 x 10^5 CFU/mL). The final volume in each well is now equal.
• Incubation and Reading: Incubate the plate under appropriate conditions (e.g., 35°C for 16-20 hours for many bacteria). The MIC is read as the lowest concentration of antimicrobial that completely inhibits visible growth [38].

The geometric progression of a two-fold dilution series and its application in an MIC test are illustrated below:

Figure 2: Logical workflow of a two-fold serial dilution in a microtiter plate, showing the step-wise halving of concentration with each transfer step [35] [36].

Calculations for Two-Fold Dilutions

The concentration at any step in a two-fold series is a simple geometric progression. If the initial concentration is ( C ), the concentration after ( n ) two-fold dilutions is ( \frac{C}{2^n} ). The total dilution factor is the product of each step's dilution factor (2). For example, after 4 two-fold dilutions, the total dilution factor is ( 2 \times 2 \times 2 \times 2 = 16 ), and the concentration is ( \frac{C}{16} ) [36] [39].

Comparative Analysis: Methodologies for ECOFF Development

A core activity in AMR research is comparing different AST methods for their utility in generating robust data for ECOFF setting. The following table summarizes a comparative framework, using recent research on Arcobacter butzleri as a case study [37].

Table 1: Comparison of reference and alternative antimicrobial susceptibility testing methods for ECOFF determination.

Method	Principle	Key Advantages	Key Limitations	Agreement with Reference (BMD) for A. butzleri
Broth Microdilution (BMD) [38] [37]	Two-fold antibiotic dilutions in liquid broth within a microtiter plate; MIC is the lowest concentration inhibiting growth.	Considered the reference standard for many pathogens. Amenable to automation.	Manual preparation is laborious and prone to error; custom plates are costly; requires specialized equipment for automation [37].	Reference Standard
Agar Dilution [38] [37]	Two-fold antibiotic dilutions incorporated into agar plates; isolates are spot-inoculated and incubated; MIC is the lowest concentration inhibiting growth.	High-throughput; multiple isolates tested per plate; more stable environment than broth; better growth for some fastidious bacteria [37].	Labor-intensive for few samples; requires large amounts of reagents/antibiotics.	High agreement for ciprofloxacin, erythromycin, and gentamicin under aerobic incubation at 24h [37].
Disk Diffusion [38]	Antibiotic-impregnated disk diffuses into agar lawn of bacteria; zone of inhibition is measured.	Low cost, flexible, and simple to perform. Provides a qualitative/categorical result (S/I/R).	Does not provide a quantitative MIC value.	Zone diameter ECOFFs established for rifampicin and ceftriaxone for B. melitensis [32].

This comparative data demonstrates that while BMD remains the gold standard, validated alternative methods like agar dilution can provide reliable, high-throughput solutions for AMR surveillance and ECOFF setting, particularly for less common pathogens [37].

Essential Research Reagent Solutions

The following table details key reagents and materials essential for conducting research into species identification and ECOFF validation.

Table 2: Essential research reagents and materials for species identification and antimicrobial susceptibility testing.

Item	Function/Application	Examples & Notes
DNA Extraction Kits	Isolation of high-quality genomic DNA from microbial or tissue samples for subsequent PCR and sequencing.	DNeasy Blood & Tissue Kit (Qiagen) is widely used for animal and bacterial samples [34]. Protocols for plants are more complex and less standardized [33].
PCR Reagents	Amplification of target DNA barcodes (e.g., COI) or resistance genes.	Includes polymerase, dNTPs, buffers, and conserved primers specific to the target gene region [33] [34].
Culture Media	Growth and propagation of microbial isolates for AST.	Mueller-Hinton Agar/Broth is the standard for AST; Columbia agar with 5% sheep blood is used for fastidious pathogens like Arcobacter and Brucella [32] [37].
Antimicrobial Agents	Preparation of stock solutions for incorporation into dilution-based AST methods.	High-purity powders or standard solutions are required. Stock solutions are serially diluted to create a concentration range for MIC testing [36] [37].
Microtiter Plates	Platform for performing broth microdilution AST.	Typically 96-well plates. Can be prepared in-house or purchased as pre-prepared, frozen panels from commercial suppliers [38].

The rigorous validation of ECOFF values and intrinsic resistance breakpoints is a multifaceted process entirely dependent on the foundational techniques of species identification and two-fold dilution series. Molecular methods, particularly DNA barcoding, provide the specificity needed to define the microbial populations under study. The two-fold serial dilution, executed through BMD or a validated alternative like agar dilution, provides the quantitative MIC data that forms the statistical basis for ECOFFs. As evidenced by recent research on pathogens like Brucella melitensis and Arcobacter butzleri, the ongoing refinement of these methods and the development of standardized protocols are critical for expanding AMR surveillance to all clinically relevant pathogens. This, in turn, supports the development of effective antimicrobial stewardship programs and evidence-based treatment guidelines, which are vital tools in preserving the efficacy of existing antimicrobials [32] [37].

The minimum inhibitory concentration (MIC) is a crucial metric in microbiology, indicating the lowest concentration of an antimicrobial agent that prevents visible growth of a microorganism. MIC values form the foundation for defining antimicrobial susceptibility and are indispensable in the global effort to combat antimicrobial resistance. The determination of reliable MIC data is a cornerstone for establishing epidemiological cut-off values (ECOFFs), which in turn help distinguish wild-type microorganisms from those with acquired resistance mechanisms. This guide objectively compares the two primary methodological approaches for MIC determination: the reference standard defined by ISO 20776-1 and other calibrated protocols that are harmonized with it.

The reproducibility of MIC values can be significantly affected by methodological variations, including differences in culture media, inoculum preparation, incubation conditions, and endpoint determination. The International Organization for Standardization (ISO) developed the ISO 20776-1 standard to provide a standardized reference broth microdilution method, thereby minimizing inter-laboratory variability and ensuring comparability of results. Alongside this, several calibrated protocols, such as those from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI), have been developed and validated against this reference. Understanding the performance characteristics, data output compatibility, and adaptability of these methods is essential for researchers, scientists, and drug development professionals engaged in validating intrinsic resistance breakpoints and ECOFF values.

Comparative Analysis of Methodological Standards

The following table summarizes the core characteristics of the ISO 20776-1 standard and calibrated protocols for MIC determination.

Table 1: Core Characteristics of MIC Determination Standards

Feature	ISO 20776-1 Standard	Calibrated Protocols (e.g., EUCAST, CLSI)
Primary Role	Definitive reference method against which others are calibrated [1]	Routine testing and research; calibrated to the reference method [5]
Methodology Basis	Standardized broth microdilution [40]	Broth microdilution and other methods (e.g., disk diffusion) calibrated to reference [5]
Data Comparability	Provides the benchmark for all MIC values [1]	Results should be within one twofold dilution of the reference method [5]
Scope & Application	Validation of other susceptibility tests [40]	High-throughput screening, clinical diagnostics, and research [40] [5]
ECOFF Determination	Forms the basis for generating comparable MIC distributions [1]	Data from calibrated methods can be amalgamated into ECOFF databases [5]
Throughput	Lower, due to reference precision requirements [40]	Higher, can be adapted for automated systems [40]

While methodological differences exist, the critical finding is that MIC distributions and resulting ECOFFs derived from ISO 20776-1 and properly calibrated protocols are functionally equivalent for surveillance and research purposes. The EUCAST database, which aggregates over 30,000 MIC distributions from worldwide sources, successfully amalgamates data from both the reference method and calibrated methods, confirming that results "rarely vary by more than one doubling dilution step" [5]. This harmonization is vital for creating the large, representative datasets needed to define robust wild-type distributions and set ECOFFs that are independent of time, geography, or infection source [1].

Experimental Protocols for MIC Determination

Core Protocol Based on ISO 20776-1

The reference method for MIC determination involves a rigorously defined broth microdilution process. The following workflow details the key experimental steps for obtaining reliable antimicrobial susceptibility data.

Key Experimental Steps:

• Preparation of Antimicrobial Stock Solutions: Accurate preparation is foundational. The protocol requires:

  • Dissolving the antimicrobial agent to achieve a stock concentration of 1 g/L or higher, depending on solubility [40].
  • Using an analytical balance pre-calibrated with weight standards [40].
  • Factoring in the powder potency for commercial antimicrobials using the formula: m = (V * c) / P, where m is mass (mg), V is diluent volume (mL), c is stock concentration (μg/mL), and P is potency (μg/mg) [40].
  • For experimental agents with unknown potency, the concentration can be determined spectrophotometrically using the Beer-Lambert law: c = A / (ϵ * l) * DF, where A is absorbance, ϵ is the molar extinction coefficient, l is the path length, and DF is the dilution factor [40].

• Preparation of Bacterial Culture and Inoculum: Standardizing the bacterial inoculum is critical for reproducibility.

  • Pre-culture bacteria in Mueller-Hinton (MH) broth at 35±1°C for 18-24 hours [40].
  • Adjust the optical density of the culture at 625 nm to match the 0.5 McFarland Standard (OD625 of 0.08-0.12), corresponding to approximately 1-2 x 10^8 CFU/mL [40].
  • Further dilute the culture to a final concentration of 10^6 CFU/mL in MH broth for testing [40].
  • Critical Step: Perform purity checks and viable colony counts to avoid cross-contamination and ensure accurate inoculum density [40].

• Testing, Incubation, and MIC Determination:

  • The standardized inoculum is added to a microdilution plate containing serial twofold dilutions of the antimicrobial agent.
  • The plate is incubated at 35±1°C for 18-24 hours [40].
  • After incubation, bacterial growth is assessed spectrophotometrically [40].
  • The MIC is identified as the lowest molar concentration of the antimicrobial that prevents discernible growth [40].

Protocol for High-Throughput Screening

For high-throughput antimicrobial screening, the core principles of the reference standard must be maintained, but the protocol can be adapted using open-source software for automated data analysis. This software automates the conversion of raw data from microdilution assays into MIC values, enhancing efficiency and reducing human error in large-scale studies [40]. The key is to ensure that any automated or high-throughput method is calibrated and validated against the reference ISO 20776-1 method to guarantee data fidelity [5].

From MIC Data to ECOFFs: Defining Wild-Type Distributions

The determination of ECOFFs relies on the analysis of aggregated MIC distributions. A wild-type distribution for a specific microorganism and antimicrobial agent is the log-normal distribution of MICs from isolates that lack phenotypically detectable acquired resistance mechanisms [1]. The ECOFF is defined as the highest MIC value within this wild-type distribution [1].

Table 2: Key Concepts in ECOFF Determination

Concept	Description	Significance in Resistance Research
Wild-Type (WT) Distribution	A log-normal distribution of MICs from organisms without acquired resistance mechanisms [1]	Serves as the "normal" baseline for a species/agent combination [1]
Non-Wild-Type (NWT) Distribution	A separate distribution of MICs from organisms with acquired resistance mechanisms [1]	Identifies isolates with reduced susceptibility [1]
Epidemiological Cut-Off Value (ECOFF)	The highest MIC value of the wild-type distribution (e.g., ≤X mg/L) [1] [5]	Provides the most sensitive measure of resistance development; isolates with MICs >ECOFF are non-wild-type [1]
Tentative ECOFF (TECOFF)	An ECOFF based on 3 or 4 distributions, indicating preliminary status [5]	Allows for initial assessment while more data is collected for a full ECOFF [5]
Data Aggregation	ECOFFs are set using data from at least 5 independent laboratories, using twofold dilution series [1] [5]	Ensures that the ECOFF is representative and accounts for technical and biological variation across different settings [1]

The process of setting ECOFFs requires careful curation of data. Distributions that are truncated at the lower end of the MIC scale are excluded to avoid distortion of the wild-type population [5]. The resulting ECOFFs are species-specific and remain consistent regardless of the geographic origin, time of collection, or source (human or animal) of the bacterial isolates, making them powerful tools for global antimicrobial resistance surveillance [1] [5].

Essential Research Reagent Solutions

The following table details key reagents and materials essential for conducting MIC determinations according to the discussed standards.

Table 3: Essential Research Reagents for MIC Determination

Reagent / Material	Function in Protocol	Critical Specifications
Mueller-Hinton (MH) Broth	Standardized culture medium for bacterial growth during susceptibility testing [40]	Composition and pH must conform to ISO 20776-1 specifications to ensure reproducible cation content [1]
Antimicrobial Reference Powders	Used to prepare stock solutions for dilution series [40]	Known potency and purity; stored as recommended to maintain stability [40]
Cation Adjustment Solutions	To modify the concentration of divalent cations (e.g., Ca²⁺, Mg²⁺) in the medium [1]	Essential for testing certain antimicrobial classes (e.g., aminoglycosides against Pseudomonas) [1]
McFarland Standards	To visually or instrumentally standardize the density of the bacterial inoculum [40]	Ensures a consistent initial inoculum of 1-2 x 10^8 CFU/mL, critical for MIC accuracy [40]
Quality Control Strains	Used to verify the accuracy and precision of the test procedure [40]	Well-characterized strains with known MIC ranges (e.g., E. coli ATCC 25922, S. aureus ATCC 29213) [40]

The comparative analysis of methodological standards for MIC determination reveals that both the ISO 20776-1 reference method and calibrated protocols are integral to a robust antimicrobial susceptibility testing ecosystem. The ISO standard provides the indispensable foundation for reproducibility and harmonization, while calibrated protocols, including those from EUCAST and CLSI, enable the widespread generation of comparable data suitable for high-throughput screening and clinical diagnostics. The rigorous application of these protocols, with careful attention to reagent quality and inoculum standardization, generates the high-fidelity MIC data required for defining wild-type distributions. These distributions are, in turn, the bedrock for establishing ECOFFs, which are critical for sensitive antimicrobial resistance surveillance and for validating intrinsic resistance breakpoints in global research and drug development.

In antimicrobial susceptibility testing, the minimum inhibitory concentration (MIC) for a specific species and agent follows a log-normal distribution rather than a single value [1]. The population of organisms devoid of phenotypically detectable, acquired resistance mechanisms is designated the "wild type" (WT) [1]. Characterizing this WT distribution is fundamental to the international system for antimicrobial susceptibility testing as it provides a reference for otherwise relative MIC values [1]. The epidemiological cut-off value (ECOFF or ECV) defines the upper end of this WT distribution, serving as the highest MIC for organisms without detectable resistance mechanisms [1] [5]. This parameter provides the most sensitive measure of resistance development in a species against an agent and enables screening for resistance while allowing comparisons between systems with different clinical breakpoints [1].

The European Committee on Antimicrobial Susceptibility Testing (EUCAST) systematically collects international MIC distributions to define ECOFFs, requiring contributions from at least five different sources to establish a validated ECOFF [1] [5]. These distributions have demonstrated remarkable consistency, remaining identical irrespective of geographical origin, time period, or source of isolates when proper methodology is employed [1]. The Clinical and Laboratory Standards Institute (CLSI) has also developed formal processes for establishing epidemiological cut-off values, with both organizations recognizing their critical role in antimicrobial resistance surveillance and breakpoint determination [1].

ECOFFinder is a Microsoft Excel spreadsheet calculator freely available to the public and designed specifically to estimate epidemiological cutoff values for wild-type bacterial or fungal populations [41]. The tool implements the statistical methodology described by Turnidge, Kahlmeter, and Kronvall in their seminal 2006 paper on characterizing bacterial wild-type MIC value distributions [41]. This method provides a standardized statistical approach for determining the point that separates microbial populations into those with and without acquired resistance based on their phenotypic profiles [41].

The software requires users to enable the Excel "Solver" add-in for proper functionality and includes enhancements such as a "Results summaries" tab for storing key outputs [41]. ECOFFinder analyzes MIC distributions obtained through traditional twofold dilution series (e.g., 0.125, 0.25, 0.5, 1, 2, 4, 8 mg/L) [1]. The methodology demands that dilution series ideally include all concentrations within the putative wild type, as series truncated at either end of this range will distort analysis and must be excluded [1]. For technical measurements that fall between traditional twofold values, such as a measured MIC of 3 mg/L, the value should be rounded up to the next highest twofold concentration (4 mg/L in this example) to maintain consistency in analysis [1].

Table 1: Key Technical Requirements for ECOFF Analysis

Feature	Requirement	Purpose
Dilution Series	Twofold dilution series (0.125, 0.25, 0.5, 1, 2, 4, 8, etc.)	Facilitates standardized analysis and comparison
MIC Rounding	Values between dilutions rounded up to next twofold concentration	Maintains consistency in data interpretation
Data Completeness	Non-truncated series encompassing full putative wild-type range	Prevents distortion of distribution analysis
Species Identification	Isolates identified to species level	Ensures accurate species-specific cut-off values
Methodology	Reference broth microdilution (ISO 20776-1) or calibrated methods	Ensures reproducibility and comparability across laboratories

Comparative Analysis of ECOFF Determination Methods

Methodological Approaches to ECOFF Determination

Two primary methodologies have emerged for calculating epidemiological cut-off values: the ECOFFinder method and Normalized Resistance Interpretation (NRI) analysis [42] [43]. While both methods calculate a mean and standard deviation for log2-transformed observations from putative wild-type isolates, they employ different statistical approaches [43]. ECOFFinder utilizes a curve-fitting approach to characterize WT distributions, whereas NRI calculates a normalized distribution of the WT observations [43]. This fundamental difference means the standard deviation values produced by each method cannot be directly compared [43].

The NRI method was specifically designed to handle situations where the distribution of MIC values for isolates with slightly reduced susceptibility overlaps with those of fully susceptible isolates [42]. It establishes a "functional peak" as a reference point for determining the portion of the distribution corresponding to WT isolates and sets cut-off values at the mean minus 2.5 times the standard deviation [9]. However, a significant limitation of NRI is its assumption that WT observations are symmetrically distributed around the peak, which may not hold true in all cases [9].

Precision Standards and Performance Metrics

Research has established precision limits for MIC data used to set epidemiological cut-off values [43]. Analysis of 151 published MIC data sets revealed that when the standard deviation of the distribution of MIC values for wild-type isolates exceeds 1.18 log2 μg/mL when calculated by NRI analysis or 1.11 log2 μg/mL when calculated by ECOFFinder, the data set should be considered imprecise and not used to set epidemiological cut-off values [43]. These precision standards have proven consistent across different testing temperatures and laboratory environments [43].

Table 2: Performance Comparison of ECOFF Determination Methods

Parameter	ECOFFinder	NRI Analysis	EUCAST Procedure
Statistical Approach	Curve-fitting	Normalized distribution of WT observations	Aggregated multi-lab distributions
Primary Application	Wild-type MIC distribution characterization	Detection of low-level resistance in overlapping distributions	International standard setting
Precision Limit (sd max)	1.11 log2 μg/mL	1.18 log2 μg/mL	Not specified
Data Requirements	MIC values from twofold dilution series	MIC or zone diameter values	Minimum 5 independent distributions
Key Advantage	International recognition and standardization	Sensitivity to low-level resistance	Comprehensive multi-laboratory validation

Comparative Performance in Resistance Detection

Studies comparing resistance interpretation across different breakpoints have demonstrated that AMR interpretation is significantly influenced by the method used [9]. Research on Escherichia coli isolates from poultry farms found that prevalence estimates of antimicrobial resistance varied considerably depending on whether CLSI breakpoints, ECOFFs, or NRI-derived breakpoints were applied [9]. For ciprofloxacin, resistance rates varied significantly: 32.2% with CLSI breakpoints, 64.4% with ECOFFs, and 18.6% with NRI-derived cut-off values [9]. This highlights how methodological choices can substantially impact resistance classification and surveillance data.

The implications of these differences extend beyond academic interest, as they can influence treatment guidelines and resistance monitoring programs. ECOFFs generally maintain that organisms within the wild-type distribution have a low likelihood of clinical treatment failure, which may translate into lower breakpoints compared to other systems [9]. This fundamental difference in philosophical approach to breakpoint setting explains much of the variation observed between methods.

Experimental Protocols for ECOFF Analysis

Protocol Workflow for ECOFF Determination

The following workflow diagram illustrates the standardized procedure for determining epidemiological cut-off values using ECOFFinder:

Step-by-Step Experimental Procedure

• Bacterial Isolation and Identification: Collect isolates from diverse sources and time periods, ensuring accurate identification to species level using appropriate methods (e.g., MALDI-TOF) [1]. For Piscirickettsia salmonis studies, this may require specially formulated media with trypticase soy agar, sodium chloride, D-glucose, L-cysteine hydrochloride, and supplemented with defibrinated sheep blood and calf bovine serum [42].

• Reference MIC Determination: Perform broth microdilution testing according to ISO standard 20776-1 or properly calibrated methods [1] [44]. For fastidious organisms, this may require protocol modifications while maintaining core principles. Use traditional twofold dilution series that encompass the entire putative wild-type range without truncation [1].

• Data Quality Assessment: Screen distributions for truncation and exclude those truncated within the putative wild-type distribution [5]. Verify that MIC values follow the expected log-normal distribution pattern and check for methodological consistency across contributing laboratories [1] [45].

• ECOFFinder Implementation: Input formatted MIC data into the ECOFFinder Excel spreadsheet, ensuring the Solver add-in is enabled. Run the analysis according to the provided instructions, storing results in the "Results summaries" tab for documentation [41].

• Multi-laboratory Validation: Aggregate data from at least five independent sources to establish a validated ECOFF, or from three to four sources for a tentative ECOFF (TECOFF) [5]. Compare the derived ECOFF with existing distributions in the EUCAST database to identify potential methodological discrepancies [5].

Quality Control and Precision Assessment

Incorporate quality control reference strains such as Escherichia coli ATCC 25922 in each susceptibility testing run [42]. Calculate the standard deviation of the normalized distribution generated by ECOFFinder and compare against established precision limits (≤1.11 log2 μg/mL) [43]. If precision thresholds are exceeded, investigate potential causes including methodological inconsistencies, taxonomic diversity issues, or heterogeneity in isolate susceptibilities [43].

For Cryptococcus species susceptibility testing, essential agreement between methods should exceed 89% at ±2 dilutions, with very major error rates maintained below 3% for reliable antifungal susceptibility testing [44]. These quality metrics ensure the derived ECOFFs have appropriate precision for resistance surveillance and screening applications.

Research Reagent Solutions for ECOFF Analysis

Table 3: Essential Research Reagents and Tools for Wild-Type Distribution Analysis

Reagent/Tool	Specification	Research Function
ECOFFinder Software	Microsoft Excel spreadsheet with Solver add-in	Statistical calculation of epidemiological cut-off values from MIC distributions
Reference Strains	e.g., E. coli ATCC 25922, C. parapsilosis ATCC 22019	Quality control for susceptibility testing method validation
Broth Microdilution System	ISO 20776-1 compliant materials	Generation of reference MIC data for wild-type distribution analysis
Specialized Media	Organism-specific formulated media (e.g., IFOP-PsM11 for P. salmonis)	Support growth of fastidious organisms for reliable MIC determination
EUCAST Database Access	Online MIC and zone diameter distributions	Reference wild-type distributions and established ECOFFs for comparison

Applications in Antimicrobial Resistance Research

ECOFFinder and wild-type distribution analysis serve multiple critical functions in antimicrobial resistance research and breakpoint determination. The primary application is resistance surveillance, where ECOFFs provide a sensitive tool for detecting resistance development independent of changing clinical breakpoints [1]. This enables meaningful comparisons across different breakpoint systems, geographic regions, and time periods [1]. Furthermore, ECOFF analysis supports clinical breakpoint determination by ensuring breakpoints do not divide wild-type distributions of target species, thus avoiding poor reproducibility in susceptibility categorization [1].

Research has demonstrated that EUCAST fails to identify different clinical outcomes for isolates with different MIC values inside the wild-type distribution, justifying the placement of clinical breakpoints outside the wild-type range [1]. Additionally, ECOFFs facilitate method calibration and validation by providing reference MIC ranges against which laboratory methods can be compared [5]. Laboratories whose distributions show wild-type modes differing by two or more twofold dilutions from established database distributions likely have methodological issues requiring investigation [5].

The validation of intrinsic resistance breakpoints represents another significant application, particularly for emerging pathogens and those from non-human sources. Research on Piscirickettsia salmonis demonstrated successful ECOFF determination using customized protocols, with NRI analysis identifying 56% of isolates showing reduced susceptibility to florfenicol and 9% to oxytetracycline [42]. Similarly, studies on Cryptococcus neoformans have established epidemiological cutoff values for antifungal drugs where clinical breakpoints are not available [44]. These applications underscore the versatility of ECOFF analysis across diverse microorganisms and clinical contexts.

Epidemiological Cut-Off Values (ECOFFs) represent a critical tool in antimicrobial susceptibility testing, providing the highest minimum inhibitory concentration (MIC) for microorganisms devoid of phenotypically detectable, acquired resistance mechanisms. ECOFFs define the upper end of the wild-type (WT) MIC distribution, typically written as "X mg/L," with the wild type designated as "≤X mg/L" and the non-wild type as ">X mg/L" [1]. Unlike clinical breakpoints that categorize microorganisms as Susceptible (S), Susceptible with increased exposure (I), or Resistant (R) based on clinical outcome predictions, ECOFFs provide a phenotypically-based reference that identifies the normal MIC distribution before defining the abnormal [46]. This distinction makes ECOFFs the most sensitive measure for detecting resistance development in a species against an antimicrobial agent [1].

The fundamental importance of ECOFFs lies in their ability to differentiate between bacterial populations with and without acquired resistance mechanisms based on their phenotypes. This capability provides multiple advantages for antimicrobial resistance surveillance and research. ECOFFs enable screening for and exclusion of resistant isolates, facilitate comparisons of resistance rates between systems with different clinical breakpoints, allow tracking of breakpoint evolution over time, and permit harmonized comparisons between human and veterinary medicine [1]. Furthermore, regulatory agencies and standard-setting organizations utilize ECOFFs as essential references when determining clinical breakpoints, with the European Committee on Antimicrobial Susceptibility Testing (EUCAST) specifically avoiding breakpoints that split wild-type distributions of target species to ensure better reproducibility of susceptibility categorization [1].

Comparative Analysis of ECOFF Development Systems

Methodological Frameworks for ECOFF Determination

Table 1: Comparative Methodological Requirements for ECOFF Development

Feature	EUCAST Approach	CLSI Approach	Significance in ECOFF Development
Isolate Identification	To species level (or species complex if indistinguishable by MALDI-TOF) [1]	To species level only [1]	Ensures taxonomic precision for accurate species-specific distributions
Reference Methods	ISO 20776-1 and methods calibrated to it (includes EUCAST & CLSI M7) [1]	M7, M11, M27, M38, M44, M45, M51, and VET05 [1]	Standardization across laboratories and manufacturers for comparable results
Dilution Series	Twofold series (0.5, 1, 2, 4 mg/L); values between rounded up [1]	Not specified but generally defaults to standard twofold dilution series [1]	Facilitates statistical analysis and distribution characterization
Minimum Distributions	5 for ECOFF, 3 for tentative ECOFF [1] [46]	Not explicitly stated in results	Ensures representativeness and reduces single-study bias
Data Curation	Exclusion of distributions truncated within putative WT [5] [1]	Not explicitly stated in results	Preserves distribution integrity for accurate ECOFF determination
Quality Control	Rigorous QC per reference method; interlaboratory variation assessment [46]	Published procedures for BMD QC [46]	Maintains technical accuracy and reproducibility

The determination of robust ECOFFs requires adherence to standardized methodological frameworks that ensure consistency and reliability across studies and laboratories. Both EUCAST and the Clinical and Laboratory Standards Institute (CLSI) have established detailed procedures for ECOFF development, with the EUCAST approach being more prescriptive regarding analysis criteria [1]. The fundamental principle underlying ECOFF development is that wild-type MIC distributions for well-defined species without acquired resistance mechanisms remain consistent regardless of geographical origin, time period, or source (hospital vs. community) when determined using equivalent methodology [1] [46]. This consistency enables the aggregation of data from multiple international sources to build comprehensive MIC distributions.

A critical requirement for ECOFF development is the use of quality-controlled, reference method-generated MIC concentration series that are non-truncated at neither end of the distribution [46]. The dilution series must ideally include all concentrations in the putative wild type, as series truncated within either end will distort the analysis and must be excluded [1]. The technical variation inherent in MIC determination – comprising both intra- and inter-laboratory components – is incorporated into the wild-type distribution, increasing the general representativeness and utility of both the distribution and the resulting ECOFF [1]. This approach acknowledges that MIC values are relative rather than absolute, with reproducibility typically within plus or minus one twofold dilution even under optimal conditions [1].

Data Aggregation and Quality Standards

Table 2: Data Quality Requirements for ECOFF Development

Requirement Category	Specific Criteria	Impact on ECOFF Robustness
Data Source Diversity	Multiple independent sources (≥5 for ECOFF) [1] [46]	Increases representativeness and reduces single-source bias
Methodological Standardization	ISO 20776-1 or calibrated methods [1]	Ensures comparability across different laboratories and studies
Distribution Completeness	Non-truncated at either end of putative WT [1] [46]	Preserves distribution shape for accurate ECOFF determination
Strain Identification	Species-level identification [1]	Ensures taxonomic precision for species-specific ECOFFs
Quality Control	Adherence to reference method QC procedures [46]	Maintains technical reliability and reproducibility
Data Collection Scope	Various geographic locations, time periods, and sources [1]	Enhances generalizability of resulting ECOFF

The aggregation of data from multiple international sources follows rigorous quality standards to ensure the resulting ECOFFs accurately represent the wild-type population. EUCAST's systematic collection of MIC distributions incorporates data from an increasing total of more than 30,000 MIC distributions from worldwide sources, representing results obtained with MIC methods performed by or calibrated to reference broth microdilution using ISO-20776-2 [5]. This comprehensive approach encompasses variation between different investigators, laboratories, geographic locations, and time periods, providing a robust foundation for ECOFF determination [5]. The EUCAST database actively incorporates data from national and international studies, resistance surveillance programs, published literature, pharmaceutical industry research, veterinary programs, and individual laboratories [5].

The curation process for aggregated MIC data involves careful screening by expert committees, with EUCAST reporting that typically 10-20% of contributed distributions are excluded from aggregated analyses, most commonly due to "lower end truncation" [5]. This quality control ensures that only distributions that accurately represent the complete wild-type population are included in ECOFF determination. For inhibition zone diameter distributions, which complement MIC data, only data generated with quality-controlled EUCAST disk diffusion methodology are included, as the wild-type distribution generated in individual laboratories should match the wild-type distributions on the EUCAST website [5]. This meticulous curation process ensures that aggregated data meets the highest standards of reliability and accuracy.

Experimental Protocols for ECOFF Development

Wild-Type MIC Distribution Analysis

The foundational protocol for ECOFF development begins with the analysis of wild-type MIC distributions using strictly standardized methodologies. The process requires MIC values based on traditional twofold dilution series (0.125, 0.25, 0.5, 1, 2, 4, 8 mg/L, etc.), with testing techniques involving concentrations between traditional twofold values rounded up to the next twofold value [1]. For instance, a measured MIC of 3 mg/L would be rounded up to 4 mg/L. This standardization facilitates consistent analysis across studies and laboratories. The experimental workflow requires isolates identified to the species level (or species complex when members cannot be distinguished by MALDI-TOF), with MIC determinations performed using ISO 20776-1 reference methods or methodologies calibrated to it [1]. Each contributing laboratory must implement rigorous quality control procedures following either EUCAST or CLSI published guidelines for broth microdilution [46].

The critical methodological consideration is ensuring that dilution series include all concentrations in the putative wild type without truncation at either end, as distributions truncated within the putative wild-type distribution distort analysis and must be excluded [1]. This requirement stems from the recognition that the upper end of the log-normal MIC distribution mirrors the lower end, and truncation prevents accurate characterization of the complete wild-type population [46]. The protocol mandates aggregation of data from at least five independent, quality-controlled distributions for definitive ECOFF establishment, with three distributions sufficient for tentative ECOFFs [1] [46]. This multi-source approach incorporates the natural variation between laboratories, reagents, and geographical locations, enhancing the representativeness and utility of the resulting ECOFF.

ECOFF Determination and Statistical Analysis

The statistical analysis and ECOFF determination process follows systematically defined procedures, with EUCAST codifying its approach in Standard Operating Procedure SOP 10.2 [1]. The process begins with the aggregation of quality-controlled, non-truncated MIC distributions from multiple international sources, with each distribution representing the log-normal distribution pattern characteristic of wild-type populations [1]. The wild-type distribution for a species and antimicrobial agent consists of all MIC values at or below the ECOFF, representing organisms without phenotypically detectable resistance mechanisms [1]. These distributions are species-specific and remain consistent irrespective of isolate source, collection time period, or geographic origin [1].

The actual ECOFF calculation identifies the highest MIC value for organisms devoid of phenotypically detectable, acquired resistance mechanisms, defining the upper end of the wild-type MIC distribution [1]. While there is currently no international standard method for selecting ECOFFs, both EUCAST and CLSI approaches share fundamental principles: they require species-level identification, traditional twofold dilution series, non-truncated concentration series encompassing the putative wild type, and multiple independent distributions [1]. The resulting ECOFF provides a versatile tool that delineates the wild-type population, sets boundaries for clinical breakpoint determination, enables resistance mechanism screening, and facilitates resistance rate measurements when other breakpoints are inadequate for comparison between different interpretation systems [46].

Essential Research Reagent Solutions

Table 3: Essential Research Reagents and Materials for ECOFF Development

Reagent/Material	Specification Requirements	Function in ECOFF Development
Reference Broth Microdilution Panels	ISO 20776-1 compliance [1]	Gold standard method for MIC determination
Quality Control Strains	EUCAST/CLSI recommended strains [46]	Monitoring technical performance and reproducibility
Culture Media	Cation-adjusted Mueller-Hinton broth or other standardized media [1]	Standardized growth conditions for reproducible MICs
Antimicrobial Agents	Reference powders of known potency [1]	Ensuring accurate concentration in dilution series
Inoculum Preparation Standards	0.5 McFarland standard or equivalent [1]	Standardized inoculum size for consistent results
Disk Diffusion Materials	EUCAST-approved disks and media [5]	Generating complementary zone diameter distributions

The development of robust ECOFFs requires carefully controlled research reagents and materials that meet international standardization specifications. Reference broth microdilution panels complying with ISO 20776-1 represent the foundational reagent for MIC determination, providing the benchmark against which all alternative methods must be calibrated [1]. These panels must incorporate appropriate concentration ranges covering the complete putative wild-type distribution for each species-drug combination, as plates with truncated concentration ranges cannot generate usable data for ECOFF development [46]. Quality control strains recommended by both EUCAST and CLSI are essential for monitoring technical performance and ensuring inter-laboratory reproducibility across the multiple independent studies contributing to ECOFF development [46].

Standardized culture media, particularly cation-adjusted Mueller-Hinton broth for most bacterial species, provide consistent growth conditions necessary for reproducible MIC determinations across different laboratories and time periods [1]. Antimicrobial agents of known potency and purity, typically reference powders from certified suppliers, ensure accurate concentrations throughout the dilution series [1]. For complementary inhibition zone diameter distributions, EUCAST-approved disks and corresponding media are essential, with data generated exclusively using quality-controlled EUCAST disk diffusion methodology included in aggregated distributions [5]. These standardized reagents and materials collectively enable the generation of comparable, reliable data from multiple international sources that can be aggregated for robust ECOFF determination.

The development of robust Epidemiological Cut-Off Values through systematic aggregation of multiple international distributions represents a cornerstone of modern antimicrobial resistance monitoring and research. The meticulous process of collecting quality-controlled, non-truncated MIC distributions from diverse sources worldwide, followed by rigorous statistical analysis and expert validation, produces ECOFFs that accurately delineate wild-type populations from those with acquired resistance mechanisms. The comparative analysis presented in this guide demonstrates that while methodological variations exist between standardization bodies like EUCAST and CLSI, the fundamental principles of ECOFF development remain consistent: species-level identification, reference methodological standards, non-truncated dilution series, and multi-source data aggregation.

The future of ECOFF development will likely involve continued expansion of international collaboration and data sharing, enhanced by digital platforms that facilitate more efficient collection and curation of MIC distributions. Furthermore, the integration of genomic data with phenotypic MIC distributions may provide additional insights into the relationship between resistance mechanisms and MIC elevations. However, the foundational requirement for quality-controlled, methodologically standardized phenotypic data will remain essential, as the ECOFF is fundamentally a phenotypic measure. The ongoing efforts by EUCAST, CLSI, and other international organizations to refine ECOFF determination methodologies and expand the available ECOFFs for various species-drug combinations will continue to support clinical microbiology, antimicrobial drug development, and public health surveillance worldwide.

Epidemiological cut-off values (ECOFFs) represent a critical tool in the microbiological assessment of antimicrobial resistance (AMR), providing a fundamental distinction between bacterial populations based on their susceptibility profiles. Unlike clinical breakpoints that predict treatment success based on pharmacological parameters, ECOFFs serve as a purely microbiological benchmark that separates bacterial isolates without phenotypically detectable acquired resistance mechanisms (wild-type) from those with such mechanisms (non-wild-type) [2] [1]. This distinction makes ECOFFs particularly valuable for AMR surveillance and for detecting emerging resistance patterns, especially for new pathogens where established clinical breakpoints may not yet exist.

The tentative ECOFF (TECOFF) serves as a provisional designation during the early stages of investigation when limited data is available. According to EUCAST standards, TECOFFs are based on only 3 or 4 distributions, whereas definitive ECOFFs require at least 5 and up to 100 or more distributions [5]. This systematic approach to ECOFF establishment provides a framework for researchers confronting novel emerging pathogens, where rapid characterization of antimicrobial susceptibility profiles is essential for both clinical management and public health response.

Fundamental Concepts and Definitions

ECOFFs vs. Clinical Breakpoints

A critical understanding for researchers working with ECOFFs is their fundamental distinction from clinical breakpoints, as these concepts serve different purposes in antimicrobial susceptibility testing:

Table 1: Key Differences Between ECOFFs and Clinical Breakpoints

Feature	ECOFF (Epidemiological Cut-off)	Clinical Breakpoint
Primary Function	Detects acquired resistance mechanisms	Predicts clinical treatment outcome
Basis	Microbiological data distribution	Pharmacokinetic/pharmacodynamic parameters, clinical outcome data
Application	Surveillance, resistance detection	Therapeutic guidance
Wild-type Population	Categorized as susceptible	May be categorized as resistant due to pharmacological considerations
Dosing Considerations	Not accounted for	Incorporates standard dosing regimens

The ECOFF is formally defined as "the highest MIC for organisms devoid of phenotypically detectable, acquired resistance mechanisms" [1]. This distinguishes it fundamentally from clinical breakpoints, which determine whether antibiotic therapy is likely to succeed or fail in a patient, taking into account the antibiotic dose which can safely be administered [2]. For some bacteria-antibiotic combinations, the MIC of wild-type bacteria will be too high to be clinically effective – a phenomenon known as intrinsic resistance [2].

Wild-Type vs. Non-Wild-Type Distributions

The theoretical foundation of ECOFF methodology rests on understanding population distributions of microbial susceptibility:

• Wild-type distributions typically span between three and five two-fold dilution steps, forming a monomodal, log-normal distribution when resistance mechanisms are absent [1]
• Non-wild-type populations emerge when resistance mechanisms are present, creating at least one additional mode in the distribution [1]
• The ECOFF position marks the upper end of the wild-type distribution, representing the highest MIC value still considered within the wild-type range [2]

In some cases, wild-type and non-wild-type distributions may overlap significantly, creating challenges in ECOFF determination that require careful statistical approaches and larger sample sizes [47].

Methodological Framework for ECOFF Establishment

Standardized Protocols for ECOFF Determination

The establishment of reliable ECOFFs follows rigorous methodological standards to ensure reproducibility and accuracy across different laboratory settings. The EUCAST Standard Operating Procedure SOP 10.2 codifies the approach for ECOFF determination, emphasizing several critical requirements [1]:

• Isolate identification to species level (or species complex if members cannot be distinguished)
• MIC values must be based on traditional twofold dilution series (0.125, 0.25, 0.5, 1, 2, 4, 8 mg/L, etc.)
• Dilution series should ideally include all concentrations in the putative wild type without truncation
• Minimum number of independent distributions required for definitive ECOFFs

The process of establishing TECOFFs for emerging pathogens follows a systematic workflow that ensures methodological rigor while acknowledging the limitations of initial datasets. The following diagram illustrates this multi-stage process:

Comparative Methodological Approaches

Different organizations have established similar but distinct approaches to ECOFF determination, reflecting varying emphases on specific methodological aspects:

Table 2: Comparison of ECOFF Establishment Methods Between EUCAST and CLSI

Feature	EUCAST Approach	CLSI Approach	Research Implications
Isolate Identification	To species level or species complex	To species level only	EUCAST allows for complexes where species discrimination is challenging
Reference Methods	ISO 20776-1 and calibrated methods	CLSI M7, M11, M27, M38, M44, M45, M51, VET05	EUCAST incorporates international standard while CLSI uses its own methods
Dilution Series	Strict twofold dilution series required	Not specified but generally defaults to standard twofold	EUCAST more prescriptive about dilution structure
Data Analysis	More prescriptive analytical approach	Structured but less prescriptive than EUCAST	EUCAST provides more specific guidance for statistical analysis

The EUCAST methodology specifically requires that distributions truncated at the lower end of the scale within the putative wild-type distribution must be excluded from analysis, as these can distort the accurate determination of the ECOFF position [5]. This is particularly relevant when working with emerging pathogens, where preliminary data may be limited or methodologically inconsistent.

Experimental Protocols and Data Analysis

Core Susceptibility Testing Methods

Establishing TECOFFs requires reliable MIC determination through standardized phenotypic methods. The most commonly employed techniques include:

Broth Microdilution Method

• Performed in 96-well plates containing serial two-fold dilutions of antimicrobial agents [48]
• Inoculated with standardized bacterial suspension (0.5 McFarland standard diluted to approximately 5 × 10⁵ CFU/mL) [49]
• Incubated at 35°C for 16-20 hours (time varies for fastidious organisms) [49]
• MIC recorded as the lowest concentration that completely inhibits visible growth [48]

Agar Dilution Method

• Antimicrobial agents incorporated into agar medium in serial two-fold dilutions [48]
• Multiple organisms (up to 60) can be tested simultaneously on each plate [48]
• Particularly recommended for fastidious organisms, including anaerobes [48]
• Inoculum applied using replicating devices for consistency [49]

Disk Diffusion Method

• Mueller-Hinton agar plates inoculated with standardized bacterial suspension [49]
• Antibiotic disks applied to inoculated surface and incubated [49]
• Zone diameters measured and recorded using calipers or automated systems [49]
• Particularly valuable for large-scale surveillance studies [47]

Data Analysis and ECOFF Determination Methods

The transformation of raw MIC data into validated TECOFFs involves multiple analytical approaches:

Visual Inspection (Eyeball Method)

• Historically used approach involving consensus among experienced personnel [47]
• Five independent reviewers examine distribution histograms to identify the separation between wild-type and non-wild-type populations [47]
• Despite being subjective, remains a valuable preliminary assessment method [47]

Statistical Modeling Approaches

• Normalized Resistance Interpretation (NRI): Uses probit analysis to establish laboratory-specific breakpoints [9]
• ECOFFinder Software: Statistical tool developed by EUCAST for objective ECOFF determination [1]
• Non-linear Regression Models: Fit idealized distributions to observed MIC frequency data [1]

A comparative study evaluating different analytical methods found that AMR interpretation is significantly influenced by the breakpoint used, with ECOFF estimates for certain drug-bug combinations being significantly higher compared to CLSI and NRI methods [9]. This highlights the importance of methodological transparency when establishing TECOFFs for emerging pathogens.

Case Study Applications and Research Validation

Species-Specific ECOFF Considerations

Research has demonstrated that reliable ECOFFs require species-specific determinations, as genus- or group-specific cutoffs can lead to interpretation errors. A comprehensive study analyzing over 30,000 clinical isolates identified several paradigmatic problems in ECOFF establishment [47]:

Staphylococcal Fluoroquinolone ECOFFs

• Ciprofloxacin ECOFFs differ significantly between S. aureus (20 mm) and coagulase-negative staphylococci (24 mm) [47]
• Uniform staphylococcal clinical breakpoints for fluoroquinolones split non-wild-type populations in coagulase-negative staphylococci [47]
• Demonstrates the necessity of species-specific determinations rather than group-level extrapolations [47]

Enterobacteriaceae and Ertapenem

• E. cloacae shows a distinct population shoulder caused by resistant subpopulations overlapping with wild-type [47]
• This complexity necessitates sufficient sample sizes (n>1000) for accurate ECOFF determination [47]
• Limited datasets (n=109 in EUCAST) may fail to capture population heterogeneity [47]

The following diagram illustrates the critical importance of species-specific considerations in ECOFF determination:

Geospatial AMR Mapping Using ECOFFs

Advanced applications of ECOFFs include geospatial mapping of antimicrobial resistance patterns. A recent large-scale study synthesized 33,802 country-level AMR prevalence estimates with 2,849 local prevalence estimates from 209 point prevalence surveys across 31 countries [50]. This research:

• Employed ECOFF values as standardized microbiological benchmarks across diverse data sources [50]
• Generated predictive AMR maps at 10×10 km resolution for E. coli, Salmonella, and Campylobacter in food-producing animals [50]
• Revealed significant heterogeneity in AMR distribution within countries, undetectable at national-level surveillance [50]
• Demonstrated the utility of ECOFF-based analysis for targeted intervention strategies in AMR hotspots [50]

This application highlights how TECOFFs for emerging pathogens could similarly be integrated into spatial epidemiological models to predict resistance spread and inform containment strategies.

Research Reagent Solutions and Essential Materials

The establishment of reliable TECOFFs requires carefully standardized materials and reagents to ensure methodological consistency and reproducible results:

Table 3: Essential Research Materials for ECOFF Establishment

Category	Specific Products/Systems	Research Application	Technical Considerations
Reference MIC Methods	ISO 20776-1 compliant materials	Gold standard for MIC determination	Essential for method calibration between laboratories
Automated AST Systems	Vitek 2, Phoenix, MicroScan WalkAway, Sensititre ARIS 2X	High-throughput susceptibility testing	Systems vary in incubation, reading technology and database support
Culture Media	Mueller-Hinton Agar (Becton Dickinson), Cation-adjusted Mueller-Hinton Broth	Standardized growth conditions	Must meet performance specifications for optimal results
Quality Control Strains	EUCAST/CLSI recommended QC strains	Monitoring test performance	Regular verification of accuracy and precision essential
Disk Diffusion Materials	i2a antimicrobial disks, Mueller-Hinton Agar (Becton Dickinson)	Zone diameter measurements	Disk potency and agar depth critically impact results
Data Analysis Tools	ECOFFinder, NRI spreadsheets, EUCAST database	ECOFF determination and validation	Statistical tools must be appropriate for distribution analysis

Quality assurance represents an integral component of TECOFF establishment, requiring robust quality control protocols including [49]:

• Regular testing of QC strains with established expected ranges
• Documentation of media, reagent, and equipment quality
• Staff competency assessments and proficiency testing
• Participation in external quality assurance programs

The establishment of tentative ECOFFs for emerging pathogens represents a critical component of the global response to antimicrobial resistance. This systematic approach enables researchers to:

• Rapidly characterize susceptibility profiles of novel pathogens before clinical breakpoints can be established
• Detect emerging resistance mechanisms through population distribution analysis
• Provide evidence-based guidance for empirical therapy while clinical outcome data accumulates
• Facilitate standardized AMR surveillance across different laboratory settings

The transition from TECOFF to definitive ECOFF requires expanding datasets to include at least five independent distributions from diverse sources, ultimately encompassing up to 100 or more distributions for robust population characterization [5]. This collaborative framework, exemplified by the EUCAST database which incorporates data from over 30,000 MIC distributions worldwide, highlights the essential role of data sharing and methodological standardization in addressing the continuous challenge of antimicrobial resistance [5].

As research continues to refine ECOFF establishment methodologies, particularly for emerging pathogens with limited initial data, the scientific community must prioritize transparent reporting, method standardization, and international collaboration to ensure that TECOFFs provide a reliable foundation for both clinical decision-making and public health response to novel antimicrobial resistance threats.

Challenges in ECOFF Determination: Troubleshooting Complex Distributions and Methodological Pitfalls

Addressing Overlapping Wild-Type and Non-Wild-Type Distributions

In antimicrobial susceptibility testing (AST), the wild-type (WT) distribution refers to the range of minimum inhibitory concentration (MIC) values for a specific bacterial species and antimicrobial agent that lacks phenotypically detectable resistance mechanisms [1]. These distributions are characteristically log-normal and typically monomodal in the absence of resistance [1]. The epidemiological cut-off value (ECOFF) is defined as the highest MIC value within this wild-type distribution, serving as a critical threshold that separates microorganisms without acquired resistance mechanisms (wild-type) from those with phenotypically detectable resistance (non-wild-type) [1] [5]. This conceptual framework is fundamental for interpreting MIC distributions and detecting emerging resistance.

The accurate determination of ECOFFs provides the most sensitive measure of resistance development in a bacterial population against a particular antimicrobial agent [1]. Unlike clinical breakpoints, which incorporate pharmacological and clinical outcome data, ECOFFs are based solely on phenotypic MIC distributions, making them invaluable for early resistance detection and surveillance [1] [51]. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) systematically characterizes these wild-type distributions and establishes ECOFFs through a rigorous process of data collection and analysis, requiring contributions from at least five independent sources for definitive ECOFF determination [1] [5].

Methodological Approaches for ECOFF Determination

Core Principles and Requirements

The reliable determination of ECOFFs depends on several methodological prerequisites. First, isolate identification must be performed at the species level to ensure distribution accuracy [1]. Second, MIC values must be determined using twofold dilution series (e.g., 0.125, 0.25, 0.5, 1, 2, 4, 8 mg/L) following reference methods such as ISO 20776-1 for bacteria [1] [45]. Third, the dilution series must be non-truncated, meaning it should encompass the entire putative wild-type distribution without cutting off either the lower or upper ends, as truncation distorts distribution analysis [5] [45]. These requirements ensure that the aggregated MIC distributions encompass the natural biological variation and technical assay variations that occur between different laboratories, investigators, and materials [1].

The EUCAST database, which forms the foundation for ECOFF determinations, contains over 40,000 MIC distributions compiled from worldwide sources [7] [45]. This extensive collection incorporates data from diverse geographic locations, time periods, and specimen sources, enhancing the representativeness of the established wild-type distributions [1] [5]. The curation process excludes approximately 10-20% of submitted distributions, most commonly due to lower-end truncation within the putative wild-type range [5]. This stringent quality control ensures that only methodologically sound data contributes to ECOFF setting.

Comparative Analysis of EUCAST and CLSI Approaches

While both EUCAST and CLSI establish epidemiological cut-off values, their approaches differ in several important aspects, as summarized in Table 1.

Table 1: Comparison of EUCAST and CLSI Approaches to ECOFF Determination

Feature	EUCAST	CLSI
Terminology	Epidemiological Cut-off Value (ECOFF)	Epidemiological Cut-off Value (ECV)
Isolate Identification	To species level (or species complex if indistinguishable by MALDI-TOF)	To species level only
Reference Methods	ISO 20776-1 and methods calibrated to it	M7, M11, M27, M38, M44, M45, M51, and VET05
Dilution Series	Twofold dilution series based on 0.5, 1, 2, 4, etc.	Not specified but generally follows standard twofold dilution series
Data Aggregation	Requires at least 5 independent distributions for definitive ECOFF	Approach described in M23 and M57 standards

[1]

EUCAST employs a more prescriptive analytical approach codified in its Standard Operating Procedure 10.2, emphasizing the need for multiple independent distributions and method calibration to reference broth microdilution [1] [7]. Both organizations agree that setting clinical breakpoints that bisect wild-type distributions should be avoided, as this leads to poor methodological reproducibility and unreliable correlation between clinical outcome and susceptibility testing results [1] [45].

Experimental Protocols for ECOFF Determination

Workflow for ECOFF Determination

The following diagram illustrates the systematic workflow for determining epidemiological cut-off values, from data collection through to application:

Research Reagent Solutions for ECOFF Studies

The experimental determination of ECOFFs requires specific materials and reagents standardized according to international reference methods. Table 2 details the essential research reagents and their functions in AST and ECOFF studies.

Table 2: Essential Research Reagents for Antimicrobial Susceptibility Testing and ECOFF Determination

Reagent/Material	Function	Specifications
Reference Broth Microdilution Panels	Determination of MIC values following international standards	ISO 20776-1 compliant; twofold dilution series (0.125, 0.25, 0.5, 1, 2, 4, 8 mg/L) [1]
Mueller-Hinton Media	Standardized growth medium for broth microdilution	Cation-adjusted, pH 7.2-7.4, compliant with ISO 20776-1 [1]
Antimicrobial Disks	Disk diffusion testing for zone diameter distributions	EUCAST-approved concentrations and quality control [5]
Quality Control Strains	Monitoring assay performance and reproducibility	EUCAST-recommended reference strains for each species-agent combination [45]
Standardized Inoculum Preparation	Ensuring consistent bacterial density across tests	0.5 McFarland standard (approximately 1-5×10^8 CFU/mL) [1]

The critical importance of using quality-controlled, non-truncated MIC series has been demonstrated in recent studies establishing ECOFFs for fastidious organisms. For example, a 2025 European multicenter study successfully defined ECOFFs for Brucella melitensis by validating standardized broth microdilution and disk diffusion methodologies across six study centers, testing 499 strains [32]. This study highlighted how properly collected phenotypic data enables sensitive detection of resistance mechanisms, with six isolates showing MIC values slightly above the ECOFFs for rifampicin, streptomycin, and trimethoprim-sulfamethoxazole, indicating potential resistance mechanisms [32].

Addressing Overlapping Wild-Type and Non-Wild-Type Distributions

Challenges in Distribution Separation

The presence of overlapping wild-type and non-wild-type distributions presents a significant challenge in ECOFF determination. In the presence of phenotypically detectable resistance, the MIC distribution becomes multimodal, with at least one additional mode representing the non-wild-type population [1]. Despite this complexity, the wild-type distribution is most often still identifiable using established statistical methods, provided sufficient quality-controlled data is available [1]. The overlap typically occurs when resistance mechanisms confer only modest MIC increases or when the resistance population exhibits heterogeneous expression.

Technical and biological variations contribute significantly to distribution width and potential overlap. Studies have shown that technical variation (both intra- and inter-laboratory) generally contributes more to MIC distribution width than biological variation, even in well-controlled quality control studies using the same reagents [1]. This underscores the importance of aggregating data from multiple sources when establishing ECOFFs, as this incorporates and accounts for the expected methodological variations encountered in real-world practice [1] [5].

Statistical Approaches for Overlapping Distributions

EUCAST employs specialized statistical methods, detailed in SOP 10.2, to identify the wild-type distribution upper end even when overlapping with non-wild-type populations [1] [7]. These approaches typically involve:

• Modal analysis to identify subpopulations within aggregated distributions
• Log-normal distribution fitting to the putative wild-type component
• Robust statistical estimation techniques that are less influenced by outlier values
• Visual inspection of histogram patterns by experienced curators

A key principle in addressing overlapping distributions is ensuring that the dilution series includes concentrations that adequately capture both wild-type and elevated non-wild-type subpopulations. Studies truncated within the wild-type distribution must be excluded from analysis, as they prevent accurate ECOFF estimation [5] [45]. The EUCAST database curation process specifically addresses this by excluding approximately 10-20% of submitted distributions, primarily due to lower-end truncation issues [5].

Verification of Wild-Type Populations

When distribution overlap occurs, additional verification methods can help confirm wild-type population boundaries:

• Correlation with genetic markers: Comparing phenotypic distributions with known resistance gene presence [45]
• Analysis of subsets: Examining distributions from surveillance programs with low resistance prevalence
• Methodological calibration: Ensuring all contributing laboratories use methods calibrated to the reference broth microdilution [1] [5]
• Tentative ECOFFs: Establishing preliminary cut-offs with fewer than five distributions (termed TECOFFs by EUCAST) with subsequent refinement [5]

This comprehensive approach allows reliable ECOFF determination even when wild-type and non-wild-type distributions demonstrate partial overlap, enabling early detection of resistance development before clear separation occurs in clinical settings.

Applications and Implications for Resistance Detection

The accurate characterization of wild-type distributions and establishment of ECOFFs have far-reaching applications in clinical microbiology and public health. ECOFFs provide the most sensitive tool for detecting emerging resistance in bacterial populations, often identifying resistance trends before they become apparent through clinical breakpoint analysis [1]. This early warning function is particularly valuable for antimicrobial stewardship programs and public health surveillance initiatives.

In laboratory practice, ECOFFs are used to screen for and exclude resistance in bacterial populations and allow comparison of resistance rates between systems with different clinical breakpoints [1]. This is especially important given the historical differences between breakpoints established by different organizations (EUCAST, CLSI, FDA) and the evolution of breakpoints over time as new resistance mechanisms emerge [1] [10]. The ECOFF remains stable despite these changes, providing a fixed reference point for resistance surveillance.

Furthermore, ECOFFs play a crucial role in the determination of clinical breakpoints. The European Committee on Antimicrobial Susceptibility Testing specifically avoids setting clinical breakpoints that split wild-type distributions of target species [1]. This practice prevents the poor reproducibility of susceptibility categorization that occurs when breakpoints bisect major populations and acknowledges that different MIC values within the wild-type distribution do not correlate with different clinical outcomes [1] [45]. This fundamental principle ensures that susceptibility categorization remains clinically relevant and methodologically robust.

The international standardization of ECOFFs enables global resistance monitoring and facilitates the comparison of resistance rates across geographic regions and time periods. As noted by EUCAST, wild-type MIC distributions for a specific species-agent combination remain consistent irrespective of when or where isolates are collected, enhancing the utility of ECOFFs as stable reference points for antimicrobial resistance surveillance [1] [5]. This stability makes ECOFFs invaluable tools for tracking the global spread of resistance and evaluating the impact of intervention strategies.

Handling Truncated Data Series and Technical Variation in MIC Testing

Establishing robust epidemiological cut-off values (ECOFFs) is fundamental to antimicrobial resistance surveillance and breakpoint validation. These values distinguish wild-type microorganisms from non-wild type populations exhibiting phenotypically detectable resistance mechanisms [5]. The process is critically dependent on reliable Minimum Inhibitory Concentration (MIC) distributions, which are inherently subject to technical variation and data quality issues, particularly truncated data series [1]. Technical variation in MIC testing arises from multiple sources, including differences in methodology, media composition, inoculum preparation, and incubation conditions, leading to an expected variation of plus or minus one twofold dilution even under optimal conditions [1]. When MIC distributions are truncated—either at the lower or upper end of the concentration range—this introduces significant artifacts that compromise the accuracy of ECOFF determination. This guide objectively compares how different methodological frameworks address these challenges, providing researchers with validated approaches for generating reliable data essential for intrinsic resistance breakpoint research.

Comparative Analysis of MIC Data Handling Frameworks

Key Standards for MIC Distribution Analysis

Table 1: Comparison of ECOFF Setting Approaches for MIC Data

Feature	EUCAST Approach [5] [1]	CLSI Approach [1]
Formal Definition	The highest MIC for organisms devoid of phenotypically detectable, acquired resistance mechanisms [1]	The MIC or zone diameter value that separates microbial populations into those with and without acquired/mutational resistance [1]
Isolate Identification	To species level (or species complex if indistinguishable by MALDI-TOF) [1]	To species level only [1]
Reference Methods	ISO 20776-1 and methods calibrated to it; includes EUCAST and CLSI M7 methods [1]	CLSI M7, M11, M27, M38, M44, M45, M51, and VET05 [1]
Dilution Series Requirement	Strict twofold dilution series (0.125, 0.25, 0.5, 1, 2, 4, 8, etc.) [1]	Not formally specified but generally defaults to standard twofold dilution series [1]
Minimum Distributions Required	ECOFFs: ≥5 distributions; TECOFFs: 3-4 distributions [5]	Not explicitly specified in available documentation
Handling of Truncated Distributions	Explicit exclusion of distributions truncated at the lower end within putative wild-type range [5]	No specific policy mentioned in available literature

Quantitative Assessment of Technical Variation Impact

Table 2: Impact of Technical Variation on MIC Distributions and ECOFFs

Parameter	Effect on MIC Distribution	Impact on ECOFF Determination	Recommended Mitigation Strategy
Inter-laboratory Variation	Widening of distribution modes by 1-2 dilutions [1]	Potential shift in ECOFF if not accounted for in aggregated data	Calibration to reference broth microdilution using ISO-20776-2 [5]
Methodological Differences	Mode variations rarely exceed one doubling dilution step [5]	Minimal impact when methods are calibrated to reference	Use of ISO 20776-1 or validated alternatives [1]
Truncated Data Series	Artificial narrowing of distribution, loss of critical upper-end values [5]	Exclusion from EUCAST curated database to prevent distortion [5]	Ensure dilution series covers full putative wild-type range [1]
Inadequate Concentration Range	Failure to capture wild-type population upper boundary	Inability to establish accurate ECOFF	Include concentrations exceeding expected wild-type range in study design
Number of Distributions	Increased representativeness with more distributions	ECOFF reliability increases with number of distributions (5-100+) [5]	Aggregate data from multiple sources, geographical areas, time periods [5]

Experimental Protocols for Valid MIC Distribution Studies

Reference Method for Broth Microdilution MIC Testing

Objective: To determine Minimum Inhibitory Concentrations using reference broth microdilution method compliant with ISO 20776-1 standards [1].

Materials:

• Cation-adjusted Mueller Hinton Broth (for bacteria) or RPMI 1640 (for fungi)
• Standardized inoculum preparation (approximately 5×10^5 CFU/mL final concentration)
• Twofold antimicrobial dilution series (e.g., 0.125, 0.25, 0.5, 1, 2, 4, 8, 16 mg/L)
• Quality control reference strains

Procedure:

• Prepare antimicrobial agent in a series of twofold dilutions across the complete concentration range expected to encompass the wild-type distribution.
• Standardize the inoculum suspension to 0.5 McFarland standard, then dilute to achieve final test concentration.
• Inoculate each well of the microdilution tray with prepared inoculum.
• Incubate trays under appropriate conditions (35±2°C for 16-20 hours for most bacteria).
• Read MIC endpoints as the lowest concentration that completely inhibits visible growth.
• Include appropriate quality control strains with each run to validate procedure.
• Record all MIC values, including those above and below the putative wild-type range.

Data Quality Control: Any distribution with truncation within the putative wild-type range should be excluded from ECOFF analysis [5]. Round MIC values from methods using intermediate concentrations to the next higher twofold dilution (e.g., 3 mg/L becomes 4 mg/L) [1].

Protocol for Handling Technical Variation in Multi-Laboratory Studies

Objective: To aggregate MIC data from multiple sources while accounting for expected technical variation.

Procedure:

• Collect MIC distributions from at least five independent sources (laboratories, studies, or surveillance programs) [5].
• Apply weighting to prevent large distributions from overwhelming smaller ones in aggregated analysis [52].
• Curate all distributions against reference method performance using ISO-20776-2 calibration standards [5].
• Exclude distributions with lower-end truncation within the putative wild-type distribution [5].
• Analyze both aggregated distributions (all accepted distributions combined) and aggregated weighted distributions (each distribution contributes equally) [52].
• Visually inspect histograms for bimodal distributions indicating wild-type and non-wild type populations.
• Apply statistical methods per EUCAST SOP 10.2 to establish the ECOFF at the upper end of the wild-type distribution [1].

Visualizing MIC Data Handling and ECOFF Determination

Data Curation Workflow for Reliable ECOFFs

Technical Variation in MIC Determination

Essential Research Reagent Solutions

Table 3: Key Research Reagents for MIC Distribution Studies

Reagent/Material	Specification Requirements	Function in ECOFF Studies
Reference Antimicrobial Powders	Certified purity with documentation; stored appropriately	Preparation of precise stock solutions for dilution series [1]
Culture Media	Cation-adjusted Mueller Hinton Broth (bacteria); RPMI 1640 (fungi)	Standardized growth conditions across laboratories [1] [53]
Inoculum Standardization	0.5 McFarland standards or spectrophotometric calibration	Ensures consistent inoculum density (∼5×10^5 CFU/mL) [1]
Quality Control Strains	ATCC or equivalent reference strains	Validation of test procedure performance with expected MIC ranges [1]
Microdilution Trays	Manufactured under quality-controlled conditions	Ensures accuracy of antibiotic concentration in each well [1]
Data Collection Templates	EUCAST-provided Excel templates for bacteria and fungi	Standardized format for contributing MIC distributions to databases [5]

The determination of Epidemiological Cut-Off Values (ECOFFs) is fundamental for distinguishing wild-type (WT) bacterial populations from those with acquired resistance mechanisms. For many antimicrobials, Minimum Inhibitory Concentration (MIC) distributions are unimodal, facilitating straightforward ECOFF establishment. However, polyether ionophores like monensin present a significant challenge due to their complex, multi-modal MIC distributions in bacteria such as Enterococcus faecium. This case study examines the specific challenges in managing these multi-modal distributions, the implications for ECOFF determination, and the broader significance for antimicrobial resistance research.

The extensive use of monensin as a feed additive in livestock production exerts substantial selection pressure on gut microbiota, making it a critical subject for One Health perspectives on antimicrobial resistance [54]. Recent discoveries of transferable resistance genes co-localized with medically important antimicrobial resistance genes have heightened concerns about the potential for co-selection of resistance traits [55].

Monensin's Properties and Applications

Chemical Characteristics and Mechanism of Action

Monensin is a carboxylic polyether ionophore antibiotic produced by Streptomyces cinnamonensis [56] [57]. Its primary mechanism involves forming lipid-soluble complexes with cations and transporting them across biological membranes. Monensin specifically mediates sodium and hydrogen exchange, disrupting intracellular ionic homeostasis [57] [54]. This disruption leads to collapse of the proton motive force, increased ATP demand, and ultimately cell death, with particular effectiveness against Gram-positive bacteria which lack protective outer membranes [56] [54].

Table 1: Properties of Monensin and Related Ionophores

Property	Monensin	Narasin	Salinomycin	Lasalocid
Ion Selectivity	Na+ > K+ [54]	K+ > Na+ [54]	K+ > Na+ [54]	Mono- & divalent cations [54]
Primary Applications	Ruminant feed efficiency, coccidiosis control [56] [58]	Poultry coccidiostat [59] [55]	Poultry coccidiostat [59] [55]	Animal production [59] [55]
ECOFF for E. faecium	Not established (multi-modal) [59] [55]	0.5 mg/L [59] [55]	1 mg/L [59] [55]	2 mg/L [59] [55]

Agricultural Usage and Market Context

Monensin is extensively used in livestock production for improving feed efficiency in ruminants and controlling coccidiosis in poultry [56] [58]. The global monensin market, valued at approximately $1,476.8 million in 2021, is projected to reach $1,787 million by 2025, demonstrating its widespread agricultural application [60]. In dairy cattle, monensin supplementation has been shown to improve feed efficiency (ECM/DMI) without negatively affecting milk fat percentage when modern dietary formulations are used [58].

The Multi-Modal Distribution Challenge inE. faecium

Experimental Evidence of Multi-Modal Distributions

A 2025 multi-laboratory study analyzing 182 E. faecium isolates revealed that monensin displayed a broad MIC range of 0.5-64 mg/L with multiple distinct modes, preventing the establishment of a definitive ECOFF [59] [55]. This multi-modal distribution contrasts sharply with other ionophores like narasin, salinomycin, and lasalocid, for which ECOFFs could be reliably determined (0.5 mg/L, 1 mg/L, and 2 mg/L, respectively) [59] [55].

Table 2: Comparative ECOFF Determination for Ionophores in E. faecium

Ionophore	MIC Range (mg/L)	Distribution Pattern	ECOFF (mg/L)	Feasibility of ECOFF
Monensin	0.5 - 64 [59] [55]	Multi-modal with multiple subpopulations [59] [55]	Not established [59] [55]	Not currently feasible [59] [55]
Narasin	Up to 32 [59] [55]	Clear separation between WT and non-WT [59] [55]	0.5 [59] [55]	Reliably established [59] [55]
Salinomycin	Up to 32 [59] [55]	Clear separation between WT and non-WT [59] [55]	1 [59] [55]	Reliably established [59] [55]
Lasalocid	Up to 32 [59] [55]	Clear separation between WT and non-WT [59] [55]	2 [59] [55]	Reliably established [59] [55]

Reversible Phenotypic Adaptation

Research indicates that E. faecium of cattle origin can develop reversible monensin adaptation, enabling growth at concentrations 32 times the baseline MIC [61]. This adaptation is associated with a thicker cell wall or glycocalyx and overexpression of a 20.5 kDa protein [61]. Crucially, this adaptation is not genetically stable but represents a phenotypic response that reverses upon serial passage without monensin pressure, with MICs returning to baseline within 21 subcultures [61].

Diagram 1: Monensin Adaptation and Reversion Cycle in E. faecium. This reversible phenotypic adaptation contributes to multi-modal MIC distributions.

Methodological Framework for ECOFF Determination

Broth Microdilution Protocol

The foundational methodology for monensin MIC determination follows international standards. The broth microdilution method was performed according to ISO 20776-1 (2019) guidelines and EUCAST standard operating procedure (SOP 10.2) [55]. Stock solutions of ionophores were prepared at 1.0 mg/mL for monensin dissolved in pure methanol, with testing concentrations ranging from 0.06-64 mg/L [55]. Bacterial suspensions were adjusted to 0.5 McFarland standard and diluted to achieve final inoculum concentrations of approximately 5 × 10^5 CFU/mL [55]. Plates were incubated at 35 ± 1°C for 18 ± 2 hours before MIC reading, defined as the lowest concentration that inhibited visible growth [55].

Quality Control and Validation

Method validation involved ≥10 replicates of antimicrobial susceptibility testing of the quality control strain Enterococcus faecalis ATCC 29212 across five European laboratories [59] [55]. Validation criteria required that inter-laboratory variation remain within ±1 two-fold dilution [59] [55]. Additionally, a blind ring trial with five E. faecium and five E. faecalis strains ensured consistency in MIC determination across participating laboratories [55].

Genetic Characterization of Isolates

The study incorporated whole-genome sequencing (WGS) and PCR-based detection of known resistance genes to correlate phenotypic distributions with genetic markers [55]. DNA extraction was performed using automated platforms with Maxwell 16 Cell DNA Purification kits or QIAamp DNA Mini Kits [55]. For WGS, Illumina technology was used for paired-end runs, followed by assembly using Unicycler software and resistance gene detection using Abricate software with custom databases [55].

Diagram 2: Experimental Workflow for Monensin MIC Determination and ECOFF Analysis in E. faecium.

Research Reagents and Essential Materials

Table 3: Key Research Reagents for Monensin Susceptibility Testing

Reagent/Equipment	Specification	Application/Function	Source/Example
Monensin Standard	USP grade, ≥95% purity	Reference standard for MIC determination	Sigma-Aldrich (1457458 USP) [55]
Culture Media	Columbia Blood Agar	Bacterial cultivation and inoculum preparation	Commercial suppliers [55]
Broth Microdilution Plates	96-well, sterile	Container for dilution series and susceptibility testing	Commercial suppliers [55]
Quality Control Strain	E. faecalis ATCC 29212	Method validation and quality assurance	ATCC [55]
DNA Extraction Kit	Maxwell 16 or QIAamp	Bacterial DNA extraction for genetic analysis	Promega or Qiagen [55]
PCR Reagents	Primers, polymerase, dNTPs	Detection of resistance genes (narAB)	Commercial suppliers [55]
Sequencing Platform	Illumina NextSeq 500	Whole-genome sequencing for resistance mechanism identification	Illumina [55]

Implications for Resistance Monitoring and Breakpoint Validation

The multi-modal distribution of monensin MICs in E. faecium has significant implications for antimicrobial resistance surveillance and breakpoint validation. The inability to establish a reliable ECOFF complicates resistance monitoring and epidemiological tracking of susceptibility patterns over time [59] [55]. This case highlights the critical need for molecular methods to complement phenotypic testing when evaluating intrinsic resistance breakpoints for antimicrobials with complex distributions.

From a One Health perspective, the extensive use of monensin in animal agriculture and the potential for co-selection of resistance to medically important antimicrobials warrants careful consideration [54]. The discovery of plasmid-encoded ABC-type transporters conferring resistance to multiple ionophores, co-located with genes conferring resistance to vancomycin and other critically important antimicrobials, suggests potential for ionophore-driven co-selection [55] [54].

The case of monensin in E. faecium exemplifies the challenges in managing multi-modal distributions for ECOFF determination. The reversible phenotypic adaptation observed in E. faecium, combined with the potential for genetically encoded resistance mechanisms, creates a complex landscape for susceptibility testing and breakpoint validation. Future research should focus on elucidating the precise molecular mechanisms underlying monensin resistance and adaptation, developing standardized approaches for interpreting multi-modal distributions, and establishing surveillance strategies that account for both phenotypic and genotypic resistance markers. This comprehensive approach is essential for validating intrinsic resistance breakpoints and informing prudent use policies for ionophores in animal agriculture.

Optimizing Growth Conditions and Medium Composition for Fastidious Organisms

Fastidious organisms present a significant challenge in clinical and research microbiology due to their complex nutritional requirements and specific environmental needs for growth. These microorganisms, characterized by their inability to synthesize certain essential metabolites, demand precisely formulated culture media and controlled incubation conditions to propagate in laboratory settings. The optimization of growth conditions for fastidious bacteria is not merely a technical exercise but a fundamental prerequisite for accurate microbiological diagnosis, antimicrobial susceptibility testing, and reliable determination of epidemiological cut-off (ECOFF) values. Without proper cultivation methodologies, fastidious pathogens may remain undetected in clinical specimens, leading to diagnostic omissions and compromised patient care. Furthermore, the validity of intrinsic resistance breakpoints and ECOFF values in antimicrobial resistance surveillance directly depends on robust methods for growing the most nutritionally demanding organisms, making media optimization a cornerstone of reliable microbiological research and diagnostic practice.

Defining Fastidious Microorganisms and Their Challenges

Fastidious organisms are microorganisms, primarily bacteria, that possess complex and specific nutritional or environmental requirements, making them difficult to cultivate in standard laboratory media [62]. This "fastidiousness" stems from an evolutionary adaptation to specific ecological niches where essential nutrients are readily available, leading to the loss of biosynthetic pathways for various growth factors [62]. The term itself originates from the Latin fastidium, denoting aversion or delicacy of taste, reflecting these organisms' "picky" nature in laboratory conditions [62].

The fundamental challenge in working with fastidious organisms lies in their pronounced auxotrophy – the inability to synthesize essential compounds such as vitamins, amino acids, or specific growth factors [62]. This nutritional dependency necessitates the use of enriched media supplemented with these components. Additionally, fastidious bacteria often display heightened sensitivity to environmental variables including oxygen tension, pH, temperature, and sometimes even quorum-sensing signals [62]. At the genomic level, this fastidious nature is frequently underpinned by reduced metabolic versatility and compact genomes resulting from reductive evolution, particularly in obligate intracellular or parasitic lifestyles [62].

From a diagnostic perspective, the failure to adequately support the growth of fastidious organisms can lead to false-negative cultures, potentially resulting in undiagnosed infections and inadequate treatment. In research settings, poor growth conditions compromise the reliability of experimental data, including antimicrobial susceptibility profiles and the determination of ECOFF values, which are crucial for distinguishing wild-type from non-wild-type bacterial populations [31].

Comprehensive Analysis of Growth Media for Fastidious Organisms

Specialized media for fastidious bacteria are formulated to address specific nutritional deficiencies through enrichment, selective inhibition of competing flora, and atmospheric control. The table below summarizes the key specialized media, their components, and applications for important fastidious pathogens.

Table 1: Specialized Growth Media for Fastidious Bacteria

Medium Name	Key Components	Target Organisms	Specific Applications	Incubation Conditions
Chocolate Agar	Lysed RBCs (providing hemin/X-factor and NAD/V-factor), casein/animal tissue digest, cornstarch [63] [64]	Haemophilus spp., Neisseria spp. [63]	Isolation of H. influenzae from respiratory specimens; isolation of N. gonorrhoeae and N. meningitidis [63]	35-37°C, humidified atmosphere with 5-10% CO₂ [63]
Modified Thayer-Martin (MTM) Agar	Chocolate agar base with antibiotics (vancomycin, colistin, nystatin, trimethoprim) [63]	N. gonorrhoeae, N. meningitidis [63]	Selective isolation of N. gonorrhoeae from genital specimens [63]	35-37°C, humidified atmosphere with 5-10% CO₂ [63]
Buffered Charcoal Yeast Extract (BCYE) Agar	Yeast extract, charcoal, L-cysteine, iron salts, buffered to pH 6.9 [63]	Legionella species [63]	Isolation of L. pneumophila from respiratory and environmental samples [63]	35-37°C, humidified atmosphere [63]
Skirrow’s Agar	Blood agar base with antibiotics (vancomycin, polymyxin B, trimethoprim) [63]	Campylobacter jejuni, C. coli [63]	Selective isolation of Campylobacter from stool samples [63]	42°C, microaerophilic atmosphere (5% O₂, 10% CO₂, 85% N₂) [63]
Bordet-Gengou (BG) Agar	Potato infusion, glycerol, 15-20% defibrinated sheep blood [63]	Bordetella pertussis, B. parapertussis [63]	Isolation of Bordetella from nasopharyngeal swabs [63]	35-37°C, humidified atmosphere [63]
Loeffler’s Serum Slant	Coagulated serum (bovine or horse), dextrose [63]	Corynebacterium diphtheriae [63]	Isolation and identification of C. diphtheriae from throat swabs [63]	35-37°C, aerobic [63]

Key Media Formulations and Their Rationale

Chocolate Agar serves as a fundamental enriched medium for many fastidious pathogens. Its unique value lies in the lysis of red blood cells, which releases intracellular nutrients such as hemin (X-factor) and NAD (V-factor) that are essential for the growth of Haemophilus and Neisseria species [63] [64]. The heating process not only lyses the cells but also inactivates enzymes that could degrade NAD [64]. The addition of cornstarch helps neutralize toxic metabolites like fatty acids, to which Neisseria species are particularly sensitive [64].

Selective Media such as Modified Thayer-Martin Agar build upon enriched bases by incorporating antimicrobial agents to suppress competing flora. This is particularly crucial for specimens with mixed microbiota, such as genital or respiratory samples, where fastidious pathogens might be overgrown by hardier organisms without selective inhibition [63].

Specialized Media for particular pathogens address unique metabolic requirements. For instance, BCYE agar provides L-cysteine and iron salts that are absolutely required by Legionella species, while charcoal in the medium removes toxic byproducts that might inhibit growth [63]. Similarly, the high protein content in Loeffler's Serum Slant not only nourishes Corynebacterium diphtheriae but also enhances the metachromatic staining of volutin granules, which aids in identification [63].

Environmental Conditions and Atmospheric Requirements

Beyond nutritional factors, atmospheric conditions and temperature play critical roles in cultivating fastidious organisms. Many fastidious bacteria require specific oxygen concentrations that reflect their native ecological niches.

Table 2: Environmental Requirements of Select Fastidious Organisms

Organism	Oxygen Requirement	Optimal Temperature	Special Considerations
Campylobacter jejuni	Microaerophilic (5% O₂) [63]	42°C [63]	Requires reduced oxygen to minimize damage from oxygen-related products [65]
Helicobacter pylori	Microaerophilic [62]	37°C [65]	Requires urease for survival in acidic environments [62]
Neisseria gonorrhoeae	Capnophilic (5-10% CO₂) [63]	35-37°C [63]	Highly sensitive to toxic substances like fatty acids [64]
Haemophilus influenzae	Capnophilic (5-10% CO₂) [63]	35-37°C [63]	Requires both X (hemin) and V (NAD) factors [63]
Legionella pneumophila	Aerobic [62]	35-37°C [63]	Naturally replicates within amoebae in aquatic environments [62]

The optimization of atmospheric conditions often requires specialized equipment such as microaerophilic generating systems or CO₂ incubators. For microorganisms like Campylobacter and Helicobacter, the microaerophilic environment is essential to reduce oxidative stress that would otherwise limit growth [65] [62]. Temperature optimization is equally crucial, as demonstrated by the elevated growth temperature (42°C) preferred by Campylobacter jejuni, which reflects its adaptation to the avian gastrointestinal tract [63].

Advanced Cultivation Methodologies and Protocols

Protocol for Preparation of Chocolate Agar

• Preparation of Hemoglobin Solution: Add hemoglobin to distilled water to a final volume of 500 ml. Mix thoroughly and autoclave at 121°C for 15 minutes. Cool to 45-50°C [64].
• Preparation of Base Medium: Add all components except hemoglobin solution to distilled water and bring volume to 500ml. Mix thoroughly and heat until boiling. Autoclave at 121°C for 15 minutes. Cool to 45-50°C [64].
• Combining Solutions: Aseptically add 500ml of sterile hemoglobin solution to the base medium and mix thoroughly [64].
• Pouring Plates: Pour into sterile Petri dishes or distribute into sterile tubes [64].
• Quality Control: Test with control organisms to ensure performance standards are met [63].

Experimental Workflow for Isolation of Fastidious Pathogens

Diagram 1: Experimental workflow for fastidious pathogen isolation and ECOFF analysis.

Method for Antimicrobial Susceptibility Testing of Fastidious Organisms

• Pure Culture Isolation: Subculture the fastidious organism on appropriate enriched media to obtain pure colonies [63].
• Inoculum Preparation: Prepare a standardized inoculum suspension in suitable broth, adjusting to the appropriate turbidity standard [31].
• Inoculation: Apply the inoculum to specialized susceptibility testing media that supports the growth of the fastidious organism while maintaining antibiotic activity [31].
• Antibiotic Application: Apply disks containing antimicrobial agents or prepare panels for MIC determination [31].
• Incubation: Incubate under the specific atmospheric and temperature conditions required by the organism [63] [31].
• Interpretation: Measure zones of inhibition or determine MIC values, and interpret using appropriate clinical breakpoints or ECOFF values [31].

The Scientist's Toolkit: Essential Research Reagents and Materials

Successful cultivation and study of fastidious organisms requires specific laboratory materials and reagents designed to meet their unique requirements.

Table 3: Essential Research Reagents for Fastidious Organism Cultivation

Reagent/Material	Function	Application Examples
Defibrinated Blood (Sheep, Horse)	Source of growth factors (X and V factors) through lysis [64]	Base component for chocolate agar and blood-containing media [63]
Hemoglobin Solution	Provides X-factor (hemin) essential for certain bacteria [64]	Component of chocolate agar for Haemophilus and Neisseria [64]
Growth Supplements (IsoVitaleX, Supplement B)	Provides V-factor (NAD) and other vitamins [63]	Enrichment for Haemophilus and other fastidious organisms [63]
L-Cysteine	Essential amino acid for certain bacteria [63]	Supplement in BCYE agar for Legionella species [63]
Charcoal	Detoxifying agent that removes toxic metabolites [63]	Component of BCYE agar for Legionella [63]
Selective Antibiotic Cocktails	Inhibition of competing flora while permitting pathogen growth [63]	Modified Thayer-Martin for Neisseria, Skirrow's for Campylobacter [63]
Microaerophilic Gas Generating Systems	Creation of reduced oxygen environments (5-15% O₂) [65]	Cultivation of Campylobacter and Helicobacter species [63]

Relationship Between Growth Optimization and ECOFF Determination

The reliable determination of epidemiological cut-off (ECOFF) values for fastidious organisms is fundamentally dependent on optimal growth conditions. ECOFF values distinguish microorganisms without acquired resistance mechanisms (wild-type) from those with acquired resistance (non-wild-type) by establishing the minimum inhibitory concentration (MIC) distribution of antimicrobial agents against wild-type populations [31]. Suboptimal growth conditions can artificially elevate MIC values, leading to misclassification of wild-type strains as non-wild-type and compromising the accuracy of resistance surveillance data.

The integration of proper cultivation methods with susceptibility testing is particularly crucial for fastidious organisms like Haemophilus influenzae, Neisseria gonorrhoeae, and other challenging pathogens. The relationship between growth optimization and reliable ECOFF determination can be visualized as follows:

Diagram 2: Impact of growth conditions on ECOFF value reliability.

When fastidious organisms are cultivated under suboptimal conditions, several problems emerge that compromise ECOFF determination: reduced growth rate may lead to smaller colony sizes that affect endpoint interpretation in dilution tests; incomplete growth can result in falsely elevated MIC values; and inconsistent growth between replicates creates wider MIC distributions that obscure the separation between wild-type and non-wild-type populations. Therefore, media optimization is not merely about achieving growth but about achieving reproducible, robust growth that enables accurate phenotypic characterization.

The optimization of growth conditions and medium composition for fastidious organisms remains a critical endeavor in both clinical microbiology and research settings. Through careful formulation of specialized media that address specific nutritional auxotrophies, coupled with precise control of environmental conditions, researchers can successfully cultivate even the most demanding fastidious pathogens. The continuous refinement of these cultivation methods directly enhances our ability to detect and characterize these organisms, ultimately supporting accurate diagnosis, appropriate treatment, and reliable antimicrobial resistance surveillance. As the field advances, the integration of these traditional microbiological approaches with molecular methods will further strengthen our capacity to study fastidious organisms and validate the essential breakpoints that guide therapeutic decision-making and public health interventions.

Resolving Discrepancies Between Agar Dilution and Broth Microdilution Methods

Antimicrobial susceptibility testing (AST) is a cornerstone of clinical microbiology and antimicrobial resistance (AMR) surveillance. The agar dilution (AD) and broth microdilution (BMD) methods represent two fundamental approaches for determining minimum inhibitory concentrations (MICs), the quantitative measure of antimicrobial activity [66]. Within research settings, particularly those focused on defining epidemiological cut-off (ECOFF) values to characterize wild-type microbial populations and detect emerging non-wild-type strains with acquired resistance mechanisms, the consistency and correlation between these methods are paramount [37] [67]. Discrepancies in MIC results can significantly impact the accuracy of ECOFF determinations, potentially leading to misclassification of isolates and obscuring true resistance trends. This guide objectively compares the performance of AD and BMD methodologies, synthesizing experimental data to highlight strengths, limitations, and optimal applications for each technique within the context of AMR research and breakpoint validation.

Methodological Principles and Standard Protocols

Agar Dilution Methodology

The agar dilution method involves incorporating the antimicrobial agent directly into the agar medium before pouring plates, creating a solid growth surface with a known, graded concentration of the drug [66].

• Medium Preparation: Mueller-Hinton agar is typically used for non-fastidious organisms. For fastidious bacteria like Campylobacter spp. or Streptococcus agalactiae, the medium is supplemented with 5% defibrinated sheep blood or other specific growth factors [68] [69] [66].
• Antimicrobial Dilution Series: A stock solution of the antimicrobial agent undergoes two-fold serial dilutions, which are then incorporated into individual agar plates [66].
• Inoculation: A bacterial suspension standardized to a 0.5 McFarland turbidity (~1 × 10⁸ CFU/mL) is prepared. Using a replicator device, a small spot (1–5 μL) of this suspension is delivered onto the surface of each agar plate, resulting in a final inoculum density of approximately 5 × 10⁴ CFU per spot [66]. A single plate can typically accommodate up to 30 different bacterial isolates.
• Incubation and Reading: Plates are incubated under conditions optimal for the target organism (e.g., 35°C for 16–18 hours for non-fastidious bacteria, or longer under microaerobic conditions for Campylobacter). The MIC is recorded as the lowest concentration of antimicrobial agent that completely inhibits visible growth on the agar surface [66].

Broth Microdilution Methodology

Broth microdilution determines the MIC in a liquid medium contained within small wells of a microtiter plate.

• Plate Preparation: Commercially prepared, freeze-dried microtiter plates (e.g., Sensititre system) are often used, containing pre-diluted antibiotics in two-fold serial concentrations [68] [70].
• Inoculum Preparation: Similar to AD, a standardized bacterial suspension (0.5 McFarland) is prepared and then further diluted in a broth medium such as Mueller-Hinton or cation-adjusted Mueller-Hinton broth (CAMHB) to achieve the target inoculum of approximately 5 × 10⁵ CFU/mL [71].
• Inoculation and Incubation: Each well of the microtiter plate is inoculated with the diluted bacterial suspension. The plate is sealed and incubated under appropriate conditions for the test organism.
• Reading Results: After incubation, the MIC is determined as the lowest concentration of antimicrobial that prevents visible growth. Turbidity can be assessed visually or with an automated optical density reader [70]. For fastidious organisms, supplementing the broth with compounds like foetal bovine serum (FBS) or lysed horse blood may be necessary, though this can complicate visual reading due to trailing growth issues [37] [69].

The experimental workflow below illustrates the key steps and decision points for both methods.

Comparative Performance Analysis

Quantitative Agreement Across Bacterial Species

The agreement between AD and BMD varies depending on the bacterial species and antimicrobial agents tested. The following table summarizes key performance metrics from recent studies.

Table 1: Comparative Performance of Agar Dilution and Broth Microdilution Methods

Bacterial Species	Antimicrobial Agents Tested	Agreement Level	Key Observations	Source
Campylobacter jejuni/coli (113 isolates)	Ciprofloxacin, Erythromycin, Gentamicin, Tetracycline	BMD vs. AD: 78.7%BMD vs. E-test: 90.0%	High categorical agreement for susceptibility classification. Agar dilution yielded lower gentamicin MICs but strong statistical correlation (P<0.01).	[68]
Streptococcus agalactiae (GBS, 24 isolates)	Benzylpenicillin, Chloramphenicol, Clindamycin, Erythromycin, Gentamicin, Levofloxacin, Tetracycline, Vancomycin	>90% for most agents87.5% (Vancomycin)83.33% (Erythromycin)52.78% (Tetracycline)	Agar dilution avoided "trailing growth" issues encountered with BMD for erythromycin. Strong agreement (Cohen's kappa 0.88–1.00) in resistance categorization.	[69]
Bovine Mastitis Pathogens (215 isolates)	Amoxicillin/Clavulanic acid, Ampicillin, Cefazolin, Ceftiofur, Enrofloxacin, Erythromycin, and 6 others	Overall: 80.7%Variable by pathogen/drug: 20%-100%	BMD was more restrictive, resulting in a higher percentage of isolates classified as Resistant or Intermediate (24.3% vs. 6.2% with ADD). Very Major Discrepancy rate was low (0.2%).	[70]
Arcobacter butzleri (415 isolates)	Ciprofloxacin, Erythromycin, Gentamicin, Tetracycline	Aerobic AD (24h) showed highest agreement with reference BMD.	Study validated AD as a reliable alternative for ECOFF determination.	[37]

Analysis of Common Discrepancies and Underlying Causes

Discrepancies between AD and BMD are not random but often stem from specific methodological and biological factors.

• Trailing Growth and Endpoint Determination: BMD is more susceptible to "trailing growth," a phenomenon where reduced but visible turbidity makes the clear determination of an MIC endpoint challenging, particularly for bacteriostatic agents like erythromycin against S. agalactiae [69]. AD provides a clearer, binary visualization of growth versus no growth on a solid surface, facilitating more straightforward MIC reading in such cases.
• Inoculum Preparation and Stability: Minor variations in inoculum density, while standardized, can disproportionately affect results in one method. Furthermore, the AD method's spot inoculation provides a stable, fixed inoculum, whereas the BMD inoculum remains in suspension [66].
• Antimicrobial Agent Diffusion and Stability: The diffusion characteristics of an antimicrobial in solid agar versus its solubility and stability in liquid broth can lead to differential bioactivity [66]. This is particularly relevant for less polar compounds.
• Growth Requirements and Medium Supplements: Fastidious organisms often require enriched media. The choice of supplement (e.g., sheep blood vs. FBS) and its impact on the antimicrobial activity can differ between solid and liquid formats, potentially leading to MIC variations, as noted with gentamicin for Campylobacter [68] [37].

Essential Research Reagents and Materials

Successful and reproducible AST requires carefully standardized reagents. The following table details key solutions and materials used in these experimental protocols.

Table 2: Key Research Reagent Solutions for Antimicrobial Susceptibility Testing

Reagent/Material	Function/Description	Application in AD/BMD
Mueller-Hinton Agar	Standardized, well-defined medium for non-fastidious bacteria.	Primary medium for AD [66].
Cation-Adjusted Mueller-Hinton Broth (CAMHB)	Broth medium with adjusted Ca²⁺ and Mg²⁺ concentrations for accurate aminoglycoside and tetracycline testing.	Primary medium for BMD [37].
Defibrinated Sheep Blood (5%)	Provides essential growth factors (e.g., NAD, hematin) for fastidious organisms.	Supplement for both AD and BMD for bacteria like Campylobacter and Streptococcus [68] [66].
Foetal Bovine Serum (FBS)	Provides growth factors for fastidious pathogens in liquid medium.	Supplement in BMD for Arcobacter and other fastidious species [37].
0.5 McFarland Standard	Turbidity standard equivalent to ~1.5 × 10⁸ CFU/mL for inoculum preparation.	Critical for standardizing the initial inoculum in both AD and BMD [66] [67].
96-Well Microtiter Plates	Sterile, U-bottom or round-bottom plates for housing broth dilutions.	Used in the BMD method; can be pre-prepared with antibiotics [72] [71].
Replicator Device	Tool for applying multiple bacterial isolates simultaneously onto agar plates.	Used to spot inoculate up to 30 isolates on a single AD plate [66].
Quality Control Strains (e.g., E. coli ATCC 25922, S. aureus ATCC 29213)	Strains with known MIC ranges to validate test performance and reagent quality.	Essential for both AD and BMD to ensure daily run validity [37] [69].

Implications for ECOFF Determination and Resistance Research

The choice between AD and BMD has direct consequences for defining wild-type populations and setting ECOFFs.

• Impact on MIC Distributions: Method-dependent MIC variations can shift the entire distribution of a wild-type population. For instance, the systematic lower gentamicin MICs observed with AD for Campylobacter would result in a lower ECOFF value compared to one derived from BMD data [68]. This underscores the necessity of specifying the reference method when publishing ECOFFs.
• Harmonization for Surveillance: The high agreement between methods for most drug-bug combinations suggests that for surveillance purposes, data generated by either method can be comparable, provided the methodology is consistent over time [68] [69]. However, when establishing reference ECOFFs, a single standardized method must be chosen, as done by EUCAST for M. tuberculosis, which designates BMD as its reference method [71].
• Detecting Non-Wild-Type Populations: Both methods are effective at categorizing isolates with major resistance mechanisms (e.g., those carrying tet(M) or erm(B) genes) as resistant [69]. The critical factor for surveillance is not necessarily the absolute MIC value but the consistent ability of a method to separate wild-type from non-wild-type populations.

The relationship between testing methods, data interpretation, and surveillance outcomes is summarized in the following workflow.

Both agar dilution and broth microdilution are robust, standardized methods for antimicrobial susceptibility testing. The choice between them should be guided by the specific research context. Broth microdilution offers efficiency and automation for high-throughput clinical testing and is often designated as the reference method for breakpoint development [71]. Agar dilution demonstrates excellent agreement with BMD for most drug-bug combinations and provides distinct advantages in research settings, particularly for fastidious organisms, avoiding trailing growth, and enabling high-throughput testing of multiple isolates against a single drug concentration for ECOFF studies [37] [69].

For researchers validating intrinsic resistance breakpoints and defining ECOFF values, consistency in methodology is more critical than the choice of method itself. Discrepancies can be managed by understanding their sources—such as trailing growth in BMD or specific drug-medium interactions in AD. Establishing and adhering to a standardized protocol, along with rigorous quality control, ensures the generation of reliable, comparable data that can effectively monitor the concerning evolution of antimicrobial resistance.

Validating and Applying ECOFFs: Comparative Analysis and Breakpoint Integration

In antimicrobial resistance (AMR) research, accurately defining the wild-type (WT) population of microorganisms is a fundamental step for establishing Epidemiological Cut-off Values (ECOFFs). An ECOFF is the minimum inhibitory concentration (MIC) that separates the wild-type population (organisms without acquired resistance mechanisms) from non-wild-type populations (those with acquired resistance traits) [7]. The validation of these breakpoints relies heavily on robust molecular methods to genetically characterize bacterial isolates, ensuring that the phenotypic data used to set ECOFFs corresponds to a genotypically wild-type (gWT) population [72]. Two primary techniques employed in this validation framework are Polymerase Chain Reaction (PCR)-based methods and Whole Genome Sequencing (WGS). WGS provides comprehensive data on the entire genetic makeup of an organism, enabling the detection of known and novel resistance mechanisms. In contrast, PCR-based methods offer targeted, cost-effective verification of specific genetic markers. This guide objectively compares the performance of these two approaches within the context of validating intrinsic resistance breakpoints and ECOFF values, providing researchers with experimental data and protocols to inform their methodological choices.

Comparative Analysis of WGS and PCR-Based Methods

The choice between WGS and PCR-based methods involves a trade-off between comprehensiveness, cost, throughput, and analytical simplicity. The table below summarizes the key performance characteristics of each approach for verifying wild-type populations.

Table 1: Performance Comparison of WGS and PCR-Based Methods for Wild-Type Population Verification

Characteristic	Whole Genome Sequencing (WGS)	PCR-Based Methods (qPCR/dPCR)
Resolution & Scope	Comprehensive detection of known and novel resistance mutations and acquired genes across the entire genome [73] [74]	Targeted detection of pre-specified mutations or resistance genes; limited to known sequences [75] [76]
Throughput & Scalability	High-throughput for large-scale surveillance and population studies [73]	High-throughput for focused screening of specific markers; suitable for rapid testing of many samples [77]
Cost per Sample	Higher cost per sample due to sequencing reagents and data analysis infrastructure [73]	Lower cost per sample, especially for routine, targeted verification [75]
Turnaround Time	Longer (1-3 days) including library preparation, sequencing, and bioinformatics analysis [73]	Shorter (several hours), primarily hands-on time for setup and amplification [77]
Data Complexity	High; requires sophisticated bioinformatics pipelines and genomic expertise [73] [74]	Low; results are typically straightforward to interpret (e.g., presence/absence of amplification, Ct values) [76]
Quantitative Capability	Not inherently quantitative for mixed populations; best for clonal isolates.	Excellent quantitative capabilities, especially with digital PCR (dPCR), allowing for precise estimation of mutant allelic fractions [75] [76]
Key Application in ECOFF	Defining a genotypically wild-type (gWT) population from large, diverse isolate collections; essential when phenotypic MIC distributions are complex or biased [72]	Rapid, cost-effective confirmation of the absence of specific resistance markers in putative wild-type isolates.

Experimental Protocols for Method Verification

Whole Genome Sequencing Protocol for gWT Population Definition

The following protocol, adapted from studies on M. tuberculosis and E. coli, outlines the steps for using WGS to define a genotypically wild-type population for ECOFF analysis [74] [72].

• Bacterial Isolates and DNA Extraction: Select a comprehensive set of bacterial isolates representing the target species. Extract genomic DNA using a validated kit (e.g., DNeasy Blood & Tissue Kit, Qiagen or Maxwell RSC Cell DNA Purification Kit, Promega). Ensure DNA purity and concentration are measured spectrophotometrically.
• Library Preparation and Sequencing: For Illumina platforms, fragment 500 ng of genomic DNA and prepare sequencing libraries using a kit such as the KAPA Hyper Plus kit. Size selection can be performed with a Pippin Prep system to achieve an average insert size of 550 bp. Libraries are pooled in equimolar amounts and sequenced on an Illumina MiSeq or NovaSeq 6000 instrument to generate paired-end reads (e.g., 2x250 bp) [74].
• Bioinformatic Analysis for gWT Classification:
  • Quality Control and Assembly: Assess sequence read quality with FastQC. Perform de novo assembly using a assembler like SPAdes.
  • Resistance Genotyping: Analyze the assembled genomes against curated resistance databases (e.g., ResFinder, PointFinder) using tools integrated into software such as BioNumerics. The gWT population is defined as those isolates lacking any acquired resistance genes and mutations known to confer resistance to the drug(s) of interest [72]. Parameters are typically set at a minimum of 95% sequence identity and 95% coverage for gene detection.
• Phenotypic Correlation: The MICs of the defined gWT population are used to establish the ECOFF, often set at the 99th percentile of the gWT MIC distribution [72].

PCR-Based Protocol for Targeted Wild-Type Verification

This protocol describes a quantitative PCR (qPCR) approach for specific verification of wild-type sequences, based on methods used in microbiome and viral population dynamics studies [77] [75].

• Primer and Probe Design: Design primers and hydrolysis probes that are uniquely complementary to the wild-type sequence of the target gene. For highly specific discrimination, especially in a background of mutants, incorporating chemical modifications like Minor Groove Binder (MGB) or Locked-Nucleic Acid (LNA) bases is recommended to increase the probe's melting temperature and specificity [76].
• DNA Template Preparation: Purify genomic DNA from bacterial isolates. For fragmented DNA sources (e.g., FFPE samples), additional fragmentation may not be required. For high molecular weight DNA, fragmentation via sonication or restriction enzyme digestion is advised to ensure optimal amplification efficiency [76].
• qPCR Reaction Setup: Prepare reactions using a commercial master mix containing DNA polymerase, dNTPs, and buffer. A typical 20 µL reaction includes 1x master mix, forward and reverse primers (e.g., 400 nM each), a wild-type-specific probe (e.g., 200 nM), and template DNA (e.g., 5-50 ng).
• Thermal Cycling and Data Analysis: Perform amplification on a real-time PCR instrument with a cycling protocol including an initial denaturation (e.g., 95°C for 10 min), followed by 40-50 cycles of denaturation (95°C for 15 sec) and annealing/extension (e.g., 60°C for 1 min). The wild-type genotype is confirmed by a cycle threshold (Ct) value indicating successful amplification, while the absence of amplification (or a significantly delayed Ct) suggests a mutant sequence [77].

Workflow and Logical Pathways for ECOFF Validation

The process of validating ECOFFs is a multi-step endeavor that integrates both phenotypic and genotypic data. The following diagram illustrates the logical workflow for establishing a wild-type population and defining the ECOFF, highlighting the roles of WGS and PCR.

The decision-making process for method selection is crucial. The pathway below outlines the key factors that guide researchers toward choosing either a WGS or PCR-based approach for their specific validation needs.

The Scientist's Toolkit: Essential Research Reagents and Solutions

Successful implementation of the validation frameworks requires specific reagents and tools. The following table details key solutions used in the featured experiments.

Table 2: Key Research Reagent Solutions for WGS and PCR Validation

Item	Function/Application	Example Products & Specifications
High-Fidelity DNA Polymerase	PCR amplification for WGS library preparation with low error rate to avoid introducing false mutations.	KAPA HyperPlus Kit [74]
WGS Platform	High-throughput sequencing of entire bacterial genomes for comprehensive resistance genotyping.	Illumina MiSeq or NovaSeq 6000 [78] [74]
cgMLST Analysis Software	High-resolution strain typing and phylogenetic analysis based on WGS data to assess clonal relatedness.	Ridom SeqSphere+ (using a defined cgMLST scheme) [78]
Hydrolysis Probes (TaqMan)	Sequence-specific detection and quantification in qPCR/dPCR; wild-type vs. mutant discrimination.	MGB or LNA-modified probes [76]
Digital PCR System	Absolute quantification of target sequences without a standard curve; ideal for detecting rare mutants.	Naica System (Sapphire Chips) [76]
Restriction Enzyme (e.g., Tru1L)	Fragmentation of high-quality genomic DNA to optimize amplification efficiency in dPCR assays.	Tru1L (must be validated to not cut the amplicon) [76]
Broth Microdilution Plates	Gold-standard phenotypic MIC testing to correlate genotypic findings with resistance profiles.	Sensititre MYCOTB / UKMYC plates [72]

Both Whole Genome Sequencing and PCR-based methods provide critical, complementary pathways for verifying wild-type populations in the establishment of reliable ECOFFs. WGS offers an unparalleled, comprehensive view of the bacterial genome, making it indispensable for large-scale surveillance studies and for defining gWT populations in genetically complex or heterogeneous samples. PCR-based methods deliver speed, cost-effectiveness, and precise quantification for targeted verification and high-throughput screening of specific resistance markers. The choice of framework is not a matter of which is universally superior, but which is most fit-for-purpose given the specific research question, the known versus unknown nature of the resistance mechanisms, and the available resources. An integrated approach, often using WGS for initial population definition and PCR for subsequent routine monitoring, represents the most robust strategy for validating intrinsic resistance breakpoints.

Epidemiological cutoff values (ECOFFs) are critical microbiological tools that distinguish between wild-type microorganisms and those with acquired resistance mechanisms by defining the upper limit of the minimum inhibitory concentration (MIC) distribution for the wild-type population [79]. Within antimicrobial susceptibility testing (AST), two major organizations—the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI)—have established methodologies for ECOFF determination. This comparative analysis examines the foundational principles, methodological approaches, and practical applications of ECOFF determination by these two standards bodies, providing researchers and drug development professionals with a framework for validating intrinsic resistance breakpoints.

Foundational Principles and Definitions

Conceptual Framework of ECOFFs

ECOFFs serve as a phenotypic baseline for detecting emerging resistance, providing a sensitive tool for resistance surveillance before clinical breakpoints are established [79]. Unlike clinical breakpoints, which incorporate pharmacokinetic-pharmacodynamic (PK-PD) parameters and clinical outcome data to categorize isolates as susceptible, intermediate, or resistant, ECOFFs are determined purely from MIC distributions of wild-type populations [79]. This fundamental distinction makes ECOFFs particularly valuable for monitoring resistance in uncommon pathogens and for new antimicrobial agents where clinical data may be limited.

Both EUCAST and CLSI define ECOFFs as the highest MIC value for a microorganism without phenotypically detectable acquired resistance mechanisms [5] [79]. Isolates with MICs above the ECOFF are designated "non-wild type" (NWT), suggesting the possible presence of acquired resistance mechanisms. This classification makes ECOFFs invaluable for resistance surveillance and detecting subtle shifts in susceptibility patterns over time [28].

Regulatory and Accessibility Context

A significant practical difference between the two organizations lies in their accessibility models. EUCAST provides all its documents, including MIC distributions and ECOFFs, freely available on its website, fostering broader accessibility, particularly in resource-limited settings [5] [26]. In contrast, CLSI guidelines are available through annual subscriptions ($500 for non-members), which may present barriers for some laboratories [26].

The decision-making processes also differ structurally. EUCAST maintains a process where pharmaceutical industry input is consultative only, while CLSI includes industry representatives in its voting committee [26]. This structural difference may influence how ECOFFs and breakpoints are established and revised.

Methodological Approaches

Data Collection and MIC Distribution Requirements

Both organizations emphasize the importance of high-quality MIC data generated using standardized reference methods, though their specific requirements show nuanced differences.

• EUCAST utilizes a collated database of MIC distributions from worldwide sources, comprising over 30,000 distributions [5]. The committee establishes ECOFFs based on at least five distributions, while tentative ECOFFs (TECOFFs) may be set with three or four distributions [5]. Data is curated according to EUCAST Standard Operating Procedure (SOP) 10.2, with distributions truncated at the lower end typically excluded from analysis [5] [32].

• CLSI similarly emphasizes robust data sets from multiple laboratories but places specific emphasis on inter-laboratory modal agreement (modes within one two-fold dilution) as a quality criterion [28]. CLSI requires data from a sufficient number of isolates to characterize the wild-type population adequately, typically including ≥100 MIC values from 3-23 independent laboratories [28].

Statistical Determination of ECOFFs

The core statistical approaches for ECOFF determination show significant convergence between the two organizations, with both utilizing similar statistical tools and software.

• Shared Analytical Tools: Both EUCAST and CLSI recommend using the ECOFFinder software, a Microsoft Excel spreadsheet calculator that implements the statistical methodology described by Turnidge et al. [41]. This tool employs a normalized resistance interpretation approach to separate wild-type from non-wild type populations [41].

• Complementary Methods: Research studies often employ multiple methods for ECOFF determination to validate results. These include:

  • Visual "eyeball" method: Visual inspection of MIC distributions [80]
  • Statistical calculation: Using ECOFFinder program and other statistical software [80]
  • Derivatization method (dECOFF): An alternative statistical approach [80]

• Harmonized Principles: Both organizations agree that ECOFFs should capture approximately 95-99% of the wild-type population, accounting for the inherent variability of MIC testing [80]. The determination process must accommodate the natural log-normal distribution of MIC values in wild-type populations.

The following diagram illustrates the general workflow for ECOFF determination shared by both EUCAST and CLSI methodologies:

Comparative Experimental Data

Candida auris Case Study

A 2017 study directly comparing EUCAST and CLSI reference microdilution methods for 123 Candida auris isolates provides valuable experimental data on method correlation [80]. The study investigated MICs for eight antifungal drugs and evaluated multiple methods for ECOFF determination.

Table 1: Comparison of CLSI and EUCAST MIC Values for Candida auris (n=123 isolates)

Antifungal Drug	CLSI MIC₅₀ (mg/L)	EUCAST MIC₅₀ (mg/L)	CLSI MIC₉₀ (mg/L)	EUCAST MIC₉₀ (mg/L)	Essential Agreement (±2 dilutions)
Fluconazole	>64	>64	>64	>64	91%
Voriconazole	0.5	0.5	16	16	86%
Amphotericin B	0.5	0.5	1	1	97%
Anidulafungin	0.5	0.5	2	2	75%
Micafungin	0.5	0.5	2	2	85%

The study found that modal MIC, geometric mean MIC, MIC₅₀, and MIC₉₀ values were in agreement for all compounds, with discrepancies not exceeding one 2-fold dilution [80]. The quantitative agreement between methods was highest for amphotericin B (97% within ±2 dilutions) and lowest for anidulafungin (75% within ±2 dilutions) [80].

Table 2: ECOFF Values (mg/L) for Candida auris Determined by Different Methods

Antifungal Drug	CLSI ECOFF Range	EUCAST ECOFF Range	Statistical Method Used
Itraconazole	0.25-0.5	0.5-1	Visual, ECOFFinder, dECOFF
Posaconazole	0.125	0.125-0.25	Visual, ECOFFinder, dECOFF
Amphotericin B	0.25-0.5	1-2	Visual, ECOFFinder, dECOFF
Voriconazole	1-32	1-32	Method-dependent

The study demonstrated that estimated ECOFFs were method-dependent for some azoles (voriconazole and isavuconazole) but consistent across methods for other antifungals [80]. This highlights the importance of specifying the determination methodology when reporting ECOFF values.

Broader Methodological Comparisons

A 2016 study comparing CLSI and EUCAST guidelines for bacterial pathogens further illuminates the correlation between the two systems [26]. Analyzing 5,165 Escherichia coli, 1,103 Staphylococcus aureus, and 532 Pseudomonas aeruginosa isolates, researchers found:

• Overall concordance between CLSI and EUCAST categorizations ranged from 78.2% to 100% for E. coli, 94.6% to 100% for S. aureus, and 89.1% to 95.5% for P. aeruginosa [26].
• Statistical agreement measured by kappa statistics varied by organism-antibiotic combination, from perfect agreement (e.g., trimethoprim-sulfamethoxazole for E. coli) to poor agreement (e.g., amikacin for E. coli) [26].

Practical Applications and Research Implementation

Implementation in Resistance Surveillance

ECOFFs play a crucial role in detecting non-wild type isolates with potentially acquired resistance mechanisms. For example, in a study of Candida auris, ECOFF analysis helped confirm uniform fluconazole resistance (100% non-susceptible by CLSI, 97.6% by EUCAST) and variable resistance to other agents [80]. This surveillance function is particularly valuable for:

• Emerging pathogens where clinical breakpoints may not yet be established
• Uncommon yeast and molds with limited clinical outcome data [79]
• Tracking resistance evolution in pathogens with increasing resistance rates

Technical Considerations and Limitations

Researchers must consider several technical factors when implementing ECOFF determinations:

• Methodological Calibration: Different MIC methods should be calibrated to reference methods, with wild-type modes expected to fall within one two-fold dilution of reference distributions [5].
• Truncation Effects: Distributions truncated at the lower end within the putative wild-type distribution are typically excluded from ECOFF determination [5].
• Modal Variability: For some drug-organism combinations, significant interlaboratory modal variability may preclude ECOFF definition, as was initially observed with Etest caspofungin MICs for Aspergillus species [28].
• Species Complexes: ECOFFs may be established for species complexes (SC) when individual species within the complex cannot be differentiated by routine methods [28].

Essential Research Toolkit

Table 3: Essential Resources for ECOFF Determination in Antimicrobial Research

Resource Category	Specific Tool/Solution	Research Application	Access Information
Statistical Software	ECOFFinder	Estimates ECOFFs from MIC distributions using normalized resistance interpretation	Freely available from CLSI website [41]
Reference Databases	EUCAST MIC Distribution Database	Provides collated MIC distributions for comparison and calibration	Freely accessible on EUCAST website [5]
Standardized Methods	CLSI M27-A3 (yeasts)	Reference broth microdilution method for antifungal susceptibility testing	Available via CLSI subscription [80]
Standardized Methods	EUCAST E.Def 7.3 (yeasts)	Reference method for antifungal susceptibility testing	Freely available from EUCAST [80]
Quality Control	EUCAST SOP 10.2	Standard operating procedure for data curation and ECOFF setting	Follows EUCAST standardization [32]

EUCAST and CLSI methodologies for ECOFF determination share fundamental principles of separating wild-type from non-wild type populations based on MIC distributions, while differing in their implementation frameworks and accessibility models. The experimental evidence demonstrates strong correlation between MIC values obtained by both methods for most antifungal agents, with essential agreement rates generally exceeding 85% within ±2 two-fold dilutions [80] [26].

The harmonization of statistical approaches, particularly the shared use of ECOFFinder software, provides a common analytical foundation despite organizational differences [41]. For researchers validating intrinsic resistance breakpoints, both methodologies offer robust frameworks for ECOFF determination, with the choice between systems often influenced by practical considerations of accessibility, regional standards, and specific pathogen-drug combinations of interest.

As antimicrobial resistance continues to evolve, ECOFFs will remain essential tools for early detection of resistance development, particularly for emerging pathogens like Candida auris and for antimicrobial agents in early stages of clinical use. The continued refinement and harmonization of ECOFF determination methodologies will strengthen global resistance surveillance and support evidence-based antimicrobial development.

The European Committee on Antimicrobial Susceptibility Testing (EUCAST) has established a systematic, evidence-based approach for developing antimicrobial susceptibility testing guidelines that is widely adopted throughout Europe and beyond. A cornerstone of this approach is the integration of Epidemiological Cutoff Values (ECOFFs), which serve as a fundamental first step in the breakpoint development process [7]. Unlike clinical breakpoints that predict therapeutic success, ECOFFs provide a purely microbiological parameter that distinguishes microorganisms without acquired resistance mechanisms (wild-type) from those with phenotypically detectable resistance mechanisms (non-wild-type) [1].

EUCAST defines the ECOFF as "the highest MIC for organisms devoid of phenotypically detectable, acquired resistance mechanisms" [1]. This definition emphasizes that ECOFFs define the upper end of the wild-type MIC distribution, typically written as "X mg/L," with the wild type designated as "≤X mg/L" and the non-wild type as ">X mg/L" [1]. This systematic characterization of wild-type populations provides an essential reference point for the otherwise relative MIC values in antimicrobial susceptibility testing, creating a stable foundation upon which clinically relevant breakpoints can be built [1].

Theoretical Foundation: The Why and How of ECOFFs

The Scientific Rationale for ECOFFs

The fundamental principle underlying ECOFF development recognizes that wild-type isolates of a single bacterial species exhibit a range of MIC values to a specific antimicrobial agent, following a log-normal distribution rather than clustering around a single value [1]. This distribution arises from a combination of technical assay variation (influenced by methodology, media, and laboratory conditions) and biological variation (inherent differences between isolates of the same species) [1]. Technical variation contributes more significantly to this distribution, with even well-controlled studies typically showing MIC variations of ±1 twofold dilution [1].

A critical principle in breakpoint development is that splitting wild-type distributions with clinical breakpoints leads to poor methodological reproducibility and poor correlation between clinical outcome and susceptibility testing results [7]. The EUCAST position is based on their failure to identify different clinical outcomes for isolates with different MIC values within the wild-type distribution [1]. This evidence supports setting clinical breakpoints above, rather than within, the wild-type MIC distribution to ensure more reliable susceptibility categorization.

Methodological Framework for ECOFF Determination

The EUCAST methodology for ECOFF determination is codified in the EUCAST Standard Operating Procedure SOP 10.2 [1]. This prescriptive approach requires several key elements:

• Isolate identification to the species level (or species complex if members cannot be distinguished)
• MIC values determined using ISO 20776-1 reference methods or methods calibrated to it
• Twofold dilution series based on traditional increments (0.5, 1, 2, 4, 8 mg/L, etc.)
• Minimum of five independent distributions from different sources before establishing an ECOFF [1]

The process of ECOFF determination begins with systematic collection and curation of MIC distributions from worldwide sources, which are aggregated and displayed through the EUCAST website [5]. The database now contains over 40,000 MIC distributions from more than 30,000 sources, incorporating data from human and animal isolates across diverse geographic locations collected over more than 70 years [5] [1]. This extensive collection ensures that ECOFFs represent a consensus wild-type distribution that accounts for methodological, geographical, and temporal variations.

Figure 1: The EUCAST ECOFF Determination Workflow. This diagram illustrates the systematic process from data collection to final integration into clinical breakpoint development.

Comparative Analysis: EUCAST vs. Alternative Approaches

EUCAST vs. CLSI Methodologies

The EUCAST approach differs in several significant aspects from the Clinical and Laboratory Standards Institute (CLSI), the other major international standards organization for antimicrobial susceptibility testing. A direct comparison reveals both philosophical and methodological distinctions:

Table 1: Comparison of EUCAST and CLSI Approaches to ECOFF/ECV Development

Feature	EUCAST Approach	CLSI Approach	Significance of Differences
Terminology	Epidemiological Cutoff Value (ECOFF)	Epidemiological Cutoff Value (ECV)	Primarily semantic
Definition	Highest MIC for organisms devoid of phenotypically detectable resistance [1]	MIC/zone value separating populations with/without resistance [1]	EUCAST emphasizes phenotypic detection
Minimum Distributions	5 independent distributions required [1]	3 independent distributions suggested [1]	EUCAST requires more extensive data
Data Accessibility	Freely available online [26]	Subscription-based access [26]	Significant resource implications
Industry Role	Consultative only, no decision-making role [26]	Voting committee includes industry representatives [26]	Potential conflict of interest concerns

These methodological differences translate into practical consequences for implementation. The EUCAST model, with its freely accessible documents and databases, provides distinct advantages for resource-limited settings and promotes broader global standardization [26]. Additionally, the more restrictive role for pharmaceutical industry representatives in EUCAST decision-making processes potentially reduces conflicts of interest in breakpoint establishment [26].

Analytical Concordance Between Systems

Despite methodological differences, studies have demonstrated generally strong agreement between EUCAST and CLSI interpretations. A comprehensive 2016 study comparing 5,165 Escherichia coli, 1,103 Staphylococcus aureus, and 532 Pseudomonas aeruginosa isolates found concordance rates ranging from 78.2% to 100% across various antibiotic-organism combinations [26].

Table 2: Concordance Analysis Between EUCAST and CLSI Breakpoints for E. coli (n=5,165)

Antibiotic	Concordance Rate (%)	Agreement Level (Kappa Statistics)	Key Discrepancies
Ampicillin	99.5	Almost Perfect (κ=0.985)	Minimal difference
Amoxicillin-Clavulanate	78.2	Moderate (κ=0.581)	EUCAST lacks intermediate category
Ciprofloxacin	98.4	Almost Perfect (κ=0.969)	Minimal difference
Cefuroxime	96.5	Almost Perfect (κ=0.924)	EUCAST lacks intermediate category
Meropenem	Not specified	Substantial	Minor variation
Amikacin	Not specified	Poor	Significant variation

For S. aureus, the agreement was generally stronger, with most antibiotics showing perfect or almost perfect agreement, including penicillin, trimethoprim-sulfamethoxazole, levofloxacin, oxacillin, linezolid, and vancomycin [26]. These findings suggest that despite different developmental approaches, both systems largely converge on similar categorical interpretations for many key drug-bug combinations.

Experimental Protocols and Research Applications

ECOFF Determination Methodology

The technical process for ECOFF determination follows a standardized statistical approach:

• Data Collection and Curation: MIC distributions are collected from multiple independent sources worldwide using the ISO 20776-1 reference method or properly calibrated alternatives [5]. Each distribution is curated according to EUCAST SOP 10.2 to exclude truncated distributions or those with methodological deficiencies [1].

• Distribution Aggregation: Data from at least five independent sources are aggregated to create a consensus distribution. The EUCAST database currently includes over 40,000 MIC distributions from more than 30,000 sources [5] [1].

• Wild-Type Population Identification: The wild-type population is identified through statistical analysis. EUCAST employs a method that fits a normal distribution to the putative wild-type population in the log₂ MIC distribution [81]. Alternative methods like Normalized Resistance Interpretation (NRI) have also been validated against EUCAST ECOFFs, showing strong agreement [81].

• ECOFF Setting: The ECOFF is set at the MIC value that defines the upper end of the wild-type distribution, typically calculated as +2.0 or +2.5 standard deviations above the mean of the normalized wild-type curve, then rounded up to the nearest regular MIC dilution step [81].

Validation Techniques

Several statistical approaches validate ECOFF determinations:

• Normalized Resistance Interpretation (NRI): This method objectively reconstructs the wild-type population in an MIC distribution by utilizing the fact that the upper part of the wild-type population is not affected by resistant isolates [81]. Studies applying NRI to EUCAST distributions have demonstrated strong agreement with established ECOFFs, with 26 of 27 S. aureus antimicrobials and 25 of 27 E. coli antimicrobials within ±1 dilution step [81].

• Multi-laboratory Comparison: The reproducibility of wild-type distributions across different laboratories, geographic regions, and time periods serves as an inherent validation mechanism [1]. The consistency of these distributions confirms their suitability as reference standards.

Table 3: Essential Research Resources for ECOFF and Breakpoint Studies

Resource/Reagent	Function/Application	Access Information
EUCAST Clinical Breakpoint Tables v. 15.0	Definitive clinical breakpoints for bacteria	Free download from EUCAST website [82]
EUCAST MIC Distributions Database	Reference wild-type distributions and ECOFFs	Publicly accessible at mic.eucast.org [5]
ISO 20776-1 Standard	Reference broth microdilution method for MIC determination	ISO standard (subscription)
EUCAST SOP 10.2	Standard procedure for ECOFF determination	Free download from EUCAST [1]
Normalized Resistance Interpretation (NRI)	Statistical method for wild-type population analysis	Protected algorithm (Bioscand AB) [81]
EUCAST Disk Diffusion Method	Standardized phenotypic susceptibility testing	Detailed in EUCAST guidance documents [5]

Advanced Concepts and Specialized Applications

Breakpoints in Brackets

EUCAST has introduced the concept of "breakpoints in brackets" to address specific clinical scenarios where evidence for monotherapy is limited. These breakpoints are essentially ECOFFs that distinguish between isolates with and without acquired resistance but come with a warning about their use without additional therapeutic measures [27]. They may represent a "best fit" ECOFF that serves more than one species and are particularly relevant for agents used in combination therapy or for specific indications where robust clinical evidence is lacking [27].

Antifungal Applications

The EUCAST approach extends beyond antibacterial agents to include comprehensive breakpoint tables for fungi, including yeasts, molds, and dermatophytes [83]. The subcommittee on Antifungal Susceptibility Testing (AFST) develops and validates these breakpoints using methodology analogous to the antibacterial process, with separate tables and specific guidance documents for interpreting MICs for rare yeast without established breakpoints [83].

The EUCAST framework for integrating ECOFFs with clinical breakpoint development represents a sophisticated, evidence-based approach to antimicrobial susceptibility testing. By systematically characterizing wild-type distributions before establishing clinical breakpoints, EUCAST ensures that susceptibility categorizations are both microbiologically valid and clinically relevant. The publicly accessible database of MIC distributions and ECOFFs, coupled with transparent methodology, provides an invaluable resource for the global antimicrobial resistance research community.

The generally strong concordance between EUCAST and CLSI interpretations, despite methodological differences, reinforces the robustness of this systematic approach to breakpoint development. As antimicrobial resistance continues to pose significant challenges to global public health, the EUCAST model of integrating epidemiological data with clinical outcome assessment will remain essential for guiding appropriate antimicrobial therapy and containing the spread of resistance.

The growing crisis of antimicrobial resistance (AMR) necessitates robust surveillance systems to track emerging threats in both human and veterinary medicine. Epidemiological Cutoff Values (ECOFFs) serve as a fundamental tool in these efforts, providing a sensitive means to detect non-wild-type microbial populations with acquired resistance mechanisms. Unlike clinical breakpoints, which predict treatment success, ECOFFs differentiate microorganisms without acquired resistance mechanisms (wild-type) from those with such mechanisms (non-wild-type) based on their minimum inhibitory concentration (MIC) distributions [7]. This distinction is crucial for early detection of resistance emergence, monitoring resistance trends over time, and informing the subsequent establishment of clinical breakpoints. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) emphasizes that setting breakpoints that bisect wild-type MIC distributions leads to poor methodological reproducibility and poor correlation between clinical outcome and susceptibility testing results, underscoring the importance of properly defined ECOFFs [7].

Surveillance across human and animal populations reveals alarming trends. According to the World Health Organization (WHO), one in six laboratory-confirmed bacterial infections in people worldwide in 2023 were resistant to antibiotic treatments, with antibiotic resistance rising in over 40% of the pathogen-antibiotic combinations monitored between 2018 and 2023 [84]. In the veterinary sector, significant gaps remain in surveillance systems, particularly for companion animals and the integration of genomic data [85]. This comparison guide examines the applications, methodologies, and data outputs of key surveillance systems tracking resistance emergence in human and veterinary pathogens, with a specific focus on the role of ECOFF validation in understanding and combating AMR across the One Health spectrum.

Comparative Analysis of Surveillance Systems and Data Outputs

Global and Regional Surveillance Frameworks

Table 1: Comparison of Major AMR Surveillance Systems in Human and Veterinary Medicine

Surveillance System	Scope/Population	Key Pathogens Monitored	Primary Data Outputs	ECOFF/Breakpoint Standards
WHO GLASS [84] [86]	Human health (104+ countries)	Acinetobacter spp., E. coli, K. pneumoniae, S. aureus	Global resistance prevalence estimates; trends for 93 infection type-pathogen-antibiotic combinations	EUCAST and CLSI standards
U.S. NARMS [85]	Human, retail meats, food animals	Salmonella spp., Campylobacter, E. coli, Enterococcus	AMR trends in enteric bacteria from ill people, retail meats, food animals	CLSI and FDA standards
EUCAST AFST [83] [32]	Human and veterinary (yeasts, moulds, bacteria)	Brucella melitensis, dermatophytes, various bacterial pathogens	Clinical breakpoints, ECOFFs, standardized testing methods	EUCAST standards
US Veterinary AMR Dashboard Initiative [85]	Livestock, poultry, companion animals	Important veterinary pathogens excluded from NARMS	Integrated AMR and antimicrobial use data; empirical treatment support	CLSI and EUCAST veterinary breakpoints

Quantitative Resistance Trends Across Human and Animal Populations

Table 2: Documented Resistance Trends in Human and Veterinary Pathogens (2023-2025)

Pathogen	Setting	Resistance Pattern	Magnitude	Time Trend
E. coli and K. pneumoniae [84]	Human healthcare (Global)	Resistance to third-generation cephalosporins	>40% for E. coli; >55% for K. pneumoniae	Rising (5-15% annually for multiple combinations)
Gram-negative bacteria [84]	Human healthcare (African Region)	Resistance to first-line antibiotics	Exceeds 70%	Worsening in regions with limited health system capacity
Salmonella [87]	Community/Asymptomatic food workers (China, 2013-2024)	Multidrug resistance	Increased to 41.9%	Emergence and escalation of tigecycline resistance (to 24.4%)
Brucella melitensis [32]	Human healthcare (European multicentre study)	Potential resistance to rifampicin, streptomycin, trimethoprim-sulfamethoxazole	6 of 499 isolates showed MIC values above ECOFFs	First standardized detection of non-wild-type populations

The data reveal critical resistance trends across different ecosystems. In human health, Gram-negative bacteria pose particularly severe threats, with more than 40% of E. coli and over 55% of K. pneumoniae globally now resistant to third-generation cephalosporins—first-line treatments for serious bloodstream infections [84]. These infections often result in sepsis, organ failure, and death, with resistance rates exceeding 70% in the WHO African Region, highlighting disparities in resistance burden and healthcare capacity [84]. Meanwhile, surveillance of community settings reveals how asymptomatic carriers serve as reservoirs for resistance amplification, with multidrug-resistant Salmonella carriage in food workers reaching 41.9% in one 12-year Chinese study [87].

The recent establishment of ECOFFs for Brucella melitensis represents a significant advancement in detecting resistance emergence for traditionally challenging pathogens. In a European multicentre study of 499 strains, six isolates showed MIC values slightly above the established ECOFFs, indicating the presence of potential resistance mechanisms to rifampicin, streptomycin, and trimethoprim-sulfamethoxazole—key therapeutic agents for human brucellosis [32]. This demonstrates ECOFFs' sensitivity in detecting early resistance emergence even in pathogens where resistance was previously difficult to characterize.

Experimental Protocols for ECOFF Determination

Standardized Methodologies for ECOFF Establishment

The determination of epidemiological cutoff values follows rigorously standardized experimental protocols to ensure reproducibility and accuracy across surveillance networks. The EUCAST standard operating procedure (SOP) 10.2 provides the definitive methodology for establishing ECOFFs through broth microdilution (BMD) and disc diffusion (DD) techniques [32]. The protocol was recently applied in a European multicentre study to establish ECOFFs for Brucella melitensis, validating both BMD and DD methods for this fastidious pathogen [32].

Key Experimental Steps:

• Strain Selection and Curation: A diverse collection of 499 B.. melitensis strains was assembled from multiple reference laboratories across Europe to ensure genetic diversity and representative sampling of wild-type populations.

• Broth Microdilution Testing: Each isolate was tested using standardized BMD methods against nine therapeutically relevant antimicrobial agents. Testing was performed at six independent study centres to assess methodological reproducibility.

• Disc Diffusion Testing: Parallel DD testing was conducted for all isolate-antimicrobial combinations using standardized disc potencies and inoculation procedures.

• Data Curation and Analysis: MIC and inhibition zone diameter distributions were curated according to EUCAST SOP 10.2. Distributions were analyzed for bimodality and the presence of non-wild-type populations.

• ECOFF Determination: The ECOFF was established as the highest MIC value or smallest zone diameter still within the wild-type distribution, identifying isolates with potential acquired resistance mechanisms.

• Validation of Methods: Both BMD and DD methodologies were validated for reproducibility across testing centres and consistency with EUCAST quality control expectations.

This standardized protocol enabled the establishment of MIC ECOFFs for all nine antimicrobial agents tested, based on five to six distributions encompassing 249 to 499 observations [32]. Zone diameter ECOFFs were established for rifampicin and ceftriaxone, while tentative ECOFFs were determined for ciprofloxacin, levofloxacin, gentamicin, and streptomycin.

Workflow for ECOFF Determination and Validation

The following diagram illustrates the comprehensive workflow for ECOFF determination and its role in antimicrobial resistance surveillance:

This workflow demonstrates how ECOFF determination serves as the foundation for reliable clinical breakpoints and effective AMR surveillance systems. The process begins with comprehensive strain collection and proceeds through standardized testing methodologies to data analysis and eventual validation across multiple testing centers [32] [7]. The established ECOFFs enable sensitive detection of resistance mechanisms and monitoring of resistance development, ultimately informing the establishment of clinical breakpoints that balance detection of resistance with prediction of clinical outcomes [32].

Research Reagent Solutions for Antimicrobial Susceptibility Testing

Table 3: Essential Research Reagents and Materials for ECOFF Determination and AMR Surveillance

Reagent/Material	Specification	Application in Surveillance	Quality Control Requirements
Cation-adjusted Mueller-Hinton broth [32]	Standardized for broth microdilution	Provides consistent growth conditions for MIC determination	Meets CLSI/EUCAST specifications for cation concentrations
Antimicrobial powder standards	≥90% purity, verified potency	Preparation of serial dilutions for MIC testing	Certificate of analysis from manufacturer; independent verification
96-well microdilution trays	Sterile, nonpyrogenic	High-throughput MIC determination for surveillance studies	Validated for consistency well-to-well and between lots
Antimicrobial susceptibility discs	Specific potencies for each drug	Disc diffusion testing for zone diameter measurements	Stored at -20°C until use; protected from moisture
Mueller-Hinton agar plates	4mm depth, specific pH range	Standardized medium for disc diffusion testing	Checked with control strains for appropriate growth and zone sizes
Reference control strains	ATCC/EUCAST recommended	Quality control for both BMD and DD methods	Includes quality control ranges for each antimicrobial
Brucella blood agar [32]	Supplemented with 5% sheep blood	Specialized medium for fastidious pathogens like B. melitensis	Supports adequate growth for reliable AST results

The selection and quality control of research reagents is critical for generating reliable, reproducible surveillance data. EUCAST emphasizes the importance of incorporating data from multiple sources and methods when establishing ECOFFs to ensure they accurately reflect wild-type distributions across different laboratory settings [7]. Standardized reagents and media that meet CLSI and EUCAST specifications help minimize technical variability, allowing for more accurate detection of biological resistance trends rather than methodological artifacts.

For fastidious pathogens like Brucella melitensis, specialized media such as Brucella blood agar is essential for obtaining sufficient growth for reliable antimicrobial susceptibility testing [32]. The European multicentre study validated both broth microdilution and disc diffusion methods for this pathogen, demonstrating that with appropriate methodological adaptations, standardized ECOFF determination is possible even for challenging microorganisms. This expands the scope of pathogens that can be effectively monitored within surveillance networks.

Integration of ECOFF Data in Surveillance Applications

From ECOFFs to Clinical Breakpoints in Surveillance Systems

The integration of ECOFF data into surveillance systems provides critical insights for antimicrobial stewardship and public health intervention. ECOFFs serve as the foundation for establishing clinical breakpoints, which are subsequently implemented in laboratory information systems and surveillance platforms like the WHO GLASS dashboard [84], the AMR package for R [31], and veterinary AMR dashboards [85]. These platforms transform raw MIC and disk diffusion measurements into interpretable SIR (Susceptible, Intermediate, Resistant) values that guide clinical decision-making and track resistance trends.

The recently developed "AMR" package for R exemplifies this integration, containing clinical breakpoints for humans, seven different animal groups, and ECOFFs from both EUCAST (2011-2025) and CLSI (2011-2025) guidelines [31]. This computational tool includes over 40,000 observations with 14 variables, enabling standardized interpretation of antimicrobial susceptibility testing results across different host species and guidelines. The package has been endorsed by both CLSI and EUCAST leadership, facilitating consistent analysis of surveillance data across institutions and research collaboratives [31].

Technological Advances in Resistance Surveillance

Table 4: Emerging Technologies and Computational Tools for AMR Surveillance

Technology/Platform	Application	Data Outputs	Surveillance Advantage
WHO GLASS Dashboard [84] [86]	Global AMR surveillance	Interactive global/regional summaries; country profiles	Standardized data from 104+ countries for cross-border comparisons
AMR R Package [31]	Computational analysis of AST data	SIR interpretations from MIC/disk values using clinical breakpoints	Standardized analysis across EUCAST/CLSI guidelines; veterinary and human hosts
Veterinary AMR Dashboards [85]	Integrated animal health data	Antimicrobial stewardship education; off-label use guidance; empirical treatment support	Addresses companion animal gap in existing systems like NARMS
Machine Learning Models [88] [87]	Prediction of AMR trends under different policy scenarios	Counterfactual policy impact assessments; resistance pattern predictions	Enables proactive rather than reactive resistance management

Recent technological advances are addressing critical gaps in traditional surveillance systems. For veterinary medicine, surveyed U.S. veterinarians expressed strong preference (over 75% consensus) for dashboard functionalities including antimicrobial stewardship education, off-label use guidance, surveillance data, and empirical treatment support [85]. These systems are particularly vital for companion animals, which are currently excluded from major surveillance programs like NARMS despite rising antimicrobial use and zoonotic transmission risks [85].

Machine learning approaches represent the next frontier in resistance surveillance, with recent award-winning projects demonstrating how global AMR data can predict resistance patterns under different policy scenarios [88]. One such approach applied machine learning to global AMR data to "predict antimicrobial resistance patterns under different policy scenarios, providing insights that can support policymakers in shaping strategies to combat AMR" [88]. These computational methods are particularly valuable for low-resource settings with sparse surveillance data, as they enable models to "borrow strength" from data-rich regions and improve predictions in countries with limited surveillance infrastructure [88].

Surveillance applications for tracking resistance emergence increasingly depend on properly validated ECOFFs to detect non-wild-type populations and monitor resistance trends across human and veterinary pathogens. Standardized methodologies for ECOFF determination, as exemplified by the EUCAST multicentre study on Brucella melitensis, provide the foundation for reliable clinical breakpoints and comparable surveillance data across institutions and geographic regions [32]. The integration of these data into digital platforms, including interactive dashboards and computational tools like the AMR R package, enables more effective translation of surveillance findings into clinical practice and public health policy [84] [31].

Critical gaps remain in current surveillance systems, particularly for companion animals, environmental monitoring, and the integration of genomic data with phenotypic resistance profiles [85]. Future directions in AMR surveillance will likely focus on enhanced data integration across the One Health spectrum, more rapid data sharing to reduce publication lags, and the application of artificial intelligence to predict emerging resistance threats before they become widespread [88] [87]. As resistance continues to escalate globally—with over 40% of pathogen-antibiotic combinations showing increased resistance between 2018 and 2023 [84]—the continued refinement of surveillance methodologies and ECOFF validation remains essential for preserving antimicrobial efficacy and protecting public health.

Validating Epidemiological Cut-Off Values (ECOFFs) is a fundamental process in antimicrobial resistance (AMR) surveillance, providing a critical threshold that separates bacterial populations without acquired resistance mechanisms (wild-type) from those with reduced susceptibility (non-wild-type). Unlike clinical breakpoints, which predict treatment outcomes, ECOFFs serve as a vital tool for monitoring the emergence and spread of resistant strains within a bacterial population. This guide presents a comparative analysis of ECOFF validation for two distinct microbiological contexts: Arcobacter butzleri, an emerging foodborne zoonotic pathogen, and veterinary ionophores against Enterococcus faecium. The data, methodologies, and interpretive frameworks presented herein provide researchers with validated approaches for AMR surveillance and a clearer understanding of the intricate process of establishing essential microbiological thresholds.

ECOFF Validation forArcobacter butzleri

Pathogen and Public Health Context

Arcobacter butzleri is a Gram-negative, aerotolerant bacterium recognized as an emerging zoonotic pathogen causing human gastrointestinal illness, characterized by symptoms such as diarrhea, abdominal pain, and fever, with potential for bacteremia in immunocompromised patients [89] [37]. Its significance as a foodborne hazard is elevated by its frequent isolation from various sources, including chicken meat (up to 36% prevalence), raw cow's milk (25%), and environmental water (28.1%) [89]. The treatment of severe arcobacteriosis typically involves antibiotics such as fluoroquinolones, macrolides, tetracyclines, and aminoglycosides, yet the absence of standardized interpretive criteria for antimicrobial susceptibility testing (AST) has historically complicated resistance monitoring and clinical management [37] [90].

Comparative Analysis of Antimicrobial Susceptibility Testing Methods

A recent pivotal study evaluated agar dilution as a practical alternative to the reference broth microdilution method for AST of A. butzleri [37]. The study tested 415 A. butzleri isolates from poultry against four antimicrobials: ciprofloxacin, erythromycin, gentamicin, and tetracycline.

Table 1: Comparison of AST Methods for A. butzleri

Testing Parameter	Broth Microdilution (Reference)	Agar Dilution (Proposed Alternative)
Approval Status	Approved by CLSI VAST subcommittee [37]	Evaluated as a reliable alternative [37]
Growth Medium	Cation-adjusted Mueller Hinton Broth + 5% FBS [37]	Mueller-Hinton Agar + 5% defibrinated sheep blood [37]
Incubation Conditions	37°C for 24 h, Aerobic [37]	37°C for 24 h, Aerobic (showed highest agreement) [37]
Key Advantages	Standardized protocol [37]	Accommodates more samples per plate; more stable growth environment; better colony visibility [37]
Key Limitations	Expensive automation; labor-intensive manual preparation; less consistent for manual testing [37]	Requires growth supplement (e.g., blood); not yet approved in CLSI standards [37]
Agreement with Reference	-	High for ciprofloxacin, erythromycin, gentamicin [37]

Proposed Tentative ECOFFs forA. butzleri

The validation study culminated in the proposal of tentative ECOFFs for key antimicrobials, which are essential for distinguishing wild-type and non-wild-type populations [37].

Table 2: Tentative ECOFFs for Arcobacter butzleri

Antimicrobial Agent	Proposed Tentative ECOFF (µg/mL)
Ciprofloxacin	0.5 [37]
Erythromycin	16 [37]
Gentamicin	2 [37]
Tetracycline	16 [37]

It is critical to note that these values are specific to A. butzleri and the testing methodologies described. Previous studies that applied ECOFFs defined for Campylobacter jejuni to Arcobacter reported potential misclassification, such as 96.2% of Arcobacter MICs for azithromycin being above the C. jejuni ECOFF of 0.25 µg/mL [89]. This underscores the necessity for pathogen-specific ECOFFs.

Figure 1: Experimental workflow for establishing tentative ECOFFs for Arcobacter butzleri, covering susceptibility testing methods, optimal conditions, and data analysis steps [37].

ECOFF Validation for Veterinary Ionophores inEnterococcus faecium

Compound and Public Health Context

Veterinary ionophores, such as narasin, salinomycin, and lasalocid, are polyether ionophores widely used as coccidiostats in intensive broiler farming [55]. Although classified as feed additives in the European Economic Area, their consumption often surpasses that of medically important antibiotics in poultry [55]. While their primary action is antiprotozoal, they also exhibit activity against Gram-positive bacteria, including Enterococcus faecium—a commensal bacterium and significant nosocomial pathogen. The recent discovery of plasmid-encoded resistance genes (narAB) against ionophores, which are co-located with genes for resistance to medically important antibiotics like vancomycin, has raised concerns about potential co-selection and highlights the need for robust resistance monitoring [55].

Standardized Broth Microdilution Methodology

A multi-laboratory study established ECOFFs for key ionophores in E. faecium using a standardized broth microdilution method [55].

• Isolate Collection: 182 E. faecium strains (122 wild-type and 60 carrying narAB genes) from human, poultry, and other sources were collected from five European laboratories [55].
• Method Validation: The method was validated by conducting ≥10 replicates of AST for Enterococcus faecalis ATCC 29212. Variation was considered acceptable if the mode of QC distributions was within ±1 two-fold dilution [55].
• Testing Procedure: MICs were determined using broth microdilution according to ISO 20776-1:2019. Ionophore stock solutions were prepared in methanol, and a concentration range of 0.03–32 mg/L was tested for narasin, salinomycin, and lasalocid. Isolates were inoculated onto plates and incubated at 35±1°C for 18±2 hours [55].
• Genetic Characterization: The presence of the narAB resistance genes was confirmed either by whole-genome sequencing or PCR, allowing for a clear correlation between MIC distributions and resistance genotypes [55].

Established ECOFFs and Correlation with Genotype

The study successfully established novel ECOFFs for three ionophores, providing a critical tool for identifying non-wild-type populations.

Table 3: ECOFFs for Ionophores in Enterococcus faecium

Ionophore	ECOFF (mg/L)	Notes on Resistance
Narasin	0.5 [55]	Below the previously suggested value of 2 mg/L; strains with narAB genes manifest a separate, higher MIC distribution [55].
Salinomycin	1 [55]	Strains with narAB genes show a distinct MIC distribution [55].
Lasalocid	2 [55]	Strains with narAB genes show a bias toward higher MICs but not a fully separate distribution [55].
Monensin	Not established	Displayed a broad MIC range (0.5–64 mg/L) with multiple modes, precluding ECOFF determination [55].

The clear bimodal distribution observed for narasin and salinomycin in relation to the narAB genotype provides strong validation for the proposed ECOFFs and underscores the utility of these thresholds in surveillance.

Figure 2: Experimental workflow for establishing ECOFFs for veterinary ionophores against Enterococcus faecium, highlighting the multi-laboratory design and genotype-phenotype correlation [55].

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 4: Key Research Reagent Solutions

Reagent/Material	Function in ECOFF Studies	Specific Example & Rationale
Growth Medium Supplements	Supports consistent growth of fastidious pathogens for reliable AST.	5% Defibrinated Sheep Blood in Mueller-Hinton Agar improves colony visualization and growth for A. butzleri in agar dilution [37]. 5% Foetal Bovine Serum (FBS) is used in broth microdilution for Arcobacter [37].
Reference Strains	Quality control for AST method validation and reproducibility.	E. coli ATCC 25922 & S. aureus ATCC 29213 for aerobic broth microdilution [37]. E. faecalis ATCC 29212 for ionophore broth microdilution validation [55].
Selective Antibiotic Mixtures	Selective isolation of target pathogens from complex samples.	CAT-Supplement for Arcobacter: Cefoperazone, Amphotericin B, 5-Fluorouracil, Novobiocin, Trimethoprim [91].
Genetic Confirmation Tools	Accurate species identification and detection of resistance genes.	Species-Specific PCR Primers (e.g., for A. butzleri [37] [90]); PCR or WGS for detection of ionophore resistance genes (narAB) [55].

This comparative guide illustrates the rigorous, method-dependent process of ECOFF validation for two distinct public health domains. The case of A. butzleri demonstrates the successful evaluation and proposal of a scalable AST method (aerobic agar dilution) alongside tentative ECOFFs, filling a critical gap for an emerging pathogen. Conversely, the work on veterinary ionophores establishes standardized ECOFFs through a multi-laboratory collaborative effort, directly linking MIC distributions to defined genetic resistance mechanisms. Together, these case studies provide researchers with validated frameworks, essential reagent information, and methodological insights crucial for advancing AMR surveillance and informing evidence-based treatment and intervention strategies.

Conclusion

The validation of ECOFF values provides an essential foundation for antimicrobial resistance surveillance and breakpoint development, serving as a sensitive indicator of resistance emergence independent of clinical outcomes. This systematic approach—from foundational understanding through methodological application to troubleshooting and validation—enables researchers to accurately distinguish wild-type from non-wild-type populations. Future directions include expanding ECOFF databases for emerging pathogens, enhancing integration of genomic and phenotypic data, and developing standardized approaches for veterinary and special-pathogen applications. As antimicrobial resistance challenges grow, robust ECOFF validation remains crucial for informing drug development, treatment guidelines, and global resistance containment strategies, ultimately supporting the One Health approach to antimicrobial stewardship.

References

• 1. Wild-type distributions of minimum inhibitory ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10732016/]
• 2. 1.2.1 Epidemiological cut-off (ECOFF) | OLCreate [https://www.open.edu/openlearncreate/mod/oucontent/view.php?id=227155§ion=2.2.1]
• 3. New definitions of susceptibility categories EUCAST 2019 [https://pmc.ncbi.nlm.nih.gov/articles/PMC9717465/]
• 4. Epidemiological cut-off value (ECOFF) [https://revive.gardp.org/resource/epidemiologcial-cut-off-value-ecoff/?cf=encyclopaedia]
• 5. MIC and Zone Distributions, ECOFFs [https://www.eucast.org/bacteria/mic-and-zone-distributions-ecoffs/]
• 6. The Minimum Inhibitory Concentration of Antibiotics [https://pmc.ncbi.nlm.nih.gov/articles/PMC7913839/]
• 7. ECOFFs—the why, the how, and the don'ts of EUCAST ... [https://www.sciencedirect.com/science/article/pii/S1198743X2200101X]
• 8. Population-based inference of aminoglycoside resistance ... [https://www.sciencedirect.com/science/article/pii/S2352396419304554]
• 9. Comparative analysis of clinical breakpoints, normalized ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10436012/]
• 10. Updating Breakpoints in Antimicrobial Susceptibility Testing [https://asm.org/articles/2022/february/updating-breakpoints-in-antimicrobial-susceptibili]
• 11. Updating breakpoints in the United States [https://pmc.ncbi.nlm.nih.gov/articles/PMC10595059/]
• 12. EUCAST abandons the term "intrinsic resistance" in favor ... [https://www.eucast.org/eucast_news/news_singleview?tx_ttnews%5Btt_news%5D=480]
• 13. Breakpoint Implementation Toolkit (BIT) | Resources [https://clsi.org/resources/breakpoint-implementation-toolkit/]
• 14. ECOFFs-the why, the how, and the don'ts of EUCAST ... [https://pubmed.ncbi.nlm.nih.gov/35218980/]
• 15. Antimicrobial surveillance: A 20-year history of the SMART ... [https://www.sciencedirect.com/science/article/pii/S0924857923002881]
• 16. Minimum inhibitory concentrations of sulfonamides and ... [https://www.sciencedirect.com/science/article/pii/S0378113525004201]
• 17. Breakpoint drift: a hidden confounder in antimicrobial ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12426181/]
• 18. Frontiers | The intrinsic resistome of bacterial pathogens [https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2013.00103/full]
• 19. Impeding pathways of intrinsic resistance in Escherichia coli ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12543169/]
• 20. Impeding pathways of intrinsic resistance in Escherichia coli ... [https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3003443]
• 21. Six-year antimicrobial resistance patterns of Escherichia coli ... [https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-025-04335-3]
• 22. Comparison of the Antibiotic Resistance of Escherichia coli ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10891912/]
• 23. Comparison of Antibiotic Resistance Profile of Escherichia ... [https://www.mdpi.com/2079-6382/10/5/575]
• 24. A comparative study on antibiotic resistant Escherichia coli ... [https://www.sciencedirect.com/science/article/pii/S1438463924000427]
• 25. Statistical characterisation of bacterial wild-type MIC value ... [https://www.sciencedirect.com/science/article/pii/S1198743X14620048]
• 26. Comparison of Clinical Laboratory Standards Institute and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4827198/]
• 27. Breakpoints in Brackets [https://www.eucast.org/bacteria/clinical-breakpoints-and-interpretation/breakpoints-in-brackets/]
• 28. Etest ECVs/ECOFFs for Detection of Resistance in Prevalent ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8522771/]
• 29. Resources | Clinical & Laboratory Standards Institute [https://clsi.org/resources/]
• 30. EUCAST calibration and validation graphs updated [https://www.eucast.org/news-detail/eucast-calibration-and-validation-graphs-updated/]
• 31. Data Set with Clinical Breakpoints for SIR Interpretation [https://amr-for-r.org/reference/clinical_breakpoints.html]
• 32. Defining epidemiological cutoff values for Brucella melitensis [https://pubmed.ncbi.nlm.nih.gov/40945717/]
• 33. Forensic species identification: practical guide for animal ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11490437/]
• 34. Single Laboratory Validated Method for DNA-Barcoding [https://www.fda.gov/food/reference-databases-and-monitoring-programs-food/single-laboratory-validated-method-dna-barcoding-species-identification-fish]
• 35. Appendix 4. Two-fold serial dilutions [https://www.fao.org/4/ac802e/ac802e0q.htm]
• 36. How to do serial dilutions (including calculations) | INTEGRA [https://www.integra-biosciences.com/united-states/en/blog/article/how-do-serial-dilutions-including-calculations]
• 37. Evaluation of agar dilution as an alternative method for ... [https://www.nature.com/articles/s41598-025-16223-x]
• 38. Antimicrobial Susceptibility Testing: A Comprehensive Review ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9024665/]
• 39. Serial Dilutions [https://www.fortislife.com/protocols/antibody-protocols/serial-dilutions]
• 40. Protocol to analyze antimicrobial susceptibility data [https://pmc.ncbi.nlm.nih.gov/articles/PMC9641264/]
• 41. ECOFFinder | Resources [https://clsi.org/resources/ecoffinder/]
• 42. Frontiers | A Novel and Validated Protocol for Performing MIC Tests to... [https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2017.01255/full]
• 43. Precision limits for MIC data required to set epidemiological ... [https://eafpbulletin.scholasticahq.com/article/38713]
• 44. of MIC Test Strip and Sensititre YeastOne with the CLSI... Comparison [https://pmc.ncbi.nlm.nih.gov/articles/PMC7179306/]
• 45. The determination of epidemiological cut-off values requires a ... [https://publications.ersnet.org/content/erj/61/5/2202259?ctkey=shareline&utm_campaign=shareline&utm_medium=shareline&utm_source=02259-2022]
• 46. The determination of epidemiological cut-off values requires a ... [https://publications.ersnet.org/content/erj/61/5/2202259]
• 47. Validation of Antibiotic Susceptibility Testing Guidelines in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4068562/]
• 48. Different antimicrobial susceptibility test methods | INTEGRA [https://www.integra-biosciences.com/united-states/en/blog/article/antimicrobial-susceptibility-tests]
• 49. Antimicrobial Susceptibility Testing - StatPearls - NCBI - NIH [https://www.ncbi.nlm.nih.gov/books/NBK539714/]
• 50. Predictive Mapping of Antimicrobial Resistance for ... [https://wwwnc.cdc.gov/eid/article/30/1/22-1450_article]
• 51. Setting and Revising Antibacterial Susceptibility Breakpoints [https://pmc.ncbi.nlm.nih.gov/articles/PMC1932754/]
• 52. MIC EUCAST [https://mic.eucast.org/]
• 53. Minimum Inhibitory Concentration (MIC) Testing [https://linnaeusbio.com/services/minimum-inhibitory-concentration-mic-testing/]
• 54. Polyether ionophore resistance in a one health perspective [https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1347490/full]
• 55. Determination of epidemiological cut-off values for Narasin ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12404726/]
• 56. Dosage‐dependent effects of monensin on the rumen ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6612561/]
• 57. Monensin intoxication due to intraruminal boluses in beef cattle [https://pmc.ncbi.nlm.nih.gov/articles/PMC12607128/]
• 58. Effect of monensin on milk production efficiency and ... [https://www.sciencedirect.com/science/article/pii/S002203022300721X]
• 59. Determination of epidemiological cut-off values for Narasin, Salinomycin, Lasalocid and Monensin in Enterococcus faecium - PubMed [https://pubmed.ncbi.nlm.nih.gov/40740068/]
• 60. Monensin Market Report 2025 (Global Edition) [https://www.cognitivemarketresearch.com/monensin-market-report]
• 61. Reversible monensin adaptation in Enterococcus faecium, ... [https://pubmed.ncbi.nlm.nih.gov/22740589/]
• 62. Fastidious organism [https://grokipedia.com/page/Fastidious_organism]
• 63. Fastidious Species | MI [https://microbiology.mlsascp.com/fastidious-species.html]
• 64. Chocolate Agar- Composition, Principle, Preparation, ... [https://microbenotes.com/chocolate-agar/]
• 65. Growing Fastidious Microorganisms in the Laboratory [https://www.news-medical.net/life-sciences/Growing-Fastidious-Microorganisms-in-the-Laboratory.aspx]
• 66. Agar Dilution - an overview [https://www.sciencedirect.com/topics/immunology-and-microbiology/agar-dilution]
• 67. Defining epidemiological cutoff values for Brucella melitensis [https://www.sciencedirect.com/science/article/pii/S1198743X25004513]
• 68. Comparison of Broth Microdilution, E Test, and Agar Dilution Methods for Antibiotic Susceptibility Testing of Campylobacter jejuni and Campylobacter coli - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC150256/]
• 69. Agar-Dilution Is Comparable to Broth Dilution for MIC ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11852353/]
• 70. Comparison between broth microdilution and agar disk diffusion methods for antimicrobial susceptibility testing of bovine mastitis pathogens - ScienceDirect [https://www.sciencedirect.com/science/article/abs/pii/S0167701223001306]
• 71. the EUCAST broth microdilution reference method for MIC ... [https://www.sciencedirect.com/science/article/pii/S1198743X20304444]
• 72. Epidemiological cut-off values for a 96-well broth microdilution ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9556810/]
• 73. Whole-genome sequencing to control antimicrobial resistance [https://pmc.ncbi.nlm.nih.gov/articles/PMC4156311/]
• 74. Genotypic resistance determined by whole genome ... [https://www.nature.com/articles/s41598-023-27723-z]
• 75. Evaluation of sequencing and PCR-based methods for ... [https://www.sciencedirect.com/science/article/pii/S0168170223000266]
• 76. Detection of Mutations using Drop-off Assay Design [https://www.stillatechnologies.com/digital-pcr/primer-design/drop-off-assay-design/]
• 77. Assessing microbiome population dynamics using wild-type ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10994841/]
• 78. Whole genome sequence analysis reveals limited diversity ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12121276/]
• 79. The role of epidemiological cutoff values (ECVs/ECOFFs) ... [https://pubmed.ncbi.nlm.nih.gov/27296911/]
• 80. Comparison of EUCAST and CLSI Reference Microdilution ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5444165/]
• 81. Normalized Resistance Interpretation as a Tool for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3008453/]
• 82. Clinical Breakpoint Tables [https://www.eucast.org/bacteria/clinical-breakpoints-and-interpretation/clinical-breakpoint-tables/]
• 83. Clinical breakpoint table [https://www.eucast.org/fungi-afst/clinical-breakpoints-and-interpretation/clinical-breakpoint-table/]
• 84. WHO warns of widespread resistance to common ... [https://www.who.int/news/item/13-10-2025-who-warns-of-widespread-resistance-to-common-antibiotics-worldwide]
• 85. A Survey of Needs and Preferences to Inform Development [https://pmc.ncbi.nlm.nih.gov/articles/PMC12568220/]
• 86. Global antibiotic resistance surveillance report 2025 [https://www.who.int/publications/i/item/9789240116337]
• 87. World Antimicrobial Awareness Week 2025 — Act Now [https://pmc.ncbi.nlm.nih.gov/articles/PMC12647938/]
• 88. Winners Announced for the 2025 Vivli AMR Surveillance ... [https://amr.vivli.org/winners-announced-for-the-2025-vivli-amr-surveillance-data-challenge-funded-by-johnson-johnson-paratek-pfizer-and-nih/]
• 89. Prevalence, antimicrobial susceptibility and virulence gene profiles of Arcobacter species isolated from human stool samples, foods of animal origin, ready-to-eat salad mixes and environmental water | Gut Pathogens | Full Text [https://gutpathogens.biomedcentral.com/articles/10.1186/s13099-021-00472-y]
• 90. Molecular characterization of Arcobacter butzleri isolates ... [https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2023.1094067/full]
• 91. Occurrence and Genetic Diversity of Arcobacter butzleri in an Artisanal Dairy Plant in Italy - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC3811483/]